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Sepsis is a systemic inflammatory response in the presence of infection that results in an 
uncontrolled release of inflammatory mediators called cytokines.  High levels of cytokines, 
especially in immune-compromised patients, can contribute to detrimental outcomes.  Previous 
attempts that targeted single mediators were unsuccessful.  The usefulness of therapies like 
hemodialysis for treating sepsis has been attributed to adsorption on the hemofiltration 
membrane rather than convective removal of cytokines.  Thus, the main focus of this work was 
to develop a device that uses the principles of adsorption to nonspecifically remove cytokines 
from blood.  The device we have developed contains highly porous, biocompatible polymer 
beads made up of a polystyrene-divinylbenzene copolymer.  In vitro testing of this device has 
demonstrated that it can remove over 90% of small cytokines such as interleukin-6 (IL-6) and 
interleukin-10 (IL-10) and up to 70% of the trimeric cytokine tumor necrosis factor (TNF) due to 
the large surface area for adsorption provided by the porous network.  We have also developed a 
mathematical model that provides a straightforward relationship between the operational 
parameters of the device and the removal rate of individual cytokines over time.  An 
experimental validation of this model shows that the rate of removal for a given cytokine-
polymer combination can be predicted with a high level of accuracy over a wide range of 
parameters.  We have used this model to test several variations on the original device, including 
the addition of immobilized antibodies on the surface of the beads to improve the specific 
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affinity for TNF.  Lastly, we have used the techniques of covalent immobilization of proteins to 
attach interleukin-8 (IL-8), a chemoattractant cytokine, on the inner lumen of polymer fibers.  By 
bringing leukocytes into contact with the IL-8 on the fibers within a device, we hope to be able 
to modulate the activation level of the cells and provide for improved outcomes in septic 
patients.  We demonstrate here that, under the correct conditions, the immobilized IL-8 device 
can in fact result in significant changes in leukocyte activity.  We feel that both of these devices 
are promising new treatment methods for sepsis and could have potential applications to other 
disease states. 
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1.0  INTRODUCTION 
Sepsis is a type of systemic inflammatory response syndrome which, by definition, results from 
an infection [1].  One must appreciate the complex immune response which causes infection to 
turn into sepsis in some cases and not in others.  The interplay of inflammatory mediators and 
other clinical factors can have vastly different effects on a septic versus a healthy patient which 
makes sepsis a disease that is as difficult to treat as it is to understand.  Sepsis remains the 
leading cause of death in non-coronary intensive care units (ICUs) [2] and costs resulting from 
treatment of sepsis are expected to top $17 billion in the United States in the next year alone [3].  
Severe sepsis affects over 750,000 Americans and kills one out of every three patients [4].  As 
many people per year die from sepsis as from acute myocardial infarction, and because sepsis 
affects the elderly at even higher rates, this number will increase as the population ages [5].   
1.1 SEPSIS 
Sepsis is a complex disease with several stages that, until recently, were not well defined.  
Clinically, the lack of a standard definition for sepsis became problematic as new therapies 
began to emerge for the treatment of sepsis.  The success of clinical trials of new treatments for 
sepsis depended on a standardized method of diagnosing the disease.  The consensus definition 
of sepsis was presented at a conference in 1991 by the American College of Chest Physicians 
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(ACCP) and the Society of Critical Care Medicine (SCCM).  They defined the following stages, 
in increasing severity, of the inflammatory response to infection: sepsis, severe sepsis, and septic 
shock.  Another important classification which arose from this conference was the designation of 
sepsis as a subset of systemic inflammatory response syndrome (SIRS) that could be diagnosed 
only in the presence of infection [1, 3]. 
SIRS is diagnosed when a patient displays two of the following symptoms concurrently: 
heart rate above 90 beats per minute, body temperature outside the range of 36-38°C (96.8-
100.4°F), respiration rate above 20 breaths per minute, a partial pressure of carbon dioxide 
(PaCO2) less than 32 mmHg, a white blood cell count outside the range of 4000-12,000 
cells/mm
3
, or the presence of greater than 10% immature neutrophils [3].  As expected, the 
incidence of SIRS is very high because this list of symptoms is so general and varied.  One 
estimate suggests that over 30% of all hospital patients, 50% of intensive care patients, and 80% 
of surgery patients meet the criteria for SIRS at any given time [6].  Rangel-Frausto et al. found 
that, in three ICUs and hospital wards over seven months, over 68% met the criteria for SIRS.  
Mortality increased with the increasing number of SIRS symptoms, with 3%, 6%, 9%, and 18% 
mortality for 0, 2, 3, or 4 of the criteria for SIRS being met, respectively [7]. 
 A diagnosis of SIRS becomes one of sepsis when the symptoms displayed are the result 
of a known infection, with further indications including fever, tachypnea, tachycardia, and 
hypotension [2].  Community-acquired infections make up over 55% of sepsis cases requiring 
hospitalization, while the remaining cases come from nosocomial infections, typically stemming 
from a pulmonary, gastrointestinal, urinary tract, or bloodstream infection [3].  The highest 
incidence of sepsis occurs in patients with co-morbidities such as patients taking 
immunosuppression drugs or patients with human immunodeficiency virus (HIV) or cancer.  
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Patients over 65 years of age, male patients, and African American patients also have a higher 
incidence of sepsis [3, 8].  Sepsis progresses into severe sepsis when acute organ dysfunction 
occurs.  The organs most commonly affected are the lung, kidney, and cardiovascular system.  
Septic shock is diagnosed for patients with severe sepsis who also demonstrate acute 
cardiovascular dysfunction [1, 6]. 
 The two mechanisms which are thought to lead to the onset of sepsis in patients with an 
infection are extrinsic, i.e. bacteria, viruses, or fungi which cause the initial microbial insult, and 
intrinsic, meaning the inflammatory mediators released in response to the infection [9].  The 
extrinsic pathway activates macrophages, endothelial cells, and the complement system, 
resulting in the release of inflammatory mediators called cytokines.  Cytokines are a family of 
over 80 intracellular signaling peptides ranging from 8-30 kDa in size which can act in an 
autocrine, paracrine, or endocrine fashion.  Three subclasses of cytokines exist: interleukins, 
which are released from and act upon leukocytes; lymphokines, which are released from 
lymphocytes; and chemokines, a special subset of cytokines which mediates chemotaxis between 
cells.  The classification of cytokines can be somewhat restrictive because of their wide range of 
biological activities and targets.  For example, some cytokines promote cytotoxicity while others 
lead to an increase in antibody-mediated immunity [10]. 
1.1.1 Hypercytokinemia 
The exact pathways responsible for inflammation in sepsis are not well known; however, the 
inflammation in a septic patient arises due to the response of the host to infection and is 
characterized by the systemic release of inflammatory mediators into the bloodstream.  The 
binding of lipopolysaccharide (LPS) or proteins from gram positive bacteria to surface receptors 
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on macrophages, monocytes, and neutrophils initiates signal transduction through 
transmembrane proteins called toll-like receptors (TLRs).  Signaling from this pathway activates 
nuclear factor κB (NF-κB) which results in the translocation of NF-κB to the nucleus and 
stimulates production of cytokines.  Viruses and fungi activate the NF-κB pathway similarly to 
LPS [9].   
Increased expression of cytokines in circulation, or hypercytokinemia, is strongly 
associated with organ failure and death [11].  The organ damage typical of septic patients leads 
to even greater levels of cytokine release.  Thus, the production of cytokines in the setting of 
sepsis is redundant and difficult to control.  The initial onset of SIRS is characterized by the 
release of pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1β (IL-
1β), interleukin-6 (IL-6), interleukin-12 (IL-12), chemokines, adhesion molecules, and 
leukotrienes [12].  This first response is counterbalanced by the release of anti-inflammatory 
cytokines such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) and other 
suppressors of immunomodulatory signaling cascades [13].   
Many attempts have been made to identify which cytokines are the most important in 
sepsis so that treatment options and mortality can be assessed earlier, treating the cytokines as 
biomarkers of the progression of sepsis as well as the mediators contributing to its worsening 
effects [9, 14-16].  For this study, we chose to focus on the cytokines interleukin-6 (IL-6), 
interleukin-10 (IL-10), and tumor necrosis factor (TNF).  The GenIMS study at the University of 
Pittsburgh found that patients who died in hospitals from sepsis had higher concentrations of 
these three cytokines on the day of presentation than patients who were eventually discharged 
[17].  Furthermore, septic patients with elevated levels of the pro-inflammatory cytokine 
interleukin-6 (IL-6) and the anti-inflammatory cytokine interleukin-10 (IL-10) at the time of 
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discharge have an increased risk of death [17].  Therefore, even conventional methods of treating 
sepsis that show improvement in patients’ conditions are suboptimal.  An urgent need exists for 
the development of new therapeutic interventions for sepsis, specifically in the area of reduction 
of circulating cytokine concentrations and attenuation of the inflammatory response. 
IL-6 is a 21 kDa glycoprotein which can act as both a pro- and anti-inflammatory 
cytokine [18].  IL-6 is produced by activated B cells, T lymphocytes, monocytes, and endothelial 
cells and induces T- and B-cell proliferation as well as stimulating the release of acute phase 
proteins resulting from inflammation or tissue damage [9].  IL-10 is a 34 kDa dimeric anti-
inflammatory cytokine which downregulates activated macrophages.  IL-10 is produced by 
epithelial cells, monocytes, and lymphocytes during inflammation [18].  TNF is a 52 kDa 
trimeric pro-inflammatory cytokine released by activated macrophages.  Elevated TNF levels 
have been linked to fever, hypotension, organ dysfunction, and neutrophil activation [19].  
Additionally, the production of TNF results in the production of other cytokines, cell adhesion 
molecules, and nitric oxide, a free radical with cytotoxic properties [18]. 
1.1.2 Sepsis-induced immune dysregulation  
The secondary release of anti-inflammatory mediators following the initial response to infection 
is known as the compensatory anti-inflammatory response syndrome (CARS), and the interplay 
of these two processes determines the immune status of the patient [13].  The term “sepsis-
induced immunoparalysis” refers to the impairment of leukocyte function as a result of a CARS-
dominant response in sepsis, one possible outcome of a hypercytokinemic state.  This type of 
immune suppression can further complicate sepsis by leaving patients susceptible to additional 
infections [20-21].  Ideally, septic patients would be classified as hyper- or hypoinflammatory 
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based on the presence and concentration of various biomarkers so that their treatment could be 
adjusted accordingly.  However, this distinction is difficult to make because SIRS and CARS 
represent a continuum of inflammatory states and they overlap and interact considerably [22]. 
Many cell types are affected by immune dysfunction in sepsis, particularly monocytes 
and macrophages, neutrophils, dendritic cells, and lymphocytes.  Apoptosis of lymphocytes and 
dendritic cells is stimulated while production of IL-12 (a pro-inflammatory cytokine) is 
decreased and IL-10 production increases.  Cytokine production from neutrophils, macrophages, 
and monocytes decreases due to inhibition of the genes encoding for NF-κB-dependent 
mediators.  Neutrophils also display decreased chemotaxis, adherence, and apoptosis; prolonged 
lifespans of neutrophils can potentially increase leukocyte-mediated tissue injury [22].   
Clearing the microbial infection in sepsis is still paramount but the recognition that such 
efforts may in fact attenuate or amplify the innate pro-inflammatory response has led to a shift in 
approaches to treating patients particularly vulnerable to immunoparalysis.  One method is 
immunostimulatory therapy, which uses either interferon-γ or granulocyte-macrophage colony 
stimulating factor (GM-CSF) to reverse the impaired TLR signaling and NF-κB responses that 
shift the immune response toward CARS [23-24].  Although preclinical trials of both treatments 
have shown promise [25-26], one concern is that immunostimulatory therapy will exacerbate the 
cytokine storm seen in SIRS.  Other methods, such as selective activation of the PI3K/Akt 
pathway in leukocytes or administration of caspase inhibitors to reduce lymphocyte apoptosis, 
are being investigated and currently, clinical trials have not yet begun [27-29]. 
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1.2 CURRENT CLINICAL THERAPIES 
In the following section, the current clinical therapies for sepsis will be discussed, including 
hemodynamic support and intensive care, early goal-directed therapy, drug therapies, 
hemofiltration, and hemoadsorption.  The use of one therapy over another varies based on the 
attending physician and the specific symptoms of the patient [30], but in general, the persistently 
high mortality rates associated with sepsis suggest that none of these therapies has been 
acceptable. 
1.2.1 Hemodynamic support and intensive care 
The oldest and most common method of treatment for sepsis is hemodynamic support and 
intensive care, which includes the monitoring of vital signs, central venous pressure, and urinary 
output to achieve predetermined hemodynamic endpoints.  The first priority with septic patients 
in particular is to achieve and maintain a reasonable mean arterial pressure and cardiac output.  
The next step is to eliminate the infection and disrupt the progression of sepsis into severe sepsis 
and septic shock.  Organ perfusion and function are continuously monitored while the patient is 
in the ICU [31].   
To achieve the desired endpoints, fluid resuscitation, vasopressor therapy, and inotropic 
therapy are used.  Fluid infusion is typically the first step in treating a septic patient, with 
hemoglobin levels monitored and maintained at recommended levels.  Invasive hemodynamic 
monitoring may be performed as necessary for those patients not responding to fluid infusion.  
Pulmonary or systemic edema may result from increased hydrostatic pressure due to fluid 
resuscitation as well as decreases in colloid osmotic pressures and increases in microvascular 
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permeability [31].  Vasopressor treatment includes administration of dopamine and 
norepinephrine to increase arterial blood pressure following successful fluid resuscitation.  
Complications of vasopressor therapy are tachycardia, myocardial ischemia or infarction, 
decreased stroke volume and cardiac output, and impaired blood flow [31].  The last method of 
hemodynamic support is inotropic therapy, involving the use of dobutamine for patients with low 
cardiac index and/or mixed venous blood saturation after fluid infusion.  While dobutamine can 
help increase cardiac index, it can cause tachycardia or other cardiac arrhythmias, myocardial 
ischemia or infarction, hypotensioin, and impaired blood flow leading to tissue necrosis [31]. 
While hemodynamic support and intensive care is one of the most prominent methods for 
treating sepsis, it is associated with many detrimental effects on the patient.  Additionally, this 
method has not shown a consistent, significant improvement in either the mortality or morbidity 
of sepsis.  This inconsistency is most likely due to the fact that the outputs monitored in 
hemodynamic therapy and intensive care are not sufficient for detection of global tissue hypoxia 
[19, 32]. 
1.2.2 Early goal-directed therapy 
Early goal-directed therapy (EGDT) was designed to address the inadequacies in the 
hemodynamic support and intensive care method.  Like the first method, EGDT also involves the 
use of a specific protocol of treatment methods to achieve specific endpoints.  These endpoints 
measure cardiac preload, afterload, and contractility to help maintain equilibrium between 
oxygen demand and delivery [33].   
Rivers et al. tested EGDT against hemodynamic support and intensive care for two sets 
of patients whose baseline parameters upon presentation were not significantly different.  EGDT 
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patients, unlike the control group, were initially treated in the emergency department and not 
placed in inpatient care for at least 6 hours.  Mortality in the EGDT and control groups was 30.5 
and 46.5%, respectively.  EGDT patients also displayed less severe organ dysfunction and higher 
mean central venous oxygen saturation than the control group [19]. 
Vasopressor use and consumption of health care resources was also reduced as a result of 
EGDT use, making it one of the best options for treatment of sepsis [34].  Even with a decreased 
morbidity, however, the survival rate for sepsis is still quite low and alternative methods have 
been investigated to improve outcomes even further.   
1.2.3 Drug therapies 
Drug therapies for sepsis have mostly targeted single mediators involved in the pro-inflammatory 
response.  Attempts to use specific antagonists such as antibodies or soluble receptors for pro-
inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) as a 
treatment for sepsis have had little success [35].  Testing of a monoclonal antibody against TNF 
showed no significant decrease in 28-day mortality in the test versus placebo group [36].  
Similarly, clinical trials to test three different doses of a receptor antagonist for IL-1 showed a 
slightly dose-dependent decrease in 28-day mortality but the patient population was too small to 
draw any meaningful conclusions about its effectiveness [37]. 
Bernard et al. showed a significant reduction in mortality using drotrecogin alfa, but the 
risk of bleeding was also significantly increased [38].  In another study, the positive effects from 
the activated protein C treatment were only observed until discharge, after which the survival 
benefit was no longer statistically relevant [39].  Annane et. al were also able to show a 
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significant increase in survival using low doses of corticosteroids [40], despite arguments that 
their patient population may have been unfairly skewed [41].  
The failures and inconsistencies of these and other drug therapies are due to an inability 
to attenuate the entire response, and as a result, recent strategies to treat sepsis involve broad-
spectrum reduction of inflammatory mediators.  Two such methods, hemofiltration and 
hemoadsorption, will be discussed in more detail below. 
1.2.4 Hemofiltration 
Other methods of broad-spectrum cytokine modulation have been developed because of their 
relative success in improving outcomes in randomized clinical trials of sepsis compared to 
therapies using specific cytokine antagonism.  The focus of these newer methods has shifted 
from pharmacological interventions to the use of dialysis-like techniques to remove harmful 
components from blood.  One such method is hemofiltration, the removal of plasma solutes by 
convection generated by a pressure gradient across a semi-permeable membrane. 
The advantage of such a system is that homeostasis can be restored by the nonspecific 
removal of both pro- and anti-inflammatory cytokines concurrently [42].  This type of removal is 
also able to regulate itself; solutes at higher concentrations will be removed more rapidly than 
those at lower, safer concentrations [43].  This autoregulation is particularly important for 
removal of inflammatory mediators because completely depleting cytokines in a patient may 
inhibit the natural ability of the patient to fight infection.  Most hemofiltration studies have been 
able to show an early decrease in cytokine concentrations followed by a drop off in capture with 
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time as the filter saturates; this result is not surprising since most hemofiltration membranes have 
a surface area of only 0.5-2.0 m
2
 [44-46].   
In one study, TNF concentrations of septic patients decreased during continuous veno-
venous hemofiltration but increased when the same patients were treated with continuous veno-
venous hemodialysis. These results suggested that convective rather than diffusive transport was 
responsible for clearance of cytokines. However, analysis of the ultrafiltrate in both cases 
showed little to no presence of cytokines. Thus, the authors concluded that their success was 
mainly due to the adsorption of cytokines to the hollow fiber membrane and not actually due to 
filtration from plasma [46].   
While hemofiltration holds potential benefits for treating sepsis, the results have been 
inconsistent and improvement is still needed.  Exploiting the apparent adsorptive removal of 
hemofiltration systems is a newer treatment method which is the basis for our work and will be 
discussed further in the section below. 
1.2.5 Hemoadsorption 
Hemoadsorption involves direct perfusion of whole blood or plasma through a device containing 
some type of adsorbent material. In the case of plasma perfusion, the plasma filter may either be 
a separate cartridge in line with the plasma adsorption device or it may be contained within the 
device itself.  Hemoadsorption as a treatment for sepsis typically takes one of two forms, either 
endotoxin or cytokine adsorption therapy. 
 Endotoxin adsorption therapy was proposed to remove the cause of cytokine 
overproduction, tissue damage, and organ failure seen in sepsis.  Polymyxin b, an LPS-
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neutralizing agent, is immobilized on α-chloroacetamide-methyl polystyrene-based fibers within 
a blood purification column and whole blood from a septic patient is perfused through the fibers 
[47]. This therapy has been used in Japan for the past decade [48] and clinical trials have shown 
significant improvement in various parameters of cardiac function within 120 minutes [49-50].  
However, studies showing that the success of endotoxin adsorption therapy may in fact be due to 
a decreased ability to produce cytokines suggest that cytokine adsorption is still a reasonable 
approach to treating sepsis [51]. 
Lixelle is an adsorbent material originally developed for β2-microglobulin removal to 
treat dialysis-related amyloidosis by Kaneka (Osaka, Japan).  This device, which uses plasma 
perfusion, has been shown to adsorb endotoxin in addition to IL-1β, IL-1 receptor antagonist, IL-
6, IL-8, and TNF.  The combined removal of endotoxin and cytokines has been shown to 
significantly improve patient outcomes [16, 52-54].  Kaneka has also developed a newer 
adsorbent material intended for direct hemoperfusion called CTR which consists of porous 
cellulose particles with a hydrophobic organic compound covalently bound to the surface.  CTR 
has shown an increase in clearance middle molecular weight proteins compared to Lixelle with 
the added improvement of excluding larger molecules not targeted for removal such as albumin 
and fibrinogen [52-53]. 
One example of a direct hemoperfusion cytokine adsorption device is the Microspheres 
Detoxification System (MDS), which uses a plasma filter containing tiny polymer adsorbent 
particles in the ultrafiltrate loop. The MDS is able to reduce circulating TNF concentration by 
80% but has not yet been tested for removal of any other cytokines [55]. Using such tiny 
adsorbent particles presents a unique challenge both in containment [56] and, in the case of 
packed bed devices, in ensuring that high shear rates do not lead to hemolysis [57]. For this 
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reason, most devices that use adsorbents with a diameter of 100 μm or less generally use a 
separate plasma filter or some type of integrated filtration/adsorption device to avoid red blood 
cell contact with the adsorbent material.  
One way of avoiding these problems is to use larger, porous adsorbents like the CTR 
polymer.  Polymer adsorbents in particular provide a key advantage for use in a direct 
hemoperfusion device because of their highly porous nature and subsequent large surface area to 
volume ratio.  Polymerization techniques provide a basis for control over pore size, surface area, 
and particle size [58].  One such polymer, CytoSorb™ (CytoSorbents, Inc.; Monmouth, NJ) [59], 
utilizes a biocompatible coating on the outermost surface of the bead, making it ideal for direct 
hemoperfusion devices.  The preliminary success of this polymer [60] was the basis for the work 
presented in this thesis.  
CytoSorb™ is made up of a polystyrene-poly(divinylbenzene) copolymer.  The spherical 
beads are 300-800 μm in diameter and are made up of pores ranging from 8-50Å.  The small 
pore size not only prevents red blood cells from accessing the internal bead area but also larger 
molecules such as albumin and fibrinogen.  Cytokines, which are middle molecular weight 
proteins, diffuse more easily into the pores and are able to access the inner surfaces onto which 
they can adsorb.  The external surface of the CytoSorb™ polymer is coated with a biocompatible 
polyvinylpyrrolidone coating.  Kellum et. al showed that columns packed with CytoSorb™ were 
able to remove over 50% of circulating cytokine concentrations in just one hour.  Additionally, 
survival time for animals treated with hemoadsorption was 21% longer than for animals 
receiving the sham treatment [61].   
The main goals of this thesis were to create an extracorporeal blood purification device 
capable of treating sepsis using two different and unique approaches.  This project used the 
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investigators’ previous data and experience in cytokine capture and device fabrication to improve 
upon a device capable of removing cytokines that contribute to poor clinical outcomes in septic 
patients.  For the first approach, we characterized cytokine removal using the CytoSorb™ 
polymer and attempted to improve upon cytokine capture dynamics using a variety of 
techniques.  We made modifications to both the polymer beads and the device to increase the 
capture rate of cytokines in our system.  We also incorporated cytokine-specific antibodies onto 
the outer surface of the beads to selectively improve capture of a single cytokine.  The second 
approach used similar techniques to develop a device that primes circulating neutrophils for an 
altered activation state in the setting of immune dysfunction due to sepsis.  We used hollow fiber 
membranes as the substrate for a chemokine that has the ability to shut down neutrophil 
migratory activity.  We measured the presence of the chemokine receptors on the neutrophils to 
determine if the interaction would be sufficient to provide the basis for a new type of therapy for 
sepsis and other related diseases.  
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2.0  CYTOKINE CAPTURE MODEL AND VALIDATION EXPERIMENTS 
Our approach to the treatment of sepsis is based upon a cytokine adsorption device (CAD) 
consisting of polymer beads packed in a column through which whole blood is directly perfused. 
The beads in this device have previously been shown to be effective in removing TNF, IL-6, and 
IL-10, and other middle-molecular weight proteins in both in vitro and ex vivo studies [60, 62]. 
Our goal was to develop a scaled-down device that could be used to compare various types of 
beads quickly and easily. A mathematical model was also concurrently developed in our lab [63] 
which uses a simple analytic expression to predict the removal rate of cytokines by the 
hemoadsorption device. The model required a rigorous validation before it could be used to 
perform simulations of various experimental scenarios. This combined approach of theoretical 
and experimental device design enabled us to determine the most efficient device parameters 
both quickly and without using costly resources such as cytokines and assay kits. We 
experimentally tested the validity of our theoretical model of cytokine capture as well as 
justifying the key assumptions of the model. The results with respect to both the mathematical 
model and the CAD were promising. 
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2.1 OVERVIEW OF THEORETICAL MODEL 
As previously mentioned, a simple mathematical model was developed in our lab [63] which 
uses the following analytic expression to predict the concentration Ci of an individual cytokine i 
over time, t: 


dCi
dt

Q
Vr
1exp
3

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1
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where Q is the volumetric flow rate, Vr is the blood or serum reservoir volume, mb is the mass of 
beads in the column, 

ˆ R  is the weighted radius of beads in the column, and ρ is the density of the 
polymer.  The only unknown parameter in the model is i , which is specific to cytokine i and its 
interaction with the bead pore and outer surfaces.  By definition,   
 iiii KqD
max   (2) 
where Di represents the diffusion coefficient of cytokine i within the beads, qi
max
 is the maximum 
capacity of cytokine i per unit mass of each bead, and Ki is the affinity constant from the 
Langmuir equilibrium adsorption isotherm.  The Langmuir adsorption isotherm describes the 
coverage of a particular adsorbing species on a surface to the concentration of that species in the 
solution from which is it adsorbing at a fixed temperature.  The affinity constant and maximum 
capacity terms in the Langmuir equation describe the strength of interaction between the 
adsorbing species and the surface and the maximum amount of the adsorbing species that can be 
bound on a surface, respectively.  The units of i are cm
2∙ml∙min-1·g-1.  The full derivation of the 
theoretical model can be found in Appendix A.  In the experiments described below, we use the 
model to find the best fit value of i for IL-6, IL-10, and TNF capture experiment data sets.  
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2.2 MODEL VALIDATION EXPERIMENTS 
2.2.1 Introduction 
Here we describe the methods for fabricating the CAD that were used for all cytokine capture 
experiments performed. As was outlined previously, our goal with these devices for this part of 
the project was to develop a scaled-down hemoadsorption device that demonstrated consistency 
and quality of engineering. Our aim was also to use these devices in experiments that would test 
the validity of the theoretical model we have briefly presented. 
One of the assumptions that is inherent in our method of testing the model is that none of 
the other parameters, Q, Vr, mb, or 

ˆ R  have any effect on i for a given cytokine polymer 
combination (ρ remains constant for all CytoSorb™ polymer used).  By varying one of these 
parameters independent of the other three, we were able to test that assumption.  Another 
important assumption of the model is that competing effects from other adsorbing species are 
negligible.  Thus we tested multiple cytokine solutions and one containing beta2-microglobulin, 
the most abundant non-cytokine middle molecular weight protein in serum [64], to determine if 
this assumption was justified.  The last part of the model that needed to be tested was the 
assumption that, in their physiologically relevant concentrations, cytokines cannot saturate the 
beads over the time course of treatment and use only the outermost portion of the beads [65].  
We sought to confirm this by running multiple capture experiments with freshly spiked cytokine 
solutions using a single device.  The device was packed with small beads to further ensure that 
saturation of any size bead within the CAD was not possible. 
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2.2.2 Methods 
2.2.2.1 Device fabrication 
 
The cytokine adsorption device (CAD) consists of a modified commercially available 
cartridge (Sigma; St. Louis, MO) filled with porous CytoSorb™ polymer beads (CytoSorbents; 
Monmouth, NJ).  The packed bead bed is approximately 1 cm in diameter and 2 cm in length and 
when packed with CytoSorb™ beads, contains approximately 1.5 g of wet polymer.  The beads 
were contained within the CAD by two polypropylene or nylon mesh filters (Small Parts; 
Miramar, FL) with 149 μm openings (in the case of the small beads, the mesh was only 
polypropylene and the size was 27 μm).  The filters, sized 1/4” and 5/16”, were glued to the 
manufacturer-supplied end caps using Clear RTV Silicone Adhesive (Permatex; Solon, OH).  
 
 
Figure 1. Filters and completed 1 ml CAD (shown here with tubing barbs). 
 
Figure 1 shows the two filters used in the CAD as well as the completed device.  As the volume 
of the scaled-down devices is approximately 300 times smaller than a device that may be used 
clinically [61], we employed a 300x scale-down factor for our baseline reservoir volume and 
flow rate as well.  The void fraction of a packed CAD is approximately 31%. 
 19 
   
Figure 2. Close-up images of CytoSorb™ polymer (left) and inner pore structure (right). 
 
The beads, seen above in Figure 2, are made up of a polystyrene divinylbenzene (PSDVB) 
copolymer and covered in a biocompatible polyvinylpyrrolidone (PVP) coating.  The chemical 
structures for both PSDVB and PVP can be seen below in Figure 3 (the actual chemical structure 
of the CytoSorb™ polymer is not available).  The beads are approximately 300-800 μm in 
diameter with a density of 1.02 g/cm
3
 and a porosity of 67.7%.  Pore sizes in the beads range 
from 8-50 Å, allowing only smaller proteins to access the inside of the bead and excluding larger 
molecules such as albumin and fibrinogen.  
A)      B)  
Figure 3. Chemical structures of A) polystyrene divinylbenzene and B) polyvinylpyrrolidone. 
 
The column components, once glued and ready to be packed with beads, were massed 
and this initial mass was subtracted from the final mass of the device filled with beads.  The 
specific bead mass of each individual column was then used as mb in the model fits described in 
Section 2.2.2.5.  Ten columns were prepared and the average bead mass was calculated to be 
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1.49 g.  The acceptable range was deemed to be ±5% of this value, from 1.416 to 1.565 g per 
column. 
In one set of experiments, 10 ml CADs were used.  The components for this column were 
also from Sigma and the filters were of the same 149 μm mesh.  Unlike the smaller columns, 
these columns contained two identical end caps into which a dual-sided rubber gasket was 
placed.  The rubber gaskets were made of a 1/16” and 1/32” thick rubber circle with a diameter 
of 9/16”.  In the thicker rubber circle, a concentric 7/16” diameter hole was punched. In the 
thinner rubber circle, a 5/16” hole was concentrically punched.  The 9/16” wide mesh circle was 
glued between the two rubber pieces and two of these completed filter seals were placed in the 
end caps.  The columns were then packed with beads following the same methods as with the 
smaller devices. Figure 4 shows the completed 10 ml device along with the filter seals. 
 
 
Figure 4. Front and back view of filter seals and completed 10 ml CAD 
 
2.2.2.2 General in vitro cytokine capture methods 
 
For each recirculation experiment, an unused CAD was packed with fresh polymer and 
connected in line with a peristaltic pump (Figure 5).  The inlet and outlet tubing ports were 
connected to a reservoir containing 8 ml of horse serum or phosphate buffered saline (PBS) 
spiked with one or more adsorbable proteins.  The reservoir fluid was pumped through the CAD 
at a set flow rate and samples were taken from the reservoir at times t=0, 15, 30, 60, 90, 120, 
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180, and 240 min.  Samples were stored at -70˚C for subsequent assay using enzyme-linked 
immunosorbent assay (ELISA).  Concentrations of IL-6, IL-10, and TNF were determined using 
BioSource ELISA kits (Invitrogen; Carlsbad, CA) according to the instructions of the 
manufacturer.  The concentration of β2-microglobulin was measured using a Quantikine IVD 
ELISA kit (R&D Systems; Minneapolis, MN), also according to the instructions of the 
manufacturer.  
 
Figure 5. CAD loop setup for capture experiments 
2.2.2.3 Model validation experiments 
 
Three trials of each model validation experiment described below were performed, and 
all experimental parameters were set at the baseline values shown below in Table 1 unless 
otherwise specified. 
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Table 1. Description of baseline parameters and their values. 
Parameter name Description Baseline value 
C0 Initial concentration of cytokine, pg/ml 1000 
Q Volumetric flow rate, ml/min 0.8 
R Average bead radius, μm 289.1 
mb Mass of beads in cartridge, g 1.5 
Vr Reservoir volume, ml 8.0 
 
In the first set of experiments, we wanted to test whether the model was able to predict 
changes in cytokine capture rate associated with changes in the model parameters (Eq. 1), 
including the initial cytokine concentration in the reservoir, perfusion rate through the cartridge, 
bead mass in the cartridge, and bead size.  To test the effect of initial cytokine concentration, we 
performed experiments of IL-6 removal using a serum reservoir spiked with either 1000 pg/ml or 
5000 pg/ml, with all other parameters at their baseline values as indicated by Table 1.  Typically, 
cytokine concentrations in septic patients do not exceed 5000 pg/ml.  We tested the effect of 
changes in flow rate by perfusing serum spiked with IL-6 at a flow rate of 0.8 ml/min or 0.08 
ml/min while keeping all other parameters at their baseline values.  We chose to validate the 
model for a flow rate below the baseline value as opposed to above it because capture of IL-6 
falls into an intermediate regime between perfusion and diffusion-limited capture.  Capture is 
more dependent on flow rate at lower perfusion rates whereas at high flow rates, capture 
becomes entirely diffusion limited and independent of flow rate.  
To test the effect of increasing bead mass in the CAD, we measured capture of IL-6 from 
serum using devices containing either 1.5 g or 10 g of the PSDVB beads.  In the case of the 10 g 
device, a reservoir volume of 80 ml and a flow rate of 8.0 ml/min were used in order to 
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accommodate the larger device.  Smaller beads were tested because of the advantage they offer 
due to their greatly increased surface area and the likelihood that such beads would be included 
in the final device design.  We tested the effect of changes to bead size by performing capture of 
IL-6 using 289.1 μm radius beads and 58.4 m radius beads in the CADs.  All other parameters 
remained at their baseline values. 
In the second series of experiments, we tested whether competitive binding effects arise 
due to the presence of multiple adsorbing species, including other cytokines and middle-
molecular weight molecules that can diffuse into the porous beads.  β2-microglobulin (β2-m) was 
chosen as the additional adsorbing species because it is the most abundant middle-molecular 
weight protein in blood that adsorbs onto the CytoSorb™ beads.  We examined whether the 
presence of β2-m affected the capture rate of IL-6.  We performed recirculation experiments 
using IL-6 alone or with an additional 1.5 μg/ml 2-m spiked into a solution of PBS and 50 
mg/ml bovine serum albumin (BSA) with all other parameters at baseline.  To directly examine 
interaction effects between key cytokines of interest, we performed simultaneous IL-6, IL-10, 
and TNF capture from serum with all parameters at their baseline values. 
One final experiment was performed to test whether the small beads became saturated 
over the 4 hour experiment.  One 8 ml aliquot of IL-6-spiked serum was perfused through a CAD 
following the previously described cytokine capture experiment protocol at the baseline 
parameters.  After 4 hours, the reservoir was switched out for a fresh 8 ml aliquot of IL-6-spiked 
serum and this solution was perfused for another 2 hours.  The model fits were obtained as 
previously described for the initial 4 hour capture data.  Next, the ΓIL-6 value from that fit was 
used to plot data for 0≤t≤4 hours.  The initial concentration of IL-6 in the second reservoir was 
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then used as the initial concentration at t=4 hours and IL-6 removal was plotted in the same way 
for 4 hours≤t≤6 hours with the same ΓIL-6 value.  
2.2.2.4 Calculation of average bead radius 
 
Each lot of beads obtained from CytoSorbents, Inc. included a histogram of the percentage of 
beads in the entire lot that fell within a certain range of bead radii, P(R).  The data from these 
histograms could be used to find a weighted average based on the distribution for that particular 
lot using the following relationship: 
  (3) 
However, because the relationship between i  and R is not directly proportional, we chose to use 
an average radius value that was weighted according to how R was used in the theoretical model.  
The adjusted weighted average, 

ˆ R , was then calculated using the following equation: 
 (4) 
We tested the adjusted weighted average against the original weighted average by performing 
model fits with both (see Section 2.2.2.5) and found that using 

ˆ R  provided a better fit (as 
determined by calculating an R
2
 value of the theoretical line to the data points in Matlab) to IL-6, 
IL-10, and TNF capture data. 

R 
P R Rdr
0


P R 
0

 dr
 where P R dr
0

 1

1e
1
ˆ R  1e
1
R P R dr
0


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2.2.2.5 Model fitting and statistical analysis 
 
The concentrations of TNF, IL-6, and IL-10 over time were normalized to the initial 
concentration of each cytokine.  These data were fit to the model by integrating Eq. 1 using 
Matlab so that the change in the reservoir volume due to sampling could be incorporated (see 
Appendix B for full Matlab code).  The integration was subject to the constraint that at t=0 
normalized concentration is 1.  The integrated value of Ci(t) was then fit to the experimental 
data.  The value of i  found to most closely model cytokine removal for each set of data was 
obtained via nonlinear regression using Matlab.  95% confidence intervals for both i  and initial 
concentration were determined along with the R
2
 value for each fit.  The average i  value was 
calculated for each set (n=3) of experiments and compared using a student’s t-test with p<0.05 
denoting a significant difference between two i  values.  
2.2.3 Results and Discussion 
Figure 6 compares IL-6 capture experiments using a serum reservoir spiked with either 1000 or 
5000 pg/ml.  The average 6IL  values obtained over three trials were 1.05E-4±2.34E-5 and 
1.17E-4±3.58E-5 cm
2∙ml∙min-1·g-1 for the low and high concentrations, respectively.  There was 
no significant difference between the average 6IL  values (p=0.63). 
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Figure 6. IL-6 capture data and respective model fits for initial concentrations of 1000pg/ml and 5000pg/ml. The 
model ΓIL-6 fits were 1.05E-4 and 1.17E-4 cm
2∙ml∙min-1·g-1 and were not statistically different (p=0.63). 
 
Figure 7 shows the results of IL-6 capture from serum perfused through the CAD at 
0.8ml/min or 0.08ml/min.  6IL  for the lower flow rate was 1.77E-4±1.62E-4  cm
2∙ml∙min-1·g-1 
and was not significantly different from that for the baseline flow rate (1.05E-4±2.34E-5 
cm
2∙ml∙min-1·g-1, p=0.49). 
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Figure 7. IL-6 capture data and respective model fits for serum flow rates of 0.8ml/min and 0.08ml/min. The model 
ΓIL-6 fits were 1.05E-4 and 1.77E-4 cm
2∙ml∙min-1·g-1 and were not statistically different (p=0.49). 
 
Figure 8 shows IL-6 capture data from serum obtained using a CAD containing either 
1.5g or 10g of beads.  Reservoir volume and flow rate were increased proportionally to the 
increase in bead mass, just as they would be for a full scale-up of the device for use in a clinical 
setting.  The average 6IL  for the larger device was 7.14E-5±4.28E-5 cm
2∙ml∙min-1·g-1, which is 
not statistically different compared to the value for the smaller device (1.05e-4±2.34E-5 
cm
2∙ml∙min-1·g-1, p=0.39).  
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Figure 8. IL-6 capture data and respective model fits for CADs containing 1.5g and 10g of polymer beads. The 
model ΓIL-6 fits were 1.05E-4 and 7.15E-5 cm
2∙ml∙min-1·g-1 and were not statistically different (p=0.39). 
 
Capture of IL-6 from serum in CADs packed with either 289.1μm or 58.4μm radius 
CytoSorb™ beads is shown in Figure 9.  The average 6IL  value was 8.14E-5±5.78E-5 
cm
2∙ml∙min-1·g-1 for the devices packed with the smaller beads; this value was not significantly 
different from that obtained with the larger beads (1.05e-4±2.34E-5 cm
2∙ml∙min-1·g-1, p=0.56). 
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Figure 9. IL-6 capture data and respective model fits for CADs containing 289.1μm and 58.4μm radius polymer 
beads. The model ΓIL-6 fits were 1.05E-4 and 8.14E-5 cm
2∙ml∙min-1·g-1 and were not statistically different (p=0.56). 
 
In Figure 10 capture results are shown for IL-6 in a solution of PBS (pH 7.4) and BSA 
alone or with 1.5μg/ml β2-m.  No statistical difference was found between the average 6IL  
values of 9.59E-5±2.11E-5 and 8.75E-5±5.84E-6 cm
2∙ml∙min-1·g-1 for the experiments with and 
without β2-m, respectively (p=0.29).  Figure 10 also shows that despite its relative abundance in 
the reservoir, β2-m was rapidly removed by the CAD.  
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Figure 10. IL-6 capture data and respective model fits for PBS/BSA reservoirs with or without an additional spike 
of 1.5μg/ml β2-m. The model ΓIL-6 fits were 9.59E-5 and 8.75E-5 cm
2∙ml∙min-1·g-1 and were not statistically different 
(p=0.29). β2-m capture data are also shown. 
 
Cytokine capture experiments were done using serum spiked with TNF, IL-10, and IL-6 
alone or in combination (Figure 11).  The average i  values for each cytokine in the 
multicomponent solution were statistically the same as those of the corresponding cytokine alone 
in solution.  P values for the comparison of i  in single-cytokine and three-cytokine solution for 
IL-6, IL-10, and TNF were 0.99, 0.15, and 0.99, respectively. 
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Figure 11. a) IL-6 capture data alone and in a three-cytokine solution. The model ΓIL-6 fits were 1.05E-4 and 6.22E-5 
cm
2∙ml∙min-1·g-1 (p=0.99). b) IL-10 capture data alone and in a three-cytokine solution. The model ΓIL-10 fits were 
6.66E-5 and 3.69E-5 cm
2∙ml∙min-1·g-1 (p=0.15). c) TNF capture data alone and in a three-cytokine solution. The 
model ΓTNF fits were 5.85E-6 and 9.05E-6 cm
2∙ml∙min-1·g-1 (p=0.99). 
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The last model validation experiment, seen in Figure 12, tested whether or not the small 
beads would saturate over the time course of a typical treatment.  One IL-6 capture experiment 
was performed using all of the baseline parameters except for bead radius.  After 240 min, the 
same device was connected to a fresh reservoir containing 1000 pg/ml IL-6 and perfused for 
another 120 min.  The average ΓIL-6 value for three trails of the saturation experiment was 4.68 ± 
1.51E-4 cm
2∙ml∙min-1·g-1 and, when compared to the baseline IL-6 values, the p value was 0.18. 
 
Figure 12. IL-6 capture data and respective model fit for the small bead saturation experiment. The model ΓIL-6 fit 
was 4.68E-4 cm
2∙ml∙min-1·g-1 and was not statistically different (p=0.18) from the ΓIL-6 value for baseline IL-6 
capture. 
 
The model fit demonstrates that the beads do not saturate after 4h and continue to display 
the behavior predicted by the model.  The i values calculated from all of the model validation 
experiments in this study are shown below in Table 2.   
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Table 2. Γi values for baseline and validation experiments. 
 
Baseline,  1 
cytokine 
Baseline,  3 
cytokines 
C0=5000 
pg/ml 
Q=0.08 
ml/min mb=10g 
ΓIL-6 
1.05E-4 
±2.34E-5 
6.22E-5 
±1.92E-5 
1.17E-4 
±3.58E-5 
1.77E-4 
±1.62E-4 
7.14E-5 
±4.28E-5 
ΓIL-10 
6.66E-5 
±2.27E-5 
3.69E-5 
±2.04E-6 ---- ---- ---- 
ΓTNF 
5.85E-6 
±1.22E-6 
9.05E-6 
±4.71E-7 ---- ---- ---- 
 R=58.4 μm 
IL-6 in 
PBS/BSA 
IL-6+β2-m in 
PBS/BSA Saturation 
ΓIL-6 
8.14E-5 
±5.78E-5 
9.59E-5 
±2.11E-5 
8.75E-5 
±5.84E-6 
4.68E-4 
±1.51E-4 
ΓIL-10 ---- ---- ---- ---- 
ΓTNF ---- ---- ---- ---- 
 
We previously developed a theoretical model that can be used to predict the time course 
of removal of cytokines from extracorporeal circulation through the CAD.  The primary goal of 
this study was to demonstrate experimentally that the model can predict the rate of cytokine 
capture associated with key design variables of the CAD.  These include initial cytokine 
concentration, perfusion rate through the CAD, and the size of the CAD and of its adsorbing 
beads.  Our experiments indicate that over a clinically relevant range of these parameters the 
single unknown model parameter (Γi), which accounts for the specific interaction of a particular 
cytokine i with the adsorbent beads, is statistically unaffected by changes in these parameters.  
The second goal of this study was to demonstrate experimentally that competitive adsorption of 
solutes, which is neglected in the model, does not affect the rate of removal of a given cytokine.  
The results indeed indicate that the presence of either multiple cytokines or relatively high 
concentrations of β2-m had no effect on the capture rate of cytokines. 
The development of our simple model of cytokine capture in the CAD was based on a 
perturbation analysis in which the effects of competitive adsorption of other solutes on cytokine 
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adsorption were predicted to be secondary.  We addressed this experimentally in several different 
ways.  First, we compared the removal rates of IL-6, IL-10, and TNF spiked individually into 
serum to their respective removal rates when spiked collectively into serum.  Γi values for each 
of the three cytokines alone in solution were determined to be statistically the same as Γi values 
for each cytokine in the multiple cytokine solution.  Cytokine levels, however, are relatively 
small (~1000 pg/ml) compared to other middle-molecular weight proteins that can be adsorbed 
within the beads of the CAD.  Accordingly, we also investigated whether the removal rate of 
cytokines could be affected by the presence of β2-m, which is among the most abundant middle-
molecular weight proteins (~1.5 μg/ml) [64].  We compared removal rate of IL-6 spiked 
individually into a solution of PBS and BSA to its removal rate spiked together with 1.5 μg/ml 
β2-m into the same solution.  The ΓIL-6 values in the two solutions were statistically the same.  
Finally, we can also compare the ΓIL-6 value for IL-6 spiked in PBS/BSA solution with that for 
IL-6 spiked in serum, which would specifically account for possible effects of all other serum 
proteins.  ΓIL-6 for capture of IL-6 from PBS and BSA was, which was not significantly different 
from that in serum (9.59e-5 cm
2∙ml∙min-1·g-1 vs. 1.05e-4 cm2∙ml∙min-1·g-1, respectively, see 
Table 2).   
We chose to validate our mathematical model by fitting values of the cytokine-specific 
parameter Γi to removal rate data and comparing those fit values for changes to other parameters 
in the model, as discussed above.  A more fundamental way to validate the model would be to 
measure independently the parameters comprising Γi, which include Di, the effective cytokine 
diffusion coefficient within the beads, and Ki and qi
max
, the Langmuir adsorption isotherm 
parameters.  Measurement of these parameters, however, is neither feasible nor practical.   
Effective diffusion coefficients in polymer matrices are typically measured in a diffusion 
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chamber apparatus in which a cast polymer film separates a solute-containing chamber from an 
initially solute-free chamber.  Our hemoadsorption polymer cannot be cast into films while 
maintaining the same pore morphology as in bead form.  Advanced microscopy techniques based 
on visualizing diffusion of labeled proteins directly within individual beads [66-67] do not 
provide Di independent of the Langmuir adsorption parameters.  Obtaining the Langmuir 
adsorption isotherm in order to determine Ki and qi
max
 is not feasible because the amount of 
cytokine required to reach equilibrium within a measurable amount of bead material is 
prohibitive.  
The model and the experiments did deviate at later time points for the 58.4 μm radius 
beads but not for the 289.1 μm radius beads.  The deviation occurred only after 90% of IL-6 was 
removed, and the ΓIL-6 values were statistically the same for both the large and small beads.  This 
discrepancy may be due to diffusion hindrance caused by partial blocking of the bead pores by 
cytokines that have already adsorbed.  If so, the model could use a variable diffusion coefficient 
that decreases in proportion to the mass of adsorbed cytokine.  Several models for a diffusion 
coefficient decreasing as a function of adsorbed species already exist [68-69].  While unlikely to 
be critical for future applications of the model, studies could be done to incorporate and validate 
a variable diffusivity. 
Our cytokine adsorption device contains a biocompatible polymer and is designed for 
direct whole blood perfusion.  We validated our model using human cytokines spiked into horse 
serum instead of blood.  Our model was developed only to predict the removal rate of cytokines 
from the plasma phase of blood.  Other complexities associated with cytokine release and other 
interactions with cellular components of blood are incorporated in a systems model of cytokine 
dynamics in sepsis being developed by our colleagues [70].  Once validated, our model does 
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apply to blood flow through the CAD provided the flow rate and volume parameters in the model 
(Eq. 1) are those associated with plasma flow and plasma volume.  Horse serum was used rather 
than human serum to avoid the interactions between cytokines and their soluble receptors.  
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3.0  IMMOBILIZATION CHEMISTRIES FOR CYTOSORB™ POLYMER 
3.1 INTRODUCTION 
While our initial focus was nonspecific adsorption of cytokines, we also wanted to develop a 
method of specific removal of one or more ligands.  This technique would allow for an 
additional level of control in the device by targeting one particular cytokine for faster and more 
efficient removal while keeping removal of all other cytokines constant.  We chose to exploit the 
small pore size as a way of immobilizing affinity ligands too large to pass through the pores 
exclusively on the outer surface of the beads.  The overwhelming majority of the available 
surface area for cytokine adsorption would still be free on the inner pore surfaces of the beads 
while the outermost surface would be reserved for specific binding of one cytokine. 
Immobilized ligands have been used extensively in affinity chromatography to improve 
purification efficiency in bead-based columns.  Their usefulness has more recently been 
expanded into a more diverse field of applications, which can be classified into one of the 
following categories according to Hermanson et al [71]:  
1. purification devices to isolate target molecules from complex solutions 
2. scavenging reagents to remove unwanted contaminants 
3. modification or catalysis to effect specific transformations 
4. separation tools to produce analytical determinations 
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The use of immobilized affinity ligands in our cytokine adsorption device (CAD) would 
correspond to the first application listed above.  The complex solution in clinical applications 
would be septic human blood but for our in vitro experiments the solution was simplified to 
serum spiked with the cytokines of interest. 
 The first consideration for any immobilization scheme is the support matrix onto which 
the affinity ligand will be bound.  The matrix can consist of any solid, insoluble substance 
capable of strongly binding, typically through covalent attachment, some type of molecule.  Both 
porous and nonporous beads are commonly used as well as hollow fiber membranes and other 
plastic surfaces and devices (e.g. polystyrene microplates).  The physical and chemical structure 
of the support matrix must be taken into consideration when choosing an appropriate 
immobilization chemistry.  
Typically, the ligand dictates the matrix that is to be used. In our case, however, the 
support matrix is predetermined and we have a very limited number of ligands from which to 
choose.  The physical characteristics of the CytoSorb™ polymer are such that molecules smaller 
than approximately 50 kDa will diffuse into the pores.  Therefore, large molecules such as 
antibodies and spacer arms such as polyethylene glycol (PEG) and poly-l-lysine (PLL) are more 
ideal for immobilization.  
Choosing an immobilization chemistry for the CytoSorb™ beads was also a challenge 
because of their chemical makeup. The beads are made up primarily of polystyrene 
divinylbenzene (PSDVB) with a coating of polyvinylpyrrolidone (PVP).  We have no 
information about the amount of PVP relative to the rest of the polymer or how it is incorporated 
into the chemical structure of the PSDVB.  The beads were independently analyzed in another 
lab using Fourier transform infrared (FTIR) spectroscopy, which confirmed the presence of the 
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double bonded oxygen in the PVP.  The samples also showed evidence of hydroxyl groups on 
the bead surfaces, most likely included to improve the wettability of the otherwise very 
hydrophobic beads [72].  No quantitative data could be obtained from the FTIR analysis.  
We also received several modified CytoSorb™ batches from CytoSorbents, Inc. to test in 
addition to the naked CytoSorb™ polymer.  The first was an aminated PSDVB bead containing 
an unknown amount of amine groups incorporated into the polymer backbone.  The other batch 
of polymer was a carboxylated CytoSorb™ made in the same way as the aminated beads but 
with carboxyl groups.  The purpose of these modified beads was to add functionality to the 
CytoSorb™ beads. 
We tried several different types of immobilization based on the following surfaces: 
polystyrene and surfaces containing carboxyl, hydroxyl, and amine groups.  In some cases, the 
chemistry was tailored to a combination of surface functionalities.  The last and simplest method 
we chose to test was passive adsorption.  The beads are so highly hydrophobic that they adsorb 
small proteins such as cytokines and large proteins such as antibodies very strongly.  
Although the surface density of functional groups like carboxyls and amines can be 
quantified using various assays, these tests do not necessarily correlate to the amount of ligand 
that can be immobilized on the beads.  Testing this is especially difficult for our particular matrix 
because of its size and shape.  Contact angle measurements can be used to test for changes in 
hydrophobicity on a flat surface containing proteins but this assay will not work on spherical 
particles [72].  
Another challenge is the cost of most affinity ligands, which results in the concentration 
of the immobilized ligand being much lower than that which can be detected using conventional 
methods.  Immobilized protein concentration can be easily measured using either bicinchoninic 
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acid (BCA) [73] or Coomassie Blue G-250 (Bradford) reagent [74].  The color change of these 
molecules when incubated with protein concentrations on the order of approximately 1.0 mg/ml 
protein is very stable and directly proportional to the amount of protein immobilized on the 
surface.  Cytokine concentrations in septic patients reach a maximum of only 1-5 ng/ml [60], 
which makes using such high amounts of affinity ligand both cost prohibitive (at approximately 
$2000/mg) and unnecessary.  
We avoided these issues by immobilizing a surrogate ligand that costs much less than 
cytokine-specific antibodies.  We used an immunoglobulin-G type antibody conjugated to 
horseradish peroxidase (HRP), an enzyme critical to the color-changing reaction in enzyme-
linked immunosorbent assays (ELISAs).  We chose this particular enzyme because the color 
change associated with it can be detected at concentrations on the order of pg/ml.  Our goal with 
this simplified assay was to test the various immobilization methods listed below quickly to 
determine a suitable candidate for the development of an affinity-based CAD. 
3.2 METHODS 
3.2.1 Water-soluble carbodiimide activation 
The chemistry chosen for initial modifications to the CytoSorb™ beads was based on that of 
Zammatteo et al. (1996) for modifying polystyrene microwells [75].  All chemicals and reagents 
were obtained from ThermoFisher (Pittsburgh, PA) unless otherwise stated.  The CytoSorb™ 
beads were modified using a ring-opening chemistry which incorporates carboxyl groups into the 
backbone of the polymer (Figure 12).  Note that in Figure 13 the PVP coating is not pictured as it 
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does not participate in the carboxylation.  Potassium permanganate, KMnO4, (5 g dissolved in 
100 ml 1.2N sulfuric acid, H2SO4) was used as the oxidizing agent.  A known mass of wet 
polymer was incubated in a filtered column on a rocker with 20 ml of oxidizing solution.  The 
reaction took place for 2 hours at 65°C and excess manganese oxide was rinsed off using 6N 
hydrochloric acid (HCl) over four 5 minute washing steps.  These washing steps were then 
repeated using DI water.  At that point, beads were assayed for surface density of carboxyl 
groups.  
 
Figure 13. Bead modification chemistry: oxidation of the PSDVB portion of CytoSorb™ 
 beads to incorporate carboxyl groups. Note that this schematic does not account for the presence of the PVP 
coating. 
 
A subpopulation of modified beads was separated to be tested for carboxyl group 
concentration.  We also performed this test on the carboxylated CytoSorb™ beads obtained 
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directly from CytoSorbents, Inc.  Both sets of carboxylated beads were incubated overnight with 
a solution of 0.01M dicyclohexylcarbodiimide (DCC) and 0.01M para-nitrophenol (PNP) in 
pyridine, which crosslinked the bright yellow PNP molecule with the carboxylated polymer.  
Unreacted PNP was washed off with tetrahydrofuran and the beads were incubated for 5, 10, 15, 
30, 45, 60, 90, or 120 minutes with NaOH to release nitrophenoxide into solution.  This initial 
experiment was used to determine the optimal amount of time needed for maximum release of 
nitrophenoxide.  For all subsequent experiments, the NaOH incubation time was set at 2 hours.  
The amount of carboxyl groups (corresponding to the total molar amount of nitrophenoxide in 
solution per unit mass of polymer) was then determined via UV/Vis spectroscopy and Beer’s 
Law using the known extinction coefficient for nitrophenoxide, 1.57E4 M
-1
cm
-1
 [76].  Three 
measurements each of three independent bead modifications were taken and averaged to get the 
average carboxyl group density of the beads. 
Those modified beads not used in the carboxylation assay were activated using the well-
characterized 1-ethyl-3-(3-dimethylaminopropyl)-4-carbodiimide hydrochloride (EDC) 
chemistry (Figure 14) [71].  The beads were incubated 1 hour at room temperature with a 
solution of 24 mg EDC (Sigma; St. Louis, MO) per gram of beads dissolved in 0.1M 2-(N-
morpholino) ethanesulfonic acid (MES) buffer, pH 4.5.  Activation was terminated by rinsing 
several times with MES buffer and DI water.  To complete the immobilization, the activated 
beads were incubated with a 40 μg antibodies per gram of beads in 0.1M sodium phosphate 
buffer at pH=7.0.  The process was completed when remaining active sites were blocked using a 
solution of phosphate buffered saline (PBS) and 0.1% v/v Tween 20.  Following immobilization 
of the antibodies, beads were washed several times with 1.0M NaCl.  The antibody-immobilized 
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beads were then preserved at 4°C in a solution of deionized water and 0.01% v/v thimerosal for 
up to 24 hours before being packed into devices for cytokine capture experiments (see Section 
4.2.2) or assayed for anti-IgG-HRP concentration (see Section 3.2.5). 
 
Figure 14. EDC activation chemistry: preparing carboxyl groups for covalent attachment to exposed amine groups 
on antibodies. 
3.2.2 Cyanogen bromide activation 
Cyanogen bromide (CNBr) activation of hydroxyl-containing matrices was one of the first 
methods of ligand immobilization described [77].  CNBr activation is most commonly used for 
polysaccharide matrices and is still widely used for affinity ligand applications [78-80].  Two 
reactive species are produced in the CNBr reaction, highly reactive cyanate esters and less 
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reactive cyclic imidocarbonates.  We do not know the surface concentration of hydroxyl groups 
on the CytoSorb™ beads but the presence of hydroxyl functionality was confirmed by FTIR 
analysis.  Without knowing the exact chemical structure of the bead surface, the relative 
percentages of each type of reactive group formed cannot be determined.  Both types of binding 
reactions are depicted in Figure 15 [81].  The particular method used for activating the 
CytoSorb™ beads was adapted from that of Hermanson et al. (1992) and is as follows [71].  All 
chemicals and reagents were from ThermoFisher unless otherwise specified. 
 
Figure 15. CNBr activation chemistry: two potential reactions for surface hydroxyl groups on beads. Cyanate esters 
are more highly reactive with the amine groups on ligands to be immobilized. 
 
Approximately 2.0 g of CytoSorb™ beads were put in a test tube and swollen in 0.2N 
NaOH for 1 hour on ice.  Beads were then rinsed with a 50/50 v/v solution of ice cold 
bicarbonate buffer and 0.5M NaCl for 15 min.  Beads were transferred to a beaker containing a 
stir bar and mixed continuously with a solution of 1.0 g cyanogen bromide (CNBr) dissolved in 
10 ml 0.2N NaOH.  The reaction causes pH to steadily decrease until it is complete, therefore the 
pH of the mixture was monitored throughout the reaction and kept above 11.0 by addition of 
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single drops of 10N NaOH.  Similarly, the temperature was continuously monitored and, as the 
reaction is exothermic, temperature was maintained below 25°C by adding ice directly into the 
beaker.  When the pH equilibrated above 11.0 without further addition of 10N NaOH, the beads 
were separated from the liquid and transferred back into a test tube.  Beads were rinsed briefly 
with DI water and bicarbonate buffer before adding 40 μg/g beads in 10 ml of 0.1M sodium 
carbonate buffer (see the next section for details on poly-l-lysine addition in an alternative 
version of this step).  The mixture was then incubated on the rocker at 4°C overnight and washed 
with 1.0M NaCl and DI water the following morning.  Next the remaining active groups were 
blocked by incubating the beads for 1 hour with 1.0M ethanolamine.  The reaction was 
completed once the beads were washed a final time with both 1.0M NaCl and DI water. 
3.2.3 Poly-l-lysine coating 
We aimed to increase the surface functionality as a means of improved antibody immobilization 
by activating the amine termini of a branched spacer arm bound to the unmodified CytoSorb™ 
beads.  The spacer arm we used was poly-l-lysine (PLL), a high molecular-weight linker 
molecule containing many exposed amine groups, ideal for increasing the functionality of the 
bead surface.  Figure 16 shows the branched structure of PLL, whose amine content is dependent 
on the molecular weight of the PLL.  Once again, all chemicals and reagents were obtained from 
ThermoFisher unless otherwise specified. 
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Figure 16. Branched amine-terminal structure of poly-l-lysine (PLL). 
 
PLL can be covalently bound to the unmodified beads using the hydroxyl groups on the 
surface and subsequently cross-linked using glutaraldehyde to terminal amines on the antibodies 
(see Figure 17).  
 
Figure 17. Glutaraldehyde cross linking of an amine bound to a solid substrate and an amine-terminal molecule. 
 
This crosslinking was accomplished using a modified version of the protocol found in Zhang et 
al. (1998) [82].  Prior to immobilization, beads were activated using CNBr according to the 
previously described procedures in Sections 3.2.2.  Once the activation steps were complete, 
beads were washed briefly according to the activation protocol and then incubated with 0.4 mg 
PLL per gram of beads for 4 hours at room temperature.  Two different molecular weight 
polymers were tested initially, 75-150 and 150-300 kDa (both from Sigma).  Beads were washed 
once again with water and sodium phosphate buffer.  Next the beads were incubated for 1 hour 
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with a 10% glutaraldehyde solution and washed thoroughly.  As mentioned above, 40 μg 
antibodies per gram of beads were then added during the immobilization step and incubated for 2 
hours, followed by a brief incubation with a solution of 0.2M glycine and 0.01M 
cyanoborohydride.  Beads were then washed one final time before being assayed for anti-IgG-
HRP concentration or packed into a device for cytokine capture.  In each case, three independent 
immobilizations for each molecular weight PLL were carried out and HRP activity was 
measured three times for each immobilization.  
Another experiment was done in which the amount of antibody during the immobilization 
step was increased three fold.  All bead samples were activated using the CNBr protocol 
previously described.  One set of beads then underwent immobilization with the 3x antibody 
concentration while two other sample sets received the 150-300 kDa PLL spacer arm.  The two 
remaining bead samples were cross-linked to anti-IgG-HRP using the aforementioned 
glutaraldehyde protocol at concentrations of either 40 or 120 μg antibody/g beads.  Each of the 
three bead samples were tested three separate times using the anti-IgG-HRP assay described in 
section 3.2.5.    
3.2.4 Passive adsorption 
Passive adsorption of antibodies was carried out by incubating unmodified beads with 40 μg 
antibodies per gram beads for 2 hours at room temperature in sodium phosphate buffer. The 
washing steps following antibody incubation were performed as described above.  Beads 
containing immobilized antibodies were then used in cytokine capture experiments (as described 
in Section 4.2.2) or assayed for HRP concentration (see Section 3.2.5). 
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3.2.5 Horseradish peroxidase quantitative immobilization assay 
The high cost of cytokine-specific antibodies and time involved in cytokine capture and 
subsequent assays make characterizing the efficiency of immobilization techniques cumbersome.  
The following enzyme-based assay is a more direct quantification technique and dramatically 
reduces the amount of time and resources involved.  Although the theory behind this assay is 
based on that of solid-phase enzyme-linked immunosorbent assay (ELISA), this particular 
protocol is especially similar to that of Mansur et al. (2005) [83].  
Beads containing immobilized or adsorbed anti-IgG-HRP antibodies were split into 3 or 
more samples of approximately 0.2-0.5 g each.  Beads were transferred using a custom-made 
filtered suction tool (shown in Figure 18), which allowed for dehydration of the beads while 
simultaneously ensuring no beads were lost or broken during transfer.  The tool consisted of a 
1/8” diameter metal tube with a hole for controlling suction.  A piece of 1/8” inner diameter 
Tygon® tubing onto which a 139 μm nylon mesh screen had been glued using silicon glue was 
placed on the end of the metal tube.  The tube was then connected to a vacuum pump and liquid 
reservoir. 
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  Figure 18. Filtered suction used for transferring beads to be massed following HRP assay. 
 
Bead samples were placed in glass test tubes and resuspended with a standard ELISA 
buffer solution.  Anti-IgG-HRP standards from 1000 pg/ml to 0 pg/ml were pipetted in duplicate 
into an empty polystyrene 96-well plate (Nalgene; Rochester, NY).  Tetramethylbenzidine 
(TMB) substrate solution was added in equal proportions to both the microwells containing 
standards and the test tubes containing the bead samples, 100 μl for the microwells and 2.5 ml 
for the test tubes.  The HRP was allowed to react with the TMB for 20 min in the dark.  Sulfuric 
acid was then added to the wells and test tubes, again in equal proportions (100 μl and 2.5 ml, 
respectively), to stop the enzyme-substrate reaction.  A small amount of liquid from the test 
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tubes containing bead samples was then diluted with deionized water prior to being pipetted in 
duplicate into microwells.  
The optical density was then read using a ThermoFisher MultiSkan optical density reader 
at 450nm.  HRP concentration in the bead samples was determined using the anti-IgG-HRP 
standard curve.  Values for moles of antibody per mass of beads were determined after 
measuring the mass of the dry beads, again using the suction method for transferring beads.  
Several control experiments were also performed to optimize the anti-IgG-HRP assay.  
The first control experiment tested whether the reaction between the HRP-conjugated antibodies 
was substrate limited by adding in an excess of TMB.  Instead of 2.5 ml of substrate, 4 ml was 
added.  Similarly, 4 ml of sulfuric acid was added to ensure that the reaction was thoroughly 
stopped.  The difference in volume was accounted for when calculating the final HRP 
concentration. 
Another control experiment was done to ensure that the enzyme-conjugated antibodies 
were not affected by the shear stress of the peristaltic pump during the capture experiment.  
Approximately 5 μg/ml of free antibody was added to 8 ml of a 50 mg/ml bovine serum albumin 
in PBS solution and circulated for 1 hour at the following conditions: 0.8 ml/min and 3/32” 
tubing (2 trials), 0.8 ml/min and 3/16” tubing (1 trial), 3.2 ml/min and 3/32” tubing (1 trial), or 
3.32 ml/min and 3/16” tubing (1 trial).  Samples were assayed using the same protocol from 
above for the control samples.  In conjunction with this experiment, the previous methods were 
repeated with a 0.5 mg/ml solution of cytochrome c, a 12 kDa protein whose concentration can 
be measured using a spectrophotometer.  The cytochrome c solution was circulated at 0.8 ml/min 
in 3/32” tubing for one hour.  Absorbance readings at 408 nm over time were compared to a 
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standard curve ranging from 0 to 0.5 mg/ml of cytochrome c to determine the amount of 
cytochrome c in the sham loop. 
The final control experiment for the anti-IgG-HRP assay tested whether any nonspecific 
signal arose from beads containing immobilized enzyme-free anti-IgG antibodies 
(ThermoFisher).  These antibodies are exactly the same as the HRP-conjugated antibodies except 
they contain no HRP and therefore should have no reaction with the TMB substrate during the 
assay.  This experiment was done using passive adsorption of anti-IgG according to the methods 
in Section 3.2.5.  The HRP assay was performed according to the protocol previously described 
and three trials of this control experiment were done. 
For all anti-IgG-HRP assays performed, a two sample student’s t-test was used to test for 
significant differences in surface antibody concentration per mass of beads between samples, 
with p<0.05 denoting a statistically relevant difference.  Three trials of all experiments were 
carried out unless otherwise stated. 
3.3 RESULTS AND DISCUSSION 
A variety of methods were used to test the functionality of the CytoSorb™ beads as a support 
matrix for an affinity ligand.  The results presented here will be applied in Chapter 4 to 
selectively increase capture of one cytokine independent of the capture of other molecules. 
CytoSorb™ beads were chemically modified to introduce carboxyl (COOH) functionality 
using potassium permanganate-mediated oxidation.  We used a colorimetric assay to determine 
the concentration of carboxyl groups on the polymer surfaces following modification of the 
beads.  Our first step was to optimize the incubation time of the modified beads containing PNP 
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with NaOH to achieve the maximum release of the yellow colored molecule nitrophenoxide.  
Figure 19 shows the results of this optimization experiment, with a net absorbance plateau 
(change of less than 3%) after 2 hours when compared to the PNP-free control.  
 
  Figure 19. Optimization of timed NaOH incubation step for colorimetric COOH assay. 
 
Thus, we chose to use 2 hours as the incubation time for all subsequent carboxylation assays.  
The average surface density of COOH groups achievable using the KMnO4 oxidation method on 
CytoSorb™ beads was 5.17 μmol COOH/g polymer.  The same assay, when performed on the 
pre-carboxylated CytoSorb™ beads yielded 39.8 μmol COOH/g polymer.  We used a 
carboxylation method intended for pure polystyrene on the polystyrene-divinylbenzene 
CytoSorb™ beads, which resulted in a two order of magnitude decrease in carboxylation of our 
beads versus pure polystyrene [76].  The EDC activation was carried out with only the oxidized 
beads modified in our lab because of a limited supply of pre-carboxylated CytoSorb™ beads.  
However, as seen below in Figure 20, the level of activation resulted in a ten times lower HRP 
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concentration compared to the passive adsorption method.  The average efficiency for EDC 
activation is 80% [71], which means that the more highly carboxylated beads would still not be 
able to match the amount of antibodies bound with passive adsorption. 
To expedite testing of these and other types of modified beads, we used a direct assay 
technique to quantify antibody concentration on a solid matrix.  An enzyme-based antibody 
assay was used to compare levels of bound or absorbed antibodies for the following 
immobilization methods: EDC-mediated immobilization on carboxylated beads, CNBr activated 
beads, and passive adsorption beads.  The results, in moles of HRP per gram of beads, can be 
seen compared to the value for naked CytoSorb™ beads in Figure 20.  The passive adsorption 
beads showed significantly higher levels (p<0.001) of adsorbed antibody compared to all other 
types of immobilization.  The values were as follows for each type of bead: EDC-activated, 8.06 
± 0.84 e-13 mol Ab/g beads; CNBr-activated, 5.47 ± 0.64 e-12 mol Ab/g beads; passive 
adsorption, 9.64 ±. 0.46 e-12 mol Ab/g beads.  For each HRP assay performed, the inter-assay 
variability between trials of the same bead samples was kept below 15%.  
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 Figure 20. HRP assay data for EDC-activated, CNBr-activated, and passive adsorption beads containing anti-IgG-
HRP antibodies. 
 
We attempted to improve the efficiency of antibody immobilization by increasing the 
number of functional groups on the surface of the beads.  To accomplish this we attached two 
different molecular weight polymers of PLL, 75-150 and 150-300 kDa.  Beads were activated 
with CNBr to bind the PLL and then glutaraldehyde was used to cross link the terminal amines 
on the PLL with the amine groups on the antibodies.  Figure 21 shows the antibody 
concentration values obtained from three trials of each type of PLL/antibody linkage: 1.61 ±. 
0.19 e-12 and 2.94 ±. 0.03 e-12 mol Ab/g beads for the low and high molecular weight PLL, 
respectively.  The higher molecular weight PLL showed significantly higher levels of antibody 
binding (p<0.001) compared to the lower molecular weight version. 
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Figure 21. HRP assay data for low and high molecular weight PLL spacer arms incorporated onto CNBr-activated 
beads containing immobilized anti-IgG-HRP. 
 
Surprisingly, both sets of PLL data indicate lower levels of antibody binding than the 
CNBr activation data in Figure 20.  We hypothesized that binding in this case was limited by the 
amount of antibody in solution and not by the amount of functional groups available.  We tested 
this hypothesis by comparing the amount of anti-IgG-HRP bound on the surface of four types of 
modified beads: direct attachment of antibodies at a one-fold or three-fold antibody 
concentration and high molecular weight PLL plus one-fold or three-fold antibody concentration.  
Our goal was to show that HRP concentration on the bead surface could be increased by 
increasing the amount of antibodies added.  The results, seen in Figure 22, were 9.18 ± 1.54E-12, 
1.39 ±. 0.14E-11, and 1.37 ±. 0.09E-11  mol Ab/g beads for the 3x direct attachment, 1x PLL 
attachment, and 3x PLL attachment methods, respectively.  Compared to the 1x direct 
attachment using CNBr activation (5.47 ±. 0.64E-12 mol Ab/g beads), both the one- and three-
fold antibody concentration on the PLL-coated beads showed a significant increase in surface 
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HRP concentration (p<0.01).  Only the direct attachment beads showed a statistically significant 
difference between the two antibody concentrations (p<0.01), whereas the PLL-coated beads 
were not statistically different for the two antibody concentrations (p>0.3).  This further proves 
that the hypothesis was incorrect and that the PLL-coated beads are in fact limited by the number 
of functional groups.  The differences between antibody concentration in Figure 21 and Figure 
22 on the normal antibody concentration beads containing PLL may be due to the added 
variability of introducing more bead processing steps for the two-part immobilization.  Had we 
chosen to continue using PLL-coated beads as the substrate for antibody immobilization, this 
technique would have needed to be refined to reduce this variability. 
 
Figure 22. HRP assay data for one- and three-fold antibody concentration conjugated to beads with and without 
high MW PLL spacer arm. 
 
We also performed several control experiments to help ensure the validity of the HRP 
assay results.  First, we tested whether the assay would detect a significant nonspecific signal 
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when testing beads that contained immobilized anti-IgG antibodies that were not conjugated to 
HRP.  Only 3.25 ± 0.22E-15 mol Ab/g beads were detected in the HRP-free beads.  The 
conclusion from this experiment is that the nonspecific signal from the antibodies is negligible 
(<0.1% of specific signal). 
The next control experiment tested whether or not the enzyme-conjugated antibodies 
were affected by the shear stress of the peristaltic pump during the experiment.  Experiments 
with dextransucrase and penicillinase suggest that, at the shear rates under which we operate our 
experiments, enzyme activity will not be significantly affected [84-85].  To test this hypothesis, 
the reservoir was spiked with anti-IgG-HRP antibodies and perfused through the pump loop in 
two different tubing sizes at two different flow rates; no columns or beads were used in this 
experiment.  The four test conditions along with the corresponding shear rates are listed in Table 
3.  
Table 3. Experimental conditions for HRP shear experiment. 
Tubing inner diameter, d Flow rate, Q (ml/min) Shear rate, γ (s-1) 
3/32” 0.8 ml/min 10.1 
3/16” 0.8 ml/min 40.2 
3/32” 3.2 ml/min 1.26 
3/32” 3.2 ml/min 5.03 
 
The shear rates in Table 3 were calculated using the following equations, derived from the 
Poiseuille equation for laminar flow in a cylindrical tube of radius r [86]:  

 
8Va vg
2r
   where   Va vg 
Q
r2
 (5) 
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The results can be seen in Figure 23: over the 1 hour perfusion, anti-IgG-HRP concentration 
decreased an average of 9.1%, from 100 to 90.9 ± 3.0%.  No significant difference in loss of 
HRP concentration was observed for changes in tubing diameter or flow rate (p>0.25 and 
p>0.35, respectively). 
 
Figure 23. Anti-IgG-HRP concentration over time in sham circuit with varying flow rates and tubing sizes. 
 
This decrease most likely corresponds to nonspecific adsorption of antibodies onto the 
pump tubing over time and would support the hypothesis that shear rate in the pump loop does 
not significantly affect enzyme activity.  To confirm that nonspecific adsorption onto the tubing 
could in fact cause this level of protein loss, we measured cytochrome c concentration in a 0.5 
mg/ml cytochrome c in buffer reservoir circulated through the pump loop and no device for one 
hour.  We chose cytochrome c because its concentration can be accurately measured using a 
spectrophotometer in the range of μg/ml.  UV/Vis measurements of the reservoir solution over 
time show that 14.0 ± 0.29 μg of cytochrome c was lost after one hour.  These data suggest that 
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the loss of anti-IgG-HRP in the sham circuit is due to adsorption onto the tubing and not a loss of 
enzyme activity. 
The last control experiment for the HRP assay tested whether the enzyme reaction in our 
standard protocol was substrate limited.  According to the Michaelis-Menten model for enzyme 
reaction kinetics, the rate of an enzymatic reaction depends on the substrate concentration up to a 
finite substrate concentration value, at which point the rate is constant (Figure 24) [87].  
 
Figure 24. Michaelis-Menten kinetics. Assumes a constant HRP concentration. 
 
Our goal was to perform the assay in the substrate concentration-independent region to maintain 
consistency across experiments.  To test the hypothesis that the assay was not substrate limited, 
we increased the amount of TMB added to the HRP-conjugated antibody beads.  Figure 25 
demonstrates that the antibody concentrations of the normal and high TMB concentration trials 
were significantly different (p<0.05), at 9.64 ± 0.46E-12 and 3.70 ± 2.2E-12 mol Ab/g bead, 
respectively.  The high TMB concentration samples consistently showed significantly lower 
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HRP concentration and significantly higher variability, with a coefficient of variation of over 
50%.  Our hypothesis is that the higher liquid volumes associated with the increased TMB 
substrate addition contributed to higher variability and a decreased ability for the enzyme-
substrate reaction to take place.  
 
Figure 25. HRP assay results for normal versus high TMB volume. 
 
Our initial goal was to covalently bind the antibodies to the beads but we were not able to 
achieve satisfactory results using any of the covalent binding methods.  The low level of 
modification during the carboxylation procedure was most likely due to the PVP coating on the 
beads.  One gram of beads has a total surface area of 850 m
2
, only 0.088 m
2
 of which is exposed 
outer surface area. The carboxylation procedure does not distinguish between the inner and outer 
bead surfaces, meaning that only about 1/10,000 of the total amount of functional groups is 
available for antibody or PLL binding. This factor, combined with the low level of 
carboxylation, results in the lack of effectiveness of covalent binding.  Similarly, we hypothesize 
that the inclusion of PLL was ineffective because hydroxyl groups are not present in high enough 
quantities on the bead surface to achieve optimal binding. 
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We developed a novel assay method for quantifying protein attachment to a solid matrix 
using an enzyme reaction and subsequent color change to directly detect the immobilized 
antibody concentration.  This method is similar to that described in Mansur et al. (2005) [83]; 
however, Mansur et al. added the enzyme-conjugated antibodies to microwells containing pre-
massed samples of modified silica gel without washing the samples before adding the substrate 
which may result in a significant nonspecific signal.  Our method avoids this issue by eliminating 
the need for extra washing steps as all samples are thoroughly washed prior to their being 
assayed.  The main advantages of this assay are the antibodies, which are much less costly than 
anti-TNF, and the time involved in performing the assay, which is under thirty minutes.  
Although the assay itself does not distinguish total antibody concentration from functional 
antibody concentration (i.e. those oriented with their antigenic site exposed), this assay is a much 
more direct way of qualifying antibody coverage than basing such measurements on cytokine 
capture results.  The activity of the enzyme may be affected by adsorption to the beads, but any 
decrease in enzyme activity due to adsorption would have been most evident in the adsorption-
only beads.  In fact these beads showed significantly higher levels of anti-IgG-HRP, indicating 
that enzyme activity was not significantly affected by adsorption to the beads.  We also assume 
that any effects from antibody or enzyme aggregation during the adsorption or immobilization 
steps would occur in all bead types equally and thus not affect the overall results.  
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4.0  IMPROVING TNF CAPTURE WITH BEADS CONTAINING ANTI-TNF 
The usefulness of blood purification, either filtration or adsorption of blood or plasma 
proteins, as a treatment for sepsis lies in its ability to remove a broad range of molecules rather 
than targeting single mediators.  Our group is currently developing a hemoadsorption device to 
treat severe sepsis by depleting circulating levels of pro- and anti-inflammatory cytokines.  This 
cytokine adsorption device (CAD) consists of a column packed with biocompatible CytoSorb™ 
polymer beads (CytoSorbents, Inc.; Monmouth, NJ), whose effectiveness for cytokine removal 
has been demonstrated in both in vitro and ex vivo experiments [60, 62].  
As seen in Chapter 2, we have modeled the performance of the beads and the device 
based on data obtained during scaled-down cytokine capture experiments for the cytokines 
interleukin-6 (IL-6), tumor necrosis factor (TNF), and interleukin-10 (IL-10).  Our results 
indicate that the beads remove almost 90% of middle-molecular weight proteins such as IL-6 and 
IL-10 (18-21 kDa) after 4h, but only 50-60% of the relatively large TNF trimer (52 kDa) [88].  
This result is not surprising due to the limited range of pore sizes available on the surface of the 
CytoSorb™ beads as the pores are designed to exclude larger molecules such as albumin (66 
kDa) and fibrinogen (340 kDa).  Lixelle (Kaneka Corporation; Osaka, Japan), an alternative 
adsorbent material being tested to treat hypercytokinemia, has shown only 20% removal of TNF 
in 4h using the same experimental setup as with the CytoSorb™ beads (unpublished data).  Our 
conclusion is that beads which target cytokines nonspecifically are not capable of removing TNF 
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at comparable levels to smaller cytokines while maintaining their ability to exclude larger 
proteins. 
Increasing removal of TNF within our device is of particular interest, as sustained high 
concentrations of TNF are negatively correlated with survival in septic patients [89].  
Neutralization of TNF in small animal sepsis models using soluble receptors and monoclonal 
antibodies has been shown to reduce mortality [90-91] and several candidates from each 
category of TNF-specific antagonists have been tested in clinical trials since 1993.  A review of 
these trials demonstrates that no statistically significant improvement in patient mortality has 
been observed; in some cases, survival rates were actually significantly better in the placebo 
group [92].  Many argue that these therapies have failed because they make no distinction 
between patients requiring immune suppression and those requiring immune augmentation, due 
to issues such as type of infection, timing, and severity of insult [93-94].  Our approach currently 
provides for either type of immunomodulation for smaller pro-inflammatory and anti-
inflammatory cytokines.  We hypothesized that a combined approach of specific and non-
specific cytokine capture would selectively increase capture of TNF to levels comparable to 
those of other cytokines, thus further increasing the efficacy of our device. 
The main goal of this study was to use the immobilization techniques and conclusions 
found in Chapter 3 to accelerate the rate of removal and overall capacity for TNF capture by 
immobilizing anti-TNF on the outer surface of the beads in the CAD.  We also explored ways of 
minimizing nonspecific binding, which is discussed in detail in Section 4.1.  Lastly, we 
characterized the retention of the passively adsorbed antibodies to evaluate treatment with a 
CAD containing adsorbed anti-TNF beads from a safety perspective. 
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4.1 NONSPECIFIC BINDING 
4.1.1 Introduction 
Nonspecific binding refers to any ionic or hydrophobic interactions which lead to adsorption of 
ligands on a surface onto which they are meant to be covalently bound [95].  For proteins, high 
levels of nonspecific binding are more likely with increasing hydrophobicity of the surface.  
Nonspecific binding is undesirable because it can decrease the efficiency of the covalent 
immobilization as well as cause safety issues due to leaching of the ligand into the bloodstream 
of the patient [96].  
Several methods have been used in applications similar to ours to minimize nonspecific 
binding. The simplest of these methods is to change the wash solution used once the 
immobilization is complete. Depending on the ligand and matrix combination, high or low pH 
wash solutions may be used along with varying salt concentrations [97-98].  Immunoglobulins in 
particular adsorb most readily at a pH of 7-10 and therefore wash buffers outside of that range 
may cause nonspecifically bound antibodies to desorb [99].  
Blocking agents make up another method of controlling nonspecific binding.  Two types 
of blocking agents are typically used for this purpose.  The first is a protein solution typically 
consisting of serum albumin, fetal calf serum, casein, or dilute skim milk [99].  These proteins 
are meant to adsorb to the nonspecific binding sites either before or after the ligand 
immobilization.  If used before immobilization, potential adsorption sites become unavailable 
and the ligands are more likely to become covalently attached.  When protein blocking solutions 
are used after immobilization, the intent is to competitively adsorb the blocking agent and 
displace the nonspecifically bound ligand.  
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The second type of blocking agent technique uses nonionic detergents such as Tween or 
Triton.  These molecules are typically low molecular weight and amphiphilic, resulting in their 
being able to effectively displace weakly bound proteins.  In contrast to protein blockers, 
detergent blocking agents mainly work by preventing hydrophobic adsorption and aggregation.  
Thus the detergents are usually added with the ligand directly during the immobilization or are 
used immediately following the immobilization [99].  
Nonspecific binding can be quantified by performing all of the steps of covalent 
immobilization without adding any of the activating reagent (e.g. CNBr, EDC, glutaraldehyde).  
Based on the methods described in Section 3.2, the passive adsorption results can be considered 
a measure of the degree of nonspecific binding for any of the activation methods.  As seen in the 
data presented in Section 3.3, passive adsorption consistently showed higher levels of anti-IgG-
HRP binding than any of the other methods.  This suggests that nonspecific binding is the 
primary method of antibody attachment on the CytoSorb™ polymer.  This result is not surprising 
because CytoSorb™ beads are intended to nonspecifically adsorb protein from blood and 
therefore highly susceptible to these effects during covalent immobilization.  
In this section we detail the methods used to minimize nonspecific binding.  We tried 
several different types of wash solutions and blocking agents as well a more sophisticated 
methods using polyethylene glycol (PEG) coating.  The first of these specialized methods uses 
PEG, polymerized ethylene oxide which has been widely used as a spacer arm for connecting 
various ligands and surfaces [96, 100].  PEG is attractive for this purpose because it can be 
modified to contain various terminal functionalities such as amine or carboxyl groups [101-103].  
Additionally, PEG is hydrophilic which contributes, along with the increased steric hindrance of 
proteins, to decreased adsorption to the original matrix [96, 104]. 
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 In this section we have also quantified the amount of ligand leached off of the beads over 
time.  Our goal was to minimize or eliminate ligand leaching using two different methods: 
glutaraldehyde cross-linking of adsorbed antibodies and photoactivated insertion of antibodies 
into the polystyrene backbone of the beads.  Both methods are meant to secure the antibodies to 
the beads following their adsorption in order to increase the stability of the adsorbed antibodies 
without using covalent attachment methods.  In section 4.2, the results of these experiments are 
expanded further and applied to cytokine capture. 
4.1.2 Methods 
The first and simplest method of controlling nonspecific binding that we tested was varying the 
wash solution following the immobilization of antibodies.  Antibodies were passively adsorbed 
onto the beads following the previously described protocol in section 3.2.4.  Briefly, 40 μg rat 
anti-human TNF antibodies or anti-human IgG-HRP conjugated antibodies (both from 
Invitrogen) per gram of beads were spiked into 10 ml of phosphate buffered saline (PBS) and 
added to a filtered reaction vessel containing a known mass of beads.  The bead suspension was 
allowed to incubate for 2 h on a rocker.  Immediately following the incubation, beads were 
washed according to one of several wash solution sequences, as listed in Table 4. In each case, 
four separate 5 min rinses with 10 ml of each reagent listed were performed. 
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Table 4. Washing steps used in nonspecific binding experiments. 
Experiment 
number 
Wash steps performed Other 
1 0.5% Tween 20 
DI water 
N/A 
2 0.5% Tween 20 
1.0M NaCl 
DI water 
N/A 
3 0.5% Tween 60 
1.0M NaCl 
DI water 
N/A 
4 2% Tween 20 
1.0M NaCl 
DI water 
2% Tween 20 added during 
adsorption step 
5 2% Tween 20 
1.0M NaCl 
DI water 
N/A 
6 2% Tween 60 
1.0M NaCl 
DI water 
N/A 
7 ELISA wash buffer (see table 6) 
DI water 
N/A 
8 0.5% Tween 20, 0.5M NaOH, 1.5M NaCl 
DI water 
0.1% Tween 20 added 
during adsorption step 
 
Three trials of each washing protocol were carried out with samples of either anti-IgG-HRP or 
anti-TNF antibody-conjugated beads.  In experiments 4 and 8, an additional aliquot of Tween 20 
was spiked into the antibody-buffer solution during the adsorption step.  The wash buffer used in 
experiment 7 was the standard enzyme-linked immunoassay (ELISA) wash buffer, and the 
reagents used can be found in Table 6.  
 Another method we used to reduce nonspecific binding was pre-adsorption of bovine 
serum albumin (BSA) onto the beads before carrying out the antibody immobilization.  To do 
this, beads were incubated with 10 ml of a 7% BSA in PBS solution for 2 hours on a rocker.  The 
BSA solution was then drained and beads were incubated for 2 hours with anti-TNF antibodies 
before being washed four times each with 0.5% Tween 20, 1.0M NaCl, and DI water.  
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 We also sought to determine if nonspecifically bound antibodies could be displaced by 
BSA.  Anti-TNF antibodies were incubated with the beads following the passive adsorption 
procedure and beads were then washed with 0.5% Tween 20, 1.0M NaCl, and DI water.  Next, 
10 ml of 7% BSA in PBS was added to the beads and the suspension was incubated on the rocker 
for 2 hours.  Beads were then once again washed with 0.5% Tween 20 and DI water. 
 PEG is commonly used to decrease the hydrophobicity and consequently the level of 
nonspecific binding of some surfaces.  We conjugated PEG to CytoSorb™ beads which were 
carboxylated according to the methods in section 3.2.1.  The beads were oxidized with potassium 
permanganate to incorporate COOH groups into the polystyrene backbone at a level of 5 μmol 
COOH groups/g beads (see Figure 13).  We conjugated 617 Da carboxy-amine PEG 
(ThermoFisher; Pittsburgh, PA) to the carboxyl groups using the same EDC-activated 
immobilization methods described in section 3.2.1 (Figure 14).  The structure of this particular 
PEG molecule, which can be seen in Figure 26, is 46.8 Å long and contains 12 ethylene glycol 
subunits and both one carboxyl and one amine terminus. 
 
Figure 26. Chemical structure of carboxy-amine polyethylene glycol (PEG). 
 
Once conjugated to PEG, the beads were washed with 0.5% Tween 20 and DI water. Anti-TNF 
antibodies were then coupled to the PEG spacer arms using EDC activation of the exposed 
COOH end the same way as previously described for the beads themselves.  The beads were 
once again washed with Tween 20 and DI water.  These PEG-coated beads were compared to 
TentaGel (Rapp Polymere; Tübingen, Germany), a commercially available polystyrene resin 
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coated in 0.2-0.6 mmol carboxyl-terminated PEG/g polymer.  These beads served as the positive 
control for PEG binding.  According to the manufacturer, this resin has an average diameter of 
300 μm with a density of 1.11 g/ml and a binding capacity of 4 nmol/bead.  Antibody 
immobilization on these beads and subsequent bead washing was carried out in the same way as 
with the CytoSorb™ polymer using the EDC activation protocol from section 3.2.1.  We also 
tested the TentaGel beads for nonspecific binding by passively adsorbing anti-TNF antibodies 
for 2 hours and washing with Tween 20, 1.0M NaCl, and DI water.  As a negative control, we 
used TentaGel containing no PEG spacer arms and hence no functional groups for activation and 
covalent immobilization.  These polystyrene beads were tested for their ability to capture TNF 
with no antibodies as well as for nonspecific binding of anti-TNF as previously described. 
 We investigated antibody binding to the TentaGel beads further by modifying the 
activation chemistry.  Two separate 2 g samples of TentaGel were activated with 0.479 g of EDC 
dissolved in 2-(N-morpholino)ethanesulfonic acid (MES, ThermoFisher) buffer as before.  An 
additional 0.288 g of N-hydroxysuccinimide (NHS, ThermoFisher) were dissolved in only one of 
the samples.  NHS has been shown to increase the efficacy of water-soluble carbodiimide 
activation by stabilizing the amine-reactive intermediate formed during activation [83].  Both 
samples were incubated on the rocker for 15 min before being washed briefly with MES buffer 
and sodium phosphate buffer.  Next 80 μg of anti-TNF were added to each bead sample and 
allowed to incubate at room temperature for 2 hours.  Beads were finally washed with 0.5% 
Tween 20 and DI water.  This process of activation using EDC and NHS was repeated for the 
carboxylated CytoSorb™ beads as well and the results were compared to those of the TentaGel.  
 The final experiment in the series of PEG and TentaGel studies tested the hypothesis that 
the EDC activation altered the hydrophobicity of the bead surface and therefore resulted in lower 
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nonspecific binding.  To test this theory, we attempted to cap the terminal amine groups on anti-
TNF antibodies in solution with acetic acid.  First, 100 μl of glacial acetic acid (ThermoFisher) 
was added to a 5 ml solution of MES buffer containing 1.59 g EDC.  This mixture was allowed 
to incubate for 15 min on the rocker before 1 ml was added to 80 μg anti-TNF in 6 ml of sodium 
phosphate coupling buffer.  This solution was incubated on the rocker for 3 h and then combined 
with 2 g of carboxylated CytoSorb™ beads suspended in 4 ml of coupling buffer.  The same 
steps were also performed without the addition of EDC in the initial activation of acetic acid as a 
negative control. 
 Three trials of cytokine capture were performed for all of the above mentioned 
experiments when anti-TNF was the ligand used in immobilization or adsorption.  The methods 
used in each capture experiment were the same as described in Section 2.2.2.2 and only TNF was 
spiked into the 8 ml horse serum aliquot.  Once again, ELISA was used to measure TNF 
concentration over time and the results were normalized to initial concentration of TNF.  The 
theoretical model presented in Chapter 2 could not be used to obtain Γi values as a means of 
comparison of different techniques because these experiments involved affinity-based cytokine 
capture.  
 For any of the above experiments in which anti-IgG-HRP antibodies were bound instead 
of anti-TNF, the relative amount of antibody bound was determined using the anti-IgG-HRP 
assay described in Section 3.2.5.  Small samples of beads were incubated with 
tetramethylbenzidine (TMB) substrate and the subsequent color change in the liquid was 
measured using a microplate reader.  Beads were massed using the filtered suction tool and the 
average mol HRP/g bead values over three trials were compared using a student’s t-test, with 
p<0.05 denoting a significant difference. 
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 We also characterized the relative strength of antibody binding by measuring the amount 
of antibody that leached off of the beads over time.  Anti-IgG-HRP antibodies were adsorbed to 
the beads using the aforementioned protocol and washed with Tween 20 and DI water as 
previously described.  Approximately 1.5 g of anti-IgG-HRP beads were then packed into a 
cytokine adsorption device (CAD) and connected to a peristaltic pump.  A solution of 50 mg/ml 
BSA in PBS was perfused through the column for up to 4 h and 100 μl samples were taken from 
the reservoir over time.  The samples were then diluted either 5, 10, or 20 times based on the 
expected concentration and 100 μl of the dilute samples were pipetted into a polystyrene 
microplate.  Next 100 μl of TMB substrate was added to each sample and allowed to incubate for 
30 min in the dark at which time 100 μl of sulfuric acid was added to stop the reaction.  The 
absorbance was then measured at 450 nm in a microplate reader and the results were plotted as 
total mass based on the liquid volume of the original sample after adjusting for dilution.  The 
concentration of bead-bound HRP prior to performing the PBS perfusion was also measured 
using the HRP bead assay in Section 3.2.5 and used to calculate the overall percentage of 
antibody lost in each experiment. 
In section 3.2.3, the method of immobilization via glutaraldehyde cross-linking was 
presented.  To control leaching of antibodies from the beads, we employed a similar method with 
the only difference being that the actual glutaraldehyde activation and amine crosslinking was 
done once the antibodies were already allowed to adsorb to the beads.  Passive adsorption was 
carried out exactly as specified in section 3.2.4, by incubating 40 μg antibody/g beads in sodium 
phosphate buffer for 2 hours at room temperature.  Beads containing anti-IgG-HRP antibodies 
were then washed with DI water and 1.0M NaCl before being incubated with 10% 
glutaraldehyde in sodium phosphate buffer.  The reaction was allowed to take place for 1 hour at 
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room temperature. Beads were again washed with coupling buffer and then incubated briefly 
with a 0.2M glycine/0.01M sodium cyanoborohydride solution.  The beads were washed once 
more with coupling buffer and DI water before being tested for leaching of anti-IgG-HRP 
antibodies over time as described above. 
We tried one other alternative method for immobilizing anti-IgG-HRP on the beads that 
involved a photochemical coupling group containing an amine functional group on one end.  
Figure 27 shows the chemistry that we used in this reaction in a protocol adapted from 
Hermanson et al (1992) [71].  The photoactivating molecule we used couples to amine groups on 
proteins and then nonselectively inserts itself into the plastic substrate upon irradiation with UV 
light.  This method differs from previous activation methods in that the antibodies are activated 
rather than the substrate. 
 
  Figure 27. Photoactivated insertion of amine-containing molecule into solid substrate. 
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Briefly, 200 ug of anti-IgG-HRP were reacted with 0.007 mg sulfosuccinimidyl-6-(4’-
azido-2’-nitrophenyl-amino)-hexanoate (sulfo-SANPAH, ThermoFisher) dissolved in 2 ml 0.1M 
sodium phosphate buffer, pH 7.2.  The reaction is allowed to proceed in the dark at 4°C 
overnight on a rocker.  The protein solution was then desalted using a desalting column 
according to the instructions of the manufacturer.  The desalting columns were placed in 15 ml 
conical test tubes and centrifuged at 1000 x g for 2 min before adding 1 ml of sodium phosphate 
buffer and repeating the centrifugation.  This preparatory step was repeated three more times to 
condition the desalting media for the buffer solution in which the antibody was dissolved.  
Finally, up to 600 μl of the antibody solution was pipetted into the middle of the column and 
spun down once more before discarding the column.  The purified antibody solutions were 
recombined and protected from light as they were added to test tubes containing approximately 2 
g of CytoSorb™ beads.  The beads and antibodies were incubated for 30 min at 37°C.  The bead 
suspension was then poured into a reaction vessel lined with aluminum foil and irradiated with 
365 nm UV light for 5 min while being continuously agitated.  The beads were then poured back 
into test tubes and washed four times with 0.05% Tween 20 in PBS.  Once the washing steps 
were complete, the beads were packed into CADs and tested for leaching of anti-IgG-HRP in the 
same way as described above for the passive adsorption beads. 
4.1.3 Results and Discussion 
In this section we investigated methods of reducing nonspecific binding of anti-TNF or anti-IgG-
HRP to CytoSorb™ beads during covalent immobilization.  The highly hydrophobic nature of 
the beads makes them susceptible to high levels of protein adsorption.  We also attempted to 
quantify the amount of adsorbed antibody that leached off of the beads.  Several techniques were 
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used to minimize the loss of adsorbed antibody as well.  Although nonspecific binding is usually 
characterized by performing the immobilization steps with no activating agent (e.g. cyanogen 
bromide, EDC, or glutaraldehyde), we simplified this process by starting each experiment with 
passively adsorbed antibodies on otherwise unmodified beads. 
We first sought to minimize nonspecific binding by using a more rigorous washing 
protocol.  Figure 28 shows the results of one such experiment which tested two different types of 
detergents, Tween 20 and Tween 60 (which differ only in the length of the fatty acid chain 
connected to the polyoxyethylene sorbitate molecule of the detergent) as well as the inclusion of 
a 1.0M NaCl rinsing step.  The surface concentration of anti-IgG-HRP was quantified using an 
enzyme reaction similar to that used in ELISA.  
 
  Figure 28. Initial wash solution comparison using anti-IgG-HRP assay. 
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 These results indicate that the Tween 60, NaCl, and DI water washing protocol resulted 
in the lowest amount of nonspecific binding, 6.75±2.6E-14 mol Ab/g bead compared to 4.36 ± 
0.49E-12 and 2.37 ± 0.16E-13 mol Ab/g bead for the Tween 20 and DI water alone and Tween 
20, NaCl, and DI water, respectively.  Both samples that included the 1.0M NaCl rinse step were 
significantly lower (p<0.005) than the one sample which did not use NaCl.  Additionally, the 
Tween 60 sample showed significantly lower HRP concentration compared to the Tween 
20/NaCl/DI water sample (p<0.005).  During the experiment, however, the extremely viscous 
Tween 60 solution caused clogging of the chromatography column used for rinsing the beads.  
Thus, Tween 60 is not an ideal detergent for our purposes as it may not rinse thoroughly from the 
beads.  As seen in Chapter 3, the method of passive adsorption with only Tween 20 and DI water 
rinsing steps results in the highest overall amount of antibody adsorbed. 
 The next set of experiments was designed to test an additional set of washing protocols as 
well as the inclusion of a blocking step for some samples.  The blocking steps, in this case done 
using 0.1% Tween 20, are designed to physically prevent adsorption of antibodies to the beads 
during the incubation.  Six separate methods were tested for their ability to remove 
nonspecifically bound anti-TNF antibodies.  Their effectiveness was measured by performing a 
capture experiment with the beads packed into a cytokine adsorption device and perfused with 
TNF-rich serum.  The most notable of these results can be seen in Figure 29.  Interestingly, the 
high pH/high salt wash solution resulted in much slower removal of TNF and less removed 
overall (34.2 ± 7.9 % of initial) than any of the other washing methods or naked CytoSorb™ 
beads (as seen in Chapter 2).  This phenomenon was presumably due to denaturation of 
antibodies under such high pH and subsequent clogging of the bead pores, which prevented TNF 
from adsorbing to the beads or binding its antibody in significant quantities.  This hypothesis is 
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further supported by the 0.1% Tween 20 block data that showed no such effect on TNF removal 
at a lower pH. 
 
  Figure 29. TNF capture over time for adsorbed anti-TNF beads washed with high salt/high pH and blocked with 
0.1% Tween 20, washed with ELISA wash buffer only, or washed with 2% Tween 20 and blocked with 0.1%Tween 
20. 
 
 As seen in Figure 29, the ELISA wash buffer resulted in somewhat different temporal 
removal of TNF.  The other four methods followed essentially the same trajectory as the 2% 
Tween 20 + 0.1% Tween 20 block and therefore the entire time course of TNF removal is not 
shown.  Figure 30 shows the percentage of TNF remaining after 4 h compared to the initial 
concentration, which ranges from 1-4%.  As mentioned in the previous section, the removal rates 
of the different bead types cannot be directly compared using our theoretical model from Chapter 
2 because the removal is partially affinity-based and our model does not include a term for such 
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removal.  Our conclusion from the data in Figure 30 is that none of the methods used had a 
significant effect on reducing nonspecific binding. 
 
  Figure 30. Final concentration for five different adsorbed anti-TNF bead washing protocols. Overall removal of 
TNF after 4 hours ranged from 96-99% for all samples. 
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  Figure 31. TNF capture over time using adsorbed anti-TNF beads treated with BSA before or after antibody 
immobilization and unmodified CytoSorb™ beads.  
 
 The results in Figure 31 suggest that pre-coating the beads not only prevented the 
adsorption of anti-TNF to the beads but also prevented TNF from being able to adsorb as well, 
similar to the high pH/high salt wash data from Figure 29.  In addition, our hypothesis about 
BSA displacing weakly bound anti-TNF seems to have been incorrect.  The data demonstrate 
that these beads were able to remove TNF as efficiently as the passive adsorption beads with no 
post-incubation with BSA.  
Polyethylene glycol (PEG) is a polymeric molecule that can be synthesized to be various 
lengths with many different possible functional groups on either end of the molecule.  PEG has 
been used to reduce the hydrophobicity of surfaces as well as provide a spacer arm for 
conjugation of ligands such as antibodies, similar to PLL.  We used a 12-monomer PEG 
containing one carboxyl and one amine terminus to reduce nonspecific binding of antibodies.  
The amine terminus was covalently bound to the EDC-activated carboxylated CytoSorb™ bead 
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surface and anti-TNF antibodies were then similarly bound to the carboxyl end of the PEG using 
EDC.  One bead sample was incubated with anti-TNF without adding EDC to test for 
nonspecific binding of the antibody to the beads containing the PEG spacer arm.  Beads were 
then packed into a column and tested for their ability to remove TNF from serum.  These results 
can be seen in Figure 32, with both the nonspecifically and covalently bound anti-TNF beads 
removing 85% of the initial concentration of TNF after 4 h.  
 
  Figure 32. TNF capture over time using CytoSorb™ beads containing anti-TNF covalently bound to PEG spacer 
arms. The dotted line shows TNF capture for antibodies nonspecifically bound to PEG.  
 
 The results in Figure 32 would suggest that all of the anti-TNF is nonspecifically bound 
to the PEG spacer arm, the bead surface, or a combination of both.  The overall amount of TNF 
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conjugated to the bead surface to effectively reduce nonspecific binding and thus aimed in the 
next set of experiments to test whether or not a commercially available PEG-coated bead could 
perform better.  
 TentaGel is a nonporous resin made up of polystyrene coated with high concentrations of 
PEG [105].  As a positive control for nonspecific binding to these beads, we chose to use naked 
nonporous polystyrene beads of the same diameter from the same manufacturer.  We tested the 
naked polystyrene and TentaGel resins for their ability to remove TNF from serum in a typical 
capture experiment.  These results were compared to capture data from the same beads 
containing passively adsorbed anti-TNF.  Figure 33 shows that, as expected, neither the naked 
polystyrene beads nor the naked TentaGel were able to remove significant amounts of TNF from 
solution. Although the polystyrene beads are highly hydrophobic, their nonporous structure 
makes them unfavorable for cytokine removal due to reduced surface area.  
 
  Figure 33. TNF capture over time using TentaGel (PEG-coated polystyrene) and pure polystyrene. The solid lines 
represent TentaGel or polystyrene beads containing adsorbed anti-TNF. 
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 The polystyrene beads were able to remove a significantly higher amount of TNF (75.7% 
of the initial TNF concentration) once the anti-TNF antibodies were allowed to passively adsorb 
to the surface of the beads.  The TentaGel beads did not show any change in TNF capture with 
the inclusion of anti-TNF, suggesting that the PEG coating did indeed prevent nonspecific 
binding of the antibodies.  These data support the hypothesis that PEG coating is effective in 
minimizing nonspecific binding when used in high enough concentrations, which we most likely 
did not achieve in our initial experiment due to a lack of functional groups on the bead surface.  
The surface density of carboxyl groups on the PEG spacer arms of the TentaGel beads is 
250 μmol/g beads which is 50 times higher than the surface density of carboxyl groups on the 
CytoSorb™ beads.  Therefore, in order to effectively test the TentaGel beads for their ability to 
covalently bind anti-TNF, we needed to increase the amount of EDC used in the activation step 
appropriately.  We compared TNF capture data for both TentaGel and CytoSorb™ beads 
activated using two different activation chemistries.  Both chemistries used an increased 
concentration of EDC, which we hypothesized would improve activation TNF capture only in 
the TentaGel beads because the CytoSorb™ beads were previously being activated with an 
excess of EDC.  We also tested a different activation chemistry using the same amount of EDC 
and an additional reagent, NHS, which has been shown to improve the efficiency of binding in a 
water-soluble carbodiimide reaction such as EDC-COOH.  Our hypothesis was that the NHS 
would improve anti-TNF binding and therefore increase TNF capture in both the TentaGel and 
CytoSorb™ beads. 
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  Figure 34. TNF capture over time using CytoSorb™ and TentaGel beads containing covalently bound anti-TNF 
antibodies. The dotted lines represent activation using both EDC and NHS for both bead types.  
 
 The results of the higher EDC and NHS experiments can be seen in Figure 34.  The 
TentaGel activated with EDC only removed 79 ± 0.7% of TNF in 4 h while the TentaGel 
activated with EDC and NHS removed 70.1 ± 0.2% of TNF.  Conversely, CytoSorb™ activated 
with EDC and NHS removed 75 ± 3.9% of the initial concentration of TNF while CytoSorb™ 
activated with EDC alone removed 68.5 ± 1.5% of TNF in 4 h.  The significance of these 
differences is difficult to characterize without being able to use the theoretical model presented 
in Chapter 2.  Our conclusion is that NHS has no significant positive effect on TNF capture for 
either bead type.  
Interestingly, we can also conclude from Figure 34 that the additional EDC used when 
activating the CytoSorb™ beads resulted in significantly lower overall TNF capture when 
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compared to the passively adsorbed anti-TNF on the same beads.  We hypothesized that the EDC 
somehow altered the hydrophobicity of the CytoSorb™ surface when used in the higher 
concentration and that this change to the surface chemistry reduced the nonspecific binding of 
antibodies.  Testing this theory proved difficult because nonspecific binding is typically 
measured by carrying out the immobilization procedure without adding the activating agent, in 
this case the EDC.  As an alternative method to test nonspecific binding while still adding EDC, 
we decided to immobilize antibodies whose terminal amine groups were capped using acetic 
acid, which would prevent their being bound to the activated surface.  The experiment was 
designed such that the methyl groups that were exposed in lieu of the amine groups would not 
react with the EDC activated bead surface and therefore the only antibodies which bound would 
be nonspecifically bound.  We also performed a negative control in which the capping agent 
(acetic acid) was not activated and therefore could not cap the antibodies. The unmodified acetic 
acid was simply incubated with the antibodies to test for any possible effects on the antibodies.  
 
  Figure 35. TNF capture over time using CytoSorb™ beads containing adsorbed anti-TNF pre-incubated with 
activated acetic acid, inactive acetic acid, or no acetic acid.  
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 The results of the acetic acid capping experiment can be seen above in Figure 35.  The 
test and control samples removed 62.6 ± 1.1% and 55 ± 1.6% of the initial concentration of TNF, 
respectively.  Our hypothesis was that capping the antibodies would significantly decrease the 
amount of TNF capture because of a reduction in nonspecific binding due to the increased EDC 
concentration during activation.  However, comparing these results to the CytoSorb™ beads 
activated with EDC only (grey line) suggests that only about 6% of the overall TNF capture 
when antibodies are immobilized under the high EDC conditions can be attributed to covalent 
binding while the remaining 62% is due to nonspecifically bound antibodies.  Additionally, these 
results are confounded by the difference in TNF capture between the negative control beads 
containing antibodies incubated with inactive acetic acid and the beads containing antibodies 
incubated with no acetic acid.  The acetic acid incubation negatively affected TNF capture which 
most likely means that the test beads containing antibodies capped with acetic acid had higher 
levels of nonspecific binding than detectable using TNF capture as a metric. 
 Our attempts to minimize nonspecific binding while maintaining significantly higher 
TNF removal rates compared to the naked CytoSorb™ beads were either unsuccessful or led to 
unfavorable TNF removal rates.  Therefore, we returned to the method that yielded the highest 
level of antibody binding, passive adsorption and washing using Tween 20 and DI water.  This 
particular protocol resulted in over one order of magnitude higher levels of anti-IgG-HRP 
binding compared to the next best set of experimental conditions.  Although nonspecific binding 
was in fact maximized in this case, we sought to quantify leaching of surface-bound antibodies 
and control the leaching rate using several techniques.  
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 The first of these techniques used glutaraldehyde to form a cross-linked mesh of 
antibodies on the bead surface that would theoretically be less likely to leach off of the beads.  
The second method used a photo-activated reagent which, when conjugated to the antibodies, 
would insert itself into the polystyrene backbone of the beads upon irradiation with UV light.  
We measured the initial amount of anti-IgG-HRP bound to the beads using each of the three 
methods (Figure 36).  The passive adsorption method once again resulted in the highest level of 
HRP binding, with 1.02 ± 0.06E-12 mol HRP/g beads compared to 2.7 ± 0.25E-13 and 4.07 ± 
0.13E-13 mol HRP/g beads for the glutaraldehyde and sulfo-SANPAH methods, respectively. 
 
  Figure 36. Initial surface density of anti-IgG-HRP antibodies on CytoSorb™ beads following adsorption using one 
of three methods. 
 
 We hypothesize that the additional post-adsorption washing steps needed for the sulfo-
SANPAH and glutaraldehyde methods resulted in decreased antibody coverage.  The data in 
Figure 28 also demonstrate this effect.  After measuring the initial concentration of anti-IgG-
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with a protein-rich buffer solution for 2 or 4 h.  Samples taken over time were assayed for HRP 
concentration to determine the amount of antibodies leaching off of the beads over time.  The 
data, reported as either the mass of anti-IgG-HRP leached per minute over time or total mass of 
anti-IgG-HRP leached over time, can be seen in Figures 37 and 38.  
 
  Figure 37. Total mass of anti-IgG-HRP leached over time following adsorption to CytoSorb™ beads using varying 
methods.  
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  Figure 38. Instantaneous rate of leaching of anti-IgG-HRP antibodies from CytoSorb™ beads following passive 
adsorption under varying conditions.  
 
The passive adsorption beads clearly result in significantly higher levels of antibody 
leaching throughout the experiment based only on the absolute mass of antibody leached overall 
or per time point.  However, when these data are normalized to the initial amount of HRP bound 
to the beads, the sulfo-SANPAH beads show the highest total amount of antibody lost, with 
46.8% of the initial amount lost.  The glutaraldehyde beads showed a total loss of 33.6% after 2 
h while the passive adsorption beads show only 28.2% leached after 4 h.  Thus the passive 
adsorption beads resulted in proportionally less leaching of antibody compared to the other two 
beads types. One would predict that the leaching rate data would show the same trend if the 
passive adsorption leaching rate had been measured at earlier than 15 min to capture the initial 
leaching behavior. 
 In this section we tested various methods of reducing nonspecific binding and were 
unable to find a method of doing so without significantly affecting the overall capture of TNF.  
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Our conclusion from the nonspecific binding experiments was that if the leaching of adsorbed 
antibody can be adequately quantified, we may be able to control it using alternative methods.  
Once again, we were unable to do so and came to the same conclusion that passive adsorption 
results in significantly higher levels of antibody binding and the lowest relative leaching rate.  In 
the next section, we explore the cytokine removal capabilities of the passive adsorption beads 
further and continue our investigation into the optimal conditions for TNF removal using 
affinity-based techniques. 
4.2 TNF CAPTURE EXPERIMENTS 
4.2.1 Introduction 
In this section we expand upon our use of passively adsorbed antibodies to selectively increase 
capture of TNF.  We have already demonstrated that the anti-TNF beads are able to remove over 
95% of circulating TNF in 4 h, an increase of 35% compared to the naked CytoSorb™ beads.  
The beads containing anti-TNF must still be able to remove smaller cytokines at rates 
comparable to the unmodified beads in order for them to maintain their original effectiveness and 
justify the use of the antibodies.  Therefore our first goal with the passively adsorbed anti-TNF 
beads was to demonstrate that the presence of the antibodies had no effect on capture of 
interleukin-6 (IL-6) or interleukin-10 (IL-10).  
Although our preliminary data would suggest that the increase in TNF removal with the 
beads containing anti-TNF is the result of a high-affinity antibody-antigen interaction, until now 
we have not sufficiently demonstrated this to be true.  Thus we also undertook to prove this 
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hypothesis using antibodies not specific for TNF.  This negative control helps to justify the use 
of the more expensive, TNF-specific antibodies. 
As mentioned in Chapter 3, several specialized samples of CytoSorb™ beads were also 
obtained.  Testing of the carboxylated beads has already been presented and here we present data 
for an additional bead set, aminated CytoSorb™ beads.  We used techniques developed in 
previous sections to test these beads for their ability to covalently bind anti-TNF and remove 
TNF in capture experiments.  
We have also shown that the rate of leaching of antibodies from the beads can be 
drastically reduced after 4 h of flushing with a buffer solution.  In this section we detail the 
methods used to characterize the performance of the beads after being thoroughly perfused with 
buffer to remove weakly bound ligand.  Currently no FDA guidelines exist for acceptable limits 
of bound ligand leaking into the bloodstream of a patient during hemofiltration or 
hemoadsorption.  Two FDA-approved immunoadsorption devices, the Prosorba and 
Immunosorba columns (Fresenuis HemoCare; Redmond, WA), contain immobilized protein A of 
staphylococcus bacterium on silica-based and agarose matrices, respectively [106-107].  No 
indication was given in the Pre-Market Approval application for Prosorba that any protein A 
leached off of the substrate at any point in the adsorption and bead regeneration processes [108].  
The usefulness of the CAD containing adsorbed antibodies depends both on its effectiveness and 
safety, particularly regarding that amount of antibody that would leach off of a full-scale device 
when compared to the same data for covalently bound ligands in other devices.  Here we present 
antibody leaching data and a correlation to the relative safety of the device when scaled up for 
clinical use. 
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4.2.2 Methods 
The first set of experiments tested whether or not the adsorbed anti-TNF antibodies could still 
maintain high levels of IL-6 and IL-10 capture in spite of the additional diffusional hindrance of 
the anti-TNF antibodies.  The CytoSorb™ beads were incubated with 40 μg anti-TNF per gram 
of beads for 2 h on the rocker.  Beads were then washed four times for five minutes each with 
both Tween 20 and DI water separately.  The beads were packed into CADs and perfused for 4 h 
with horse serum containing 1-3000 pg/ml of IL-6, IL-10, and TNF.  Three trials were done 
using anti-TNF beads and all three cytokines in solution.  400 μl samples were taken over time 
and assayed individually for concentrations of each cytokine using ELISA kits according to the  
instructions of the manufacturer.  The cytokine concentration data over time for IL-6 and IL-10 
was analyzed using the theoretical model in Matlab to determine Γi values for all three trials.  
These values were compared to Γi values for the naked CytoSorb™ beads using a two-sample 
student’s t-test, with p<0.05 denoting a statistically significant difference. 
 TNF capture data using the passively adsorbed anti-TNF beads was also compared to that 
of beads containing adsorbed IgG antibodies.  The purified rat IgG (Invitrogen) was adsorbed to 
the CytoSorb™ beads at a concentration of 40 μg/g beads in the same way as the rat anti-human 
TNF antibodies.  The same washing steps were carried out and TNF capture from serum was 
performed under the aforementioned conditions.  Once again, ELISA kits (Invitrogen) were used 
to assay for TNF concentration according to the instructions of the manufacturer. 
In addition to the work with the unmodified CytoSorb™ beads, antibodies were directly 
crosslinked onto the aminated beads using the previously described glutaraldehyde procedure.  
Before doing so, the level of amination was measured using the ninhydrin assay, a colorimetric 
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assay which measures the concentration of amine groups in a liquid or solid sample [71].  Figure 
39 shows the reaction used in the ninhydrin assay, using the following protocol.  
 
Figure 39. Chemical reaction involved in the ninhydrin assay. Ruhemann’s purple concentration is directly 
proportional to both absorbance at 570 nm and amine group concentration. Figure adapted from Hermanson et al. 
(1992) [71]. 
 
First, a stock solution of 3.0 μmol glycine/ml water was prepared.  The standards for the 
calibration curve were made by diluting the stock solution to concentrations of 1.5, 1.25, 1.0, 
0.75, 0.5, and 0.25 μmol/ml.  To each standard, 1.0 ml of ninhydrin reagent (0.35 g of ninhydrin 
in 100 ml of ethanol) was added.  The contents of each standard were gently mixed and 
incubated in a 100°C oven for 30 min.  The standards were allowed to cool for 10 min and 1 ml 
of 50% isopropyl alcohol (IPA) was added.  The standards were mixed once more and 1 ml of 
 92 
the final solution of each standard was pipetted into a cuvet and assayed in the UV/Vis 
spectrophotometer (Genesys 5, ThermoFisher) at a wavelength of 570 nm.  To test the aminated 
beads samples, approximately 0.1 g of beads were put into a test tube and suspended in 1 ml of 
DI water to which 1 ml of ninhydrin reagent was added.  Once again, the samples were mixed 
and incubated for 30 min at 100°C before being cooled, diluted in 1 ml 50% IPA, and mixed 
again.  The purpose of the IPA is to fully solubilize the Ruhemann’s purple molecules, 
responsible for the color change, from the substrate.  As with the standards, 1 ml of the final 
solution was pipetted into cuvets and the absorbance was measured at 570 nm.  The mass of each 
bead sample was obtained using the suction tool described below in section 3.2.6 and used to 
obtain values for μmol NH2 per gram of beads in each sample based on the standard curve that 
was generated. 
 The final set of experiments aimed to once again quantify leaching of weakly adsorbed 
antibodies from the beads within a CAD, this time at four times higher flow rate to simulate an 8 
h perfusion.  Anti-IgG-HRP antibodies were passively adsorbed onto CytoSorb™ beads using 
the aforementioned protocol (Section 3.2.4).  Beads were then packed into a 1ml CAD and 
perfused continuously for 1 hour at a flow rate of 3.2 ml/min with a 40 ml solution of PBS 
containing 50 mg/ml bovine serum albumin (BSA).  After 1 hour, the buffer solution was 
replaced with fresh PBS/BSA containing no HRP and perfused for one more hour.  Samples of 
the solution were taken over time and assayed using the anti-IgG-HRP direct quantification 
method previously described. Three trials of this experiment were performed. 
 The antibody adsorption and 2 h high flow rate flushing steps were repeated with anti-
TNF antibodies.  No samples were taken during the initial buffer recirculation.  These beads 
were then perfused with horse serum spiked with TNF following the previously described 
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protocol for cytokine capture and TNF concentration over time was measured using ELISA.  
Three trials of this experiment were performed. 
4.2.3 Results and Discussion 
In this section we further characterize the effectiveness and safety of the passively adsorbed anti-
TNF beads.  We performed multicomponent capture of IL-6, IL-10, and TNF from serum using 
unmodified beads and adsorbed anti-TNF beads.  These results can be seen in Figure 40; overall 
TNF capture after 4h improved 33% compared to the unmodified CytoSorb™ beads.  The 
unmodified and anti-TNF beads removed 85.8 ± 2.8% and 82.1 ± 0.72% of the initial IL-6 
concentration, respectively.  For IL-10, the unmodified beads removed 87.7 ± 0.58% while the 
anti-TNF beads removed 80.8 ± 1.3% relative to the initial concentration.  
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Figure 40. Comparison of multicomponent capture of A) IL-6, B) IL-10, and C) TNF using adsorbed anti-TNF and 
unmodified CytoSorb™ beads. 
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IL-6 and IL-10 capture data for each of the three trials were plugged into the theoretical 
model to obtain Γi values.  For the unmodified and adsorbed anti-TNF beads, ΓIL-6 values were 
6.47 ± 2.6E-5 and 2.17 ± 0.08E-5 cm
2∙ml∙min-1·g-1, respectively.  The model fits demonstrate taht 
removal of IL-6 (p>0.1) was not significantly affected by the presence of the anti-TNF 
antibodies, with p>0.10.  ΓIL-10 using the unmodified beads was equal to 3.26 ± 0.22E-5 
cm
2∙ml∙min-1·g-1 while ΓIL-10 for the antibody coated beads was 1.56 ± 0.1E-5 cm
2∙ml∙min-1·g-1.  
Although IL-10 removal was significantly slower with the anti-TNF beads (p<0.005) compared 
to the unmodified beads, the actual percentage difference in overall removal was only 7%. 
Diffusion of IL-10 to the bead pores in the presence of anti-TNF was most likely more affected 
than IL-6 because IL-10 exists primarily as a homodimer in neutral pH solutions, making it 
nearly twice as large as IL-6 [109]. 
We also performed TNF capture using beads containing adsorbed IgG antibodies which 
were not specific to TNF to demonstrate the specificity of the adsorbed antibodies.  Figure 41 
shows these results compared to TNF capture using adsorbed anti-TNF and unmodified beads.  
The beads containing IgG antibodies removed only 37% of TNF, while the unmodified beads 
removed 55% and the adsorbed anti-TNF beads removed 98%. 
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Figure 41. Comparison of TNF capture using adsorbed anti-TNF, adsorbed IgG, and unmodified CytoSorb™ beads. 
 
Our last test with the passively adsorbed antibody beads tested the hypothesis that 
leaching was independent of the antibody concentration in solution as the experiment progressed.  
To test this hypothesis we replaced the reservoir solution after one hour with the expectation that 
the rate of leaching would continue to gradually rather than significantly increase.  The results of 
this experiment can be seen in Figure 42; the original hypothesis was correct and the rate of 
leaching was not affected by the replacement of the buffer solution after 1 hour.  In the first and 
second hour of buffer recirculation, 59.4 and 8.8% of the initial amount of adsorbed anti-IgG-
HRP leached off, respectively.  The rate of antibody leaching dropped from a maximum of 7750 
pg antibody leached/min to a steady rate of 215 pg/min. 
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  Figure 42. Leaching of anti-IgG-HRP antibodies over time (♦) and total mass of anti-IgG-HRP (□) leached after 2 
h. The dotted line represents the time point at which the buffer being perfused through the CADs was replaced with 
fresh solution. 
 
The same 2h flushing procedure was carried out for beads containing adsorbed anti-TNF 
with no buffer replacement.  We performed three trials of TNF capture using anti-TNF beads that 
had been prepared with and without the pre-flush step and saw no difference in TNF capture 
ability between the two types of beads (Figure 43).  
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  Figure 43. Comparison of TNF capture with passively adsorbed anti-TNF beads with and without the 2 h pre-flush 
with buffer. 
 
Previous attempts to covalently bind antibodies to the CytoSorb™ beads were 
unsuccessful due to high levels of nonspecific binding and a lack of surface functional groups. 
We sought to avoid these issues using glutaraldehyde cross-linking of antibodies directly onto 
aminated CytoSorb™ beads.  We first tested the beads, in both 50-100 μm and 300-700 μm 
diamter versions, to determine their level of amination using a colorimetric reaction with 
ninhydrin.  The small and large aminated beads contained 14.9 ± 4.9 and 15.4 ± 5.6 μmol NH2/g 
beads.  While the variability in this assay was unusually high even after six trials of each bead 
size, these results do provide an estimate of the order of magnitude of amination on the polymer.  
The results of the glutaraldehyde cross-linking can be seen in Figure 44. The aminated beads 
containing cross-linked antibodies removed 70.8 ± 2.9% of the initial TNF, a 6% improvement 
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over the naked CytoSorb™. However, this level of removal was still well under that of the 
passively adsorbed anti-TNF beads, at 98.1% capture after 4 h.  
 
  Figure 44. Comparison of TNF capture over time using unmodified CytoSorb™ beads with and without anti-TNF 
and aminated CytoSorb™ beads cross-linked anti-TNF. 
 
Our goal in this study was to demonstrate that TNF capture in our cytokine adsorption 
device (CAD) could be improved by incorporating anti-TNF antibodies on the adsorbent 
polymer in the device.  We tested several types of immobilization methods and found that, due to 
the highly hydrophobic nature of the beads, passive adsorption results in a 12-fold increase in 
surface antibody coverage than covalent immobilization.  Using the passively adsorbed anti-TNF 
beads, overall TNF capture after 4h was increased by over 30%.  Multicomponent capture 
experiments demonstrated that the presence of the anti-TNF results in less than a 10% decrease 
in total amount of IL-6 or IL-10 removed from solution over four hours of recirculation.  The 
abundance of surface area on the inner surfaces of the beads ensure that other proteins can still 
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adsorb effectively without interfering with the specific binding of TNF occurring at the outer 
layer of the beads. 
We have also shown that the rate of leaching of the passively adsorbed antibody can be 
reduced to 300 pg/min after a 2 h flush in a 1.5 g CAD without any loss to functionality of the 
beads.  Our conclusion is that the antibodies leaching off during the flushing were actually 
loosely adsorbed upon surface-bound antibodies that do not leach off.  Therefore, the monolayer 
of antibodies that remains is still able to retain the cytokine capture ability of the stacked 
antibody configuration.  For a 4 h clinical treatment with a 500g cartridge, the total amount of 
antibody leached following the 2 h flush would correspond to approximately 24 μg.  This value 
is well within a safe range for clinical purposes when considering that similar monoclonal anti-
TNF antibodies that are FDA approved for the treatment of autoimmune diseases such as 
rheumatoid arthritis and Crohn’s disease are given in doses ranging from 3-10 mg/kg [110-112]. 
We wanted to demonstrate that the effect due to anti-TNF coated beads was the result of 
a specific interaction between TNF and anti-TNF to justify the use of monoclonal anti-TNF 
($75/100μg) over a more inexpensive protein.  To do so, we immobilized polyclonal IgG 
antibodies that were not specific to TNF on the beads and performed TNF capture.  TNF capture 
experiments done with the beads containing adsorbed IgG showed a 60 and 18% decrease in 
TNF removal compared to the adsorbed anti-TNF and unmodified beads, respectively.  We 
attribute this effect to diffusion hindrance caused by the antibodies, which prevents adsorption of 
TNF to the bare polymer surfaces. 
The CAD originally used only nonspecific adsorption to deplete a wide range of middle 
molecular weight cytokines but was unable to effectively remove TNF.  The inclusion of specific 
antibody-mediated cytokine capture provides an additional level of control over cytokine 
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removal in our device and depletes over 99% of TNF in 4 h.  These improvements can be 
incorporated into the existing extracorporeal setup without adjusting the current proposed 
treatment scheme of 4 h of continuous hemoperfusion.  In addition to using this new antibody 
adsorption technique to dramatically improve TNF capture, we can also investigate ligands 
specific for other molecules that may play pivotal roles in sepsis. 
4.3 ANTIBODY CHARACTERIZATION 
4.3.1 Introduction 
As described in Chapter 3, the effectiveness of any immobilized ligand depends on the matrix, 
immobilization chemistry, and ligand.  More antigen will be bound when more antibody is 
present; however, antibodies with a higher affinity can be immobilized in lower concentrations 
than their lower affinity counterparts.  This advantage is particularly important for our purposes 
due to the high cost of the monoclonal rat anti-human TNF antibodies that we currently use 
($700/mg).  
Currently, two types of anti-TNF antibodies have been FDA approved for clinical use by 
to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.  
Infliximab (Remicade) is a chimeric anti-TNF monoclonal antibody while adalimumab (Humira) 
is a fully human anti-TNF antibody.  The binding affinities of infliximab and adalimumab with 
TNF, KD, are 9.05 ± 0.20E-9 and 5.51 ± 0.43E-10 M, respectively.  Another experimental 
antibody, TSK114, has been shown using the same measurement technique to have a KD of 5.28 
± 0.51E-12 M [113].  According to the manufacturer, the rat anti-human TNF antibodies used in 
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previous experiments, RHTNFA00, has a binding affinity on the order of 10
-8
 M, which is much 
lower than any of the other three antibodies.  Figure 45 shows, for various starting concentrations 
of TNF, the relative amount of antibody needed for maximum removal of TNF. 
 
  Figure 45. Comparison of TNF capture over time using unmodified CytoSorb™ beads with and without anti-TNF 
and aminated CytoSorb™ beads cross-linked anti-TNF. 
 
 We assume a monolayer coverage of antibody on the surface of the beads in Figure 45.  
The markers on the plot show where each of the aforementioned antibodies would lie on the 
1000 pg/ml line, the approximate starting concentration of TNF in our capture experiments.  
While these results are merely an estimate of the relative differences between the antibodies, 
they do demonstrate the advantage of using a higher affinity antibody for such experiments.  
Assuming all antibodies cost the same as the RHTNFA00, the cost for each to achieve maximum 
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cytokine removal would be as follows: RHTNFA00, $3213.63/g polymer; infliximab 
(Remicade), $321.93/g polymer; adalimumab (Humira), $32.76/g polymer; TSK114, $0.95/g 
polymer. 
 Another method to reduce the cost of anti-TNF adsorption to the beads is the reuse of the 
initial high concentration antibody solution.  As seen in the HRP data in Chapter 3, when 40 ug 
(approximately 300 pmol) of anti-IgG-HRP are incubated with 1 g of CytoSorb™ beads, the 
HRP assay reports that only 10 pmol remain on the beads after the washing steps are completed.  
Our hypothesis was that the amount of antibody remaining in the eluted incubation solution, over 
99% of the initial concentration, would be sufficient for comparable antibody binding when 
reusing that solution in subsequent bead adsorptions.  
In this section we compare the affinity of the original antibody, RHTNFA00, to other 
anti-TNF antibodies.  Additionally, we sought to optimize the adsorption procedure by 
determining the lowest concentration of antibody that could be used to achieve levels of TNF 
capture comparable to previous results.  Our goal was to reduce the overall cost and therefore 
increase the clinical suitability of our device.  
4.3.2 Methods 
We began by testing the original antibody, RHTNFA00, for its ability to capture TNF when 
adsorbed at lower concentrations.  Previously, 40 μg/g beads were incubated with the beads 
during passive adsorption.  We repeated the same method of 2 h incubation followed by washing 
with Tween 20 and DI water, as described in Section 3.2.4, using a 10 and 20-fold dilute 
antibody solution.  Beads that had been incubated with 2, 4, or 40 μg/g beads were then packed 
into CADs and connected to a peristaltic pump.  Capture of TNF was carried out as described in 
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Section 2.2.2.2, at a flow rate of 0.8 ml/min with 100 μl samples taken over 4 h. TNF 
concentration over time was measured using ELISA (Invitrogen) according to the instructions of 
the manufacturer.   
 A mouse monoclonal anti-human TNF antibody (Invitrogen), MsAb1, was tested at the 
same concentrations as the RHTNFA00 antibody under the same adsorption conditions.  One 
trial of TNF capture using beads incubated with each starting concentration of antibody was 
performed and samples were once again assayed using ELISA.  A second type of mouse 
monoclonal anti-human TNF antibody (Invitrogen), MsAb2, was also tested using the same 
experimental procedure.  One trial of TNF capture with the 200 μg Ab/g beads adsorption 
condition was performed and samples were assayed using ELISA.  As previously described, no 
statistical analysis was done on any of the mouse or rat monoclonal antibody concentration 
experimental data because TNF capture was affinity-based and therefore did not apply to the 
theoretical model from Chapter 2. 
 The final experiment tested whether the 40 μg/g bead RHTNFA00 solution could be 
drained and reused for subsequent bead adsorption experiments.  The passive adsorption protocol 
was carried out as previously described and immediately following the initial incubation, the 
buffer/antibody solution was drained into a second reaction vessel containing the same mass of 
beads and incubated for 2 h at room temperature.  This process was repeated once more and all 
three bead samples were washed and tested for TNF capture using the above mentioned cytokine 
capture techniques.  Samples from one trial of cytokine capture using each of the sequential 
incubation beads were assayed using ELISA. 
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4.3.3 Results and Discussion 
Several techniques were tested to improve the efficiency of the antibody adsorption and reduce 
the cost of the adsorbed anti-TNF beads.  The first method involved testing of alternative 
antibodies and concentrations of antibodies to maximize affinity and optimize the concentration 
needed during adsorption.  We first examined the effect of decreasing the amount of rat anti-
human TNF (RHTNFA00) added during the adsorption step.  The results can be seen below in 
Figure 46; one trial each of the two highest antibody concentrations was done and two trials of 
the lowest antibody concentration were done.  Once again, the 40 μg antibody/g bead sample was 
able to remove 97.9 ± 0.08% of the initial TNF concentration after 4 h.  The 4 μg Ab/g bead 
sample removed 67.1 ± 1.5% while the 2 μg Ab/g bead sample removed 59 ± 8.4%. 
 
 
  Figure 46. Comparison of TNF capture over time using beads containing adsorbed rat anti-human TNF at varying 
concentrations. 
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 Next we compared the same set of initial concentrations of another antibody, a mouse 
anti-human TNF monoclonal antibody (MsAb1).  The results of this experiment, as seen in 
Figure 47, show that the 1x and 10x diluted antibody concentrations had comparable levels of 
TNF capture after 2 h.  In order of decreasing antibody concentration (40, 4, and 2, μg/g bead), 
the MsAb1 beads removed 92.3 ± 1.1%, 89.7 ± 0.7%, and 72.0 ± 0.2% of the initial amount of 
TNF in solution, respectively. 
 
  Figure 47. Comparison of TNF capture over time using beads containing adsorbed mouse anti-human TNF at 
varying concentrations. 
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  Figure 48. TNF capture over time using beads containing an alternative adsorbed mouse anti-human TNF. 
 
 The final experiment tested whether the antibody solution could be reused with no loss to 
TNF capture using the RHTNFA00 antibody-coated beads (Figure 49).  The first set of beads, 
incubated with the original antibody solution, removed 97.8 ± 0.1% of the initial amount of TNF 
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  Figure 49. Comparison of TNF capture over time using beads incubated consecutively with the same initial anti-
TNF solution. 
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also conclude that for starting concentrations on the order of 40 μg/g beads or lower, TNF 
capture is significantly decreased with decreasing antibody concentration.  The relationship 
between TNF capture and antibody concentration varies for RHTNFA00 and MsAb1, with the 
latter appearing to demonstrate limiting TNF capture behavior above 4 μg/g beads.  TNF capture 
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at a concentration above 40 μg/g beads would need to be performed in order to determine the 
maximum removal rate using the RHTNFA00 beads. 
 Our attempts to reuse the antibody solution following adsorption to the CytoSorb™ beads 
were unsuccessful.  TNF removal with the second and third consecutive bead samples was 
significantly slower than the first set of anti-TNF beads.  Only the initial elution from the bead 
samples was reused as a way of keeping the volume low enough for effective diffusion of the 
antibodies to the beads during the second and third incubations.  Most likely, the majority of the 
free anti-TNF remaining after the incubation was either adsorbed onto the reaction vessel itself 
or did not get eluted until subsequent washing steps.  This problem may be avoided by halving 
the original volume of the incubation liquid and adding to it the liquid from one bead wash with 
the same volume, thereby including additional antibodies that were not eluted with the first try 
without increasing subsequent incubation volumes.  
4.4 FLUIDIZED BED DEVICE 
4.4.1 Introduction 
Fluidized bed adsorption processes are used for many different applications, such as removal of 
volatile organic solvents from air using activated carbon.  The advantage of a fluidized bed in an 
industrial application is that pressure drop is independent of flow rate once the particle bed is 
fully fluidized.  Thus, heat and mass transfer capabilities increase in the area external to the 
particles [114].  The mass transfer processes occurring in our CAD, as described in Appendix A, 
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are convection through the device, diffusion to the bead boundary layer, diffusion into the pores 
of the bead, and adsorption to the bead surface.   
Mass transfer is limited by diffusion into the pores for a species adsorbing onto the pore 
surfaces of the beads.  TNF capture using beads containing anti-TNF antibodies is limited, 
however, by diffusion through the surface boundary layer because rapid affinity binding is taking 
place on the bead surface and very little TNF penetrates the pores.  If U is the velocity just 
outside of the boundary layer, we can assume that at the edge of the boundary layer the velocity 
is approximately 0.99*U.  Boundary layer thickness is described by the following equation 
[146]: 

yb  ln 0.01U  (6) 
Therefore, as convection around the bead increases, the surface boundary layer decreases, as 
seen in Figure 50.   
 
  Figure 50. Graphical representation of boundary layer thickness as a function of convection just outside the surface 
of the bead. 
 
 In this section we explore the phenomenon of fluidized bed capture dynamics by testing a 
newly designed CAD which incorporates internal mixing to minimize mass transfer limitations 
within the surface boundary layer.  This device is intended to be combined with the anti-TNF 
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technology previously described to further enhance capture of TNF due to the fact that cytokines 
binding to antibodies are limited only by their rate of diffusion through the bead boundary layer, 
which is effectively decreased in the fluidized bed system.  
4.4.2 Methods 
We began by studying the effects of different types of mixing on middle molecular weight 
protein removal using cytochrome c.  Cytochrome c, as previously described, is a surrogate 
middle molecular weight protein which is less expensive and simpler to assay than cytokines.  
We tested full and half-full CADs in various systems of passive or active mixing, as depicted in 
Figure 51.  Capture for each type of column and mixing was done by circulating 14 ml of 0.5 
mg/ml cytochrome c in tris buffer solution through the CADs at 1.0 ml/min, with 1 ml samples 
being taken every 5 min for a total of 30 min.  The absorbance of each sample at 408 nm was 
measured and compared to a standard curve to obtain removal rate data for each device.  The 
baseline experiments were performed with one full and one half-full CAD that were kept 
completely stationary throughout the capture experiment.  The beads in the half-full CAD were 
contained with a filter that prevented them from moving throughout the rest of the cartridge.  
Additionally, one full CAD, one half full CAD, and one half full CAD containing 1/16” stainless 
steel balls were tested for cytochrome c capture while being continuously mixed on the rocker.  
The final experiment tested an active mixing setup in which a full CAD containing a magnetic 
stir bar was placed on a magnetic stirrer and perfused with cytochrome c/tris solution. 
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  Figure 51. Types of CADs used in cytochrome c mixing study: A) full CAD, no mixing; B) half full CAD, no 
mixing; C) full CAD on rocker; D) half full CAD on rocker; E) half full CAD on rocker with weights; F) full CAD 
containing stir bar on magnetic stirrer. 
 
In addition to testing the original CAD design for active and passive mixing performance, 
we sought to design and fabricate a new device to test a more realistic fluidized bed setup.  The 
beads in a non-packed bed device would settle to the bottom of a device at the flow rates used for 
serum perfusion in our scaled-down experiments with no active mixing mechanism.  Therefore, 
we increased the size of the new CAD to accommodate a magnetic stir bar.  The original aspect 
ratio of 9/2 (length/diameter) was maintained and the overall dimensions were changed to 9 cm 
long by 2 cm in diameter.  The device was also designed to run vertically, similar to industrial 
fluidized bed adsorbers.  The new orientation of the device eliminated the need for a filter on the 
bottom, inlet port where 1/16” inner diameter Tygon® tubing was connected to a peristaltic 
pump and the sampling reservoir.  A nylon mesh filter was glued into the top of the device just 
beneath a liquid reservoir containing an air trap.  An outlet port on top of the liquid reservoir was 
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connected to the sampling reservoir once again by Tygon® tubing.  A diagram of the active 
mixing CAD can be seen in Figure 52. 
 
  Figure 52. Active mixing CAD recirculation loop setup. 
 
Using the new CAD design, we calibrated the magnetic stirrer for the RPM achievable at 
each numerical setting.  RPM was measured for two different types of stir bars, a standard 
cylindrical rod stirrer and a test tube stirrer (depicted in Figure 52).  Our goal was to determine 
which stir bar could achieve the greatest lift at the lowest RPM.  A range of RPMs was recorded 
for each of 10 settings on the magnetic stirrer and the critical point, the point at which 1.5 g of 
CytoSorb™ beads were completely fluidized, for both types of magnetic stir bars was noted. 
We tested the active mixing CAD for its ability to remove cytochrome c from solution 
via adsorption over a range of RPMs and compared these data to cytochrome c removal using a 
packed bed CAD.  Cytochrome c capture was performed as described above for 60 min using the 
active mixing CAD at 55, 130, 415, and 550 RPM using the test tube stir bar.  The reservoir 
volume for both the active mixing and standard CAD experiments was increased to 40 ml to 
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accommodate the larger device and the mass of beads was held constant at 1.5 g for each 
experiment.  Samples were once again assayed using the UV/Vis spectrophotometer at a 
wavelength of 408 nm. 
Capture of TNF was also measured at varying RPM rates using unmodified CytoSorb™ 
beads.  Once again a 40 ml reservoir volume and 1.5 g of beads were using in the active mixing 
device and capture of TNF at 55, 130, and 550 RPM was measured and assayed using ELISA. 
The results are compared to theoretical results of TNF capture using ΓTNF=7.5E-6, the average 
value of ΓTNF determined in Chapter 2 using the mathematical model.   
4.4.3 Results and Discussion 
In this section we sought to design a device which would enhance mass transfer inside the CAD 
to a point where capture of cytokines was limited only by diffusion to the beads even at clinically 
relevant flow rates.  Our initial attempts at designing such a device was to use the original CAD 
cartridge with some form of internal (magnetic stir bar) or external (rocker) mixing.  First, we 
tested several types of bead mixing systems to determine the effect, if any, that they had on 
cytochrome c removal.  Both full and half-full CADs were tested on the rocker or stationary as 
well as one experiment each using weights or a stir bar contained inside the CAD.  The 
hypothesis was that the magnetic stirrer setup would lead to the most efficient capture followed 
by the other forms of mixing, depending on the amount of beads in the column.  In both the full 
(Figure 53A) and half-full trials (Figure 53B), however, the stationary setup outperformed or was 
equal to all of the mixing devices.   
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  Figure 53. Cytochrome c capture results using A) full and B) half-full CADs in various stationary or mixed setups. 
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 Our next design for the mixed bead device used a vertical column with a stir bar at the 
bottom.  The cartridge was designed to be big enough to contain the full amount of beads found 
in one CAD while allowing for extra space to ensure adequate mixing.  The new device can be 
seen in Figure 54; also shown is the difference in bead mixing for various stir rates.  Figure 54B 
demonstrates what we call the “critical point”, the first point as one increases the stir rate at 
which all beads appear to be homogeneously mixed.   
A)    B)    C)  
  Figure 54. Mixing CAD device operating at A) 55, B) 130 (critical mixing point), and C) 550 RPM. 
 
We calibrated the magnetic stirrer to determine the RPM of two different types of stir 
bars within the device.  The results can be seen in Table 5.  By doing so, we were able to choose 
the best type of stir bar for the device which would achieve maximum bead lift at minimum 
RPM and therefore lower shear rates.  Minimizing shear rate within such a device is important to 
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keep hemolysis low and maintain biocompatibility of the device.  The stir bar we decided to use 
in the device, as shown in Figure 54, is the test tube stirrer. 
Table 5. RPM calibration for two types of magnetic stirrers. 
 Cylindrical rod stir bar* Test tube stirrer† 
Setting RPM RPM 
1 N/A 50-55 
2 47-55 58-64 
3 99-108 102-109 
4 150-162 149-156 
5 200-226 203-230 
6 260-290 262-290 
7 403-430 400-422 
8 565-609 535-584 
9 918-924 812-860 
10 1201-1206 1103-1181 
*Critical point=325 RPM 
†Critical point=130 RPM 
 
Next we sought to determine if the newly designed and fabricated mixing CAD would 
improve cytochrome c capture from a buffer solution.  We tested cytochrome c removal over one 
hour in a packed CAD and the mixing CAD at 55, 130, 415, and 550 RPM.  The results of this 
experiment can be seen in Figure 55; capture data at 415 RPM is not shown because it overlaps 
the 130 RPM data.  The results were as expected according to our hypothesis: capture would 
improve with increasing stir rate up to the critical mixing point (130 RPM).  The mixing CAD 
removed 72.9% of the initial amount of cytochrome c after one hour while the packed CAD 
removed only 65.8% in the same amount of time.  The variability in the earlier time points of the 
55 RPM data is most likely due to the heterogeneous bead mixing, which can be seen in Figure 
54A. 
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  Figure 55. Cytochrome c capture in the packed CAD and mixing CAD at 55, 130, and 550 RPM. The 415 RPM 
data overlap the 130 RPM data and are therefore not shown. 
 
Based on the results of cytochrome c capture in the mixing CAD, we hypothesized that 
we could achieve the same results using TNF in serum.  Cytokine capture data were obtained in 
the mixing CAD at 55, 130, and 550 RPM and compared to theoretical data for the packed CAD 
at the same experimental conditions (flow rate, reservoir volume, and bead mass) as the mixing 
CAD.  As seen in Figure 56, our hypothesis was partially correct.  The model predicted that the 
packed CAD would remove 8.3% of the initial concentration of TNF in one hour while the 
experimental data show that the mixing CAD at 55, 130, and 550 RPM removed 9.4 ± 1.9%, 
33.9 ± 0.1, and 14.5 ± 6.8% after one hour, respectively.  
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  Figure 56. TNF capture in the packed CAD (theoretical data) and mixed CAD (experimental data) at 55, 130, and 
550 RPM. 
 
The hypothesis was only partially correct because at 550 RPM, capture was less efficient 
than at the critical mixing point, 130 RPM.  This phenomenon may have been due to an increase 
in cytokine desorption due to the high shear rates in the device.  Otherwise, these results tend to 
suggest that the mixing CAD at 130 RPM is indeed an improvement in cytokine capture 
compared to the packed CAD.  We expect that the inclusion of anti-TNF antibodies would 
further increase removal rate and that the combination of the mixing CAD and adsorbed anti-
TNF beads would lead to a significantly increased rate of removal and overall TNF capture.  
Both of these technologies are ready to be tested in a small animal model to further characterize 
their ability to remove TNF and other cytokines.  
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5.0  ALTERNATIVE METHODS TO IMPROVE EFFICIENCY OF CAD 
We have presented the baseline capture data for the packed and mixed CADs as well as an 
antibody immobilized CAD in Chapters 2-4.  Here we explore several alternative methods to 
improve the efficiency of the CAD using various modifications to the beads and device.  First, 
several sets of modified beads were tested to determine the effect of various non-affinity ligands 
and changes to the pore size.  We also tested two types of ligands which had shown some affinity 
for TNF, heparin and TNF-specific DNA aptamer.  Lastly, smaller beads were tested in a device 
designed to minimize biocompatibility issues to test the effect of increasing surface area for 
adsorption within the CAD. 
5.1 MODIFIED CYTOSORB BEADS 
5.1.1 Introduction 
CytoSorb™ beads are synthesized using suspension polymerization, in which droplets of 
monomer are dropped into an immiscible liquid and allowed to polymerize upon dispersion.  As 
this process occurs, the monomer droplets are chemically grafted to the dispersion media, which 
in this case contains poly(N-vinylpyrrolidone) (PVP) [59].  This polymerization method allows 
for inclusion of various other ligands during the process by adding them to the PVP aqueous 
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phase.  Here, we investigate several coated beads that were pre-loaded with different molecules 
that were chosen for their potential to increase the capture rate of middle molecular weight 
cytokines.   
The molecules that were tested were lysozyme, phenylalanine dimer, 
fluorenylmethyloxycarbonyl chloride (Fmoc), α-tocopherol (vitamin E), and Evans blue.  The 
chemical structures of each of these ligands except lysozyme can be seen in Figure 57.  Note that 
only the phenylalanine monomer is shown because the exact structure of the dimerized molecule 
is not known [116].  
 
  Figure 57. Ligands incorporated onto CytoSorb™ bead surface for testing in this section: A) Fmoc, B) α-
tocopherol, C) phenylalanine (monomer), and D) Evans blue. 
 
Each bead coating was chosen based on evidence that including such a coating in the 
cytokine adsorption device (CAD) may have some positive effect on cytokine removal within the 
device or cellular production of cytokines.  Fmoc was chosen as one of the coatings because it is 
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used in solid phase peptide synthesis reactions and could therefore be useful in binding other 
affinity ligands if the beads could be shown to be as effective in removing other cytokines as the 
unmodified CytoSorb™ [117].  Vitamin E supplements have been shown to increase production 
of cytokines from T helper cells in mice and humans infected with certain types of cancer or 
influenza and may therefore be useful to stimulate production of cytokines in a patient suffering 
from sepsis-induced immune suppression [118-119].  Contrastingly, low turnover of 
phenylalanine has been loosely correlated with chronic immune stimulation in autoimmune 
disorders and its inclusion in the CAD may therefore benefit patients in a hyperinflammatory 
state [120-122].  Evans blue is commonly used in determining plasma volume and was chosen 
for this study because of its ability to bind human serum albumin with high affinity [123-124].  
Lysozyme is a 14.7 kDa protein found in granulocytes and secretions such as human milk, 
mucus, saliva, and tears.  Several studies have shown that lysozyme binds lipopolysaccharide 
(LPS) with a high affinity and in turn inhibits in vivo production of TNF and release of IL-6 
[125-126].  The purpose of testing the ability of lysozyme-coated CytoSorb™ was to try to take 
advantage of the cytokine and LPS binding properties of the beads and the coating to make the 
CAD more effective. 
The pore size of the beads can also be controlled during the synthesis process by 
modulating the amount of crosslinking agent added into the aqueous phase during synthesis [59].  
We also present data for three versions of CytoSorb™ with a modified pore structure or no pores 
at all.  As previously described in Chapter 4, we hypothesized that TNF removal was 
significantly slower than removal of IL-6 or IL-10 because diffusion into the pores was hindered 
due to the larger size of trimeric TNF.  One set of beads that we test in this section has a larger 
pore structure intended to improve TNF capture. 
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5.1.2 Methods 
Capture experiments were performed with one or more of the cytokines IL-6, IL-10, or TNF or 
cytochrome c for each type of bead.  For each capture experiment, one CAD was packed with 1.5 
g of the appropriate type of adsorbent material.  Cytochrome c capture experiments began at a 
concentration of approximately 0.5 mg/ml and ran for 60 min at a flow rate of 0.8 ml/min.  The 1 
ml samples were taken from the 8 ml liquid reservoir and the absorbance was measured at 408 
nm using the UV/Vis spectrophotometer.  Cytochrome c capture was performed for the baseline 
CytoSorb™ beads and beads coated with phenylalanine dimer, Fmoc, lysozyme, and alpha 
tocopherol. 
Individual capture experiments with CytoSorb™ beads and phenylalanine dimer, Fmoc, 
lysozyme, and alpha tocopherol coated beads were performed using IL-6, IL-10, and TNF as the 
target analyte.  The same three cytokines were measured in capture experiments using CADs 
packed with poreless and lysozyme-coated poreless CytoSorb™ beads.  The Evans blue coated 
beads were tested for TNF capture only while the large pore beads were tested for removal of 
TNF and IL-6.  Each combination of bead and cytokine were tested in the same way, with 1.5 g 
of adsorbent material packed into a CAD and perfused with 8 ml of cytokine-spiked horse serum 
for either 120 or 240 min at a flow rate of 0.8 ml/min.  Samples were taken over time and 
assayed for cytokine concentration using enzyme-linked immunosorbent assay (ELISA) kits 
(Invitrogen) according to the instructions of the manufacturer. 
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5.1.3 Results and Discussion 
We tested several new types of coated beads and beads with altered pore morphologies for their 
ability to remove cytochrome c or various cytokines.  The first set of experiments tested 
CytoSorb™ beads coated with lysozyme, phenylalanine dimer, α tocopherol, or Fmoc for 
cytochrome c capture versus the baseline CytoSorb™ beads.  These results can be seen in Figure 
58; the lysozyme coated beads removed significantly less cytochrome c than all other beads, 
73.2% versus an average of 98.3 ± 1.0% for all other bead types.   
 
  Figure 58. Cytochrome c removal over time using uncoated CytoSorb™ beads and beads coated with lysozyme, 
Fmoc, phenylalanine dimer, and α tocopherol. 
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 We also performed individual cytokine capture experiments with IL-6, IL-10, and TNF 
with each of the coated beads and the uncoated CytoSorb™ beads.  Figure 59 shows the IL-6 
data, in which the lysozyme coated beads once again removed the least amount of target analyte, 
38.8%.  The uncoated beads removed significantly more IL-6 than any of the coated beads, 85.8 
± 2.8% in 120 min. 
 
  Figure 59. IL-6 removal over time using uncoated CytoSorb™ beads and beads coated with lysozyme, Fmoc, 
phenylalanine dimer, and vitamin E. 
 
 The results for IL-10, seen below in Figure 60, were similar to those of IL-6.  The 
untreated CytoSorb™ beads once again showed the most cytokine removal, 76.2 ± 0.5% after 
120 min.  The lysozyme coated beads demonstrated the least removal of IL-10, with only 38.2% 
of the initial concentration of IL-10 removed after 120 min.  
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  Figure 60. IL-10 removal over time using uncoated CytoSorb™ beads and beads coated with lysozyme, Fmoc, 
phenylalanine dimer, and vitamin E. 
 
 Capture of TNF was also performed with the coated beads (Figure 61).  While the 
untreated beads again showed the most cytokine removal over time, the results did not differ 
significantly from the coated beads. The unmodified CytoSorb™ beads removed 52.5 ± 1.7% of 
the initial amount of TNF in 120 min.  Unlike the IL-6 and IL-10 data, the lysozyme coated 
beads did not the lowest capture rate of all of the coated beads.  The phenylalanine dimer coated 
beads showed the least amount of TNF capture, with 73.0% of the initial TNF remaining after 
120 min. 
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  Figure 61. TNF removal over time using uncoated CytoSorb™ beads and beads coated with lysozyme, Fmoc, 
phenylalanine dimer, and vitamin E. 
 
 We also tested beads coated with Evans blue, an azo dye molecule known for its albumin 
binding properties.  These beads were used only in TNF capture experiments because TNF 
capture is the slowest of all three cytokines and therefore the most in need of improvement.   
Figure 62 shows the results of this experiment, the Evans blue-coated beads removed 51.8 ± 
2.2% of TNF in 4 h compared to the unmodified beads, which removed 65.1 ± 1.5% in the same 
amount of time. 
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  Figure 62. TNF removal over time using uncoated CytoSorb™ beads and beads coated with Evans blue dye. 
 
 The last set of beads tested incorporated an altered pore morphology from the original 
CytoSorb™ beads.  The first of these adsorbent materials had a larger pore size which we 
hypothesized would increase capture of TNF, which naturally occurs as a trimer and is therefore 
larger than IL-6 or IL-10.  We tested the larger pore beads for removal of IL-6 and TNF to 
determine if the increased pore size had any effect on capture of either cytokine.  The results 
seen below in Figure 63 demonstrate that these beads had no effect on capture of either cytokine.  
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  Figure 63. Removal of A) IL-6 and B) TNF over time using unmodified and large pore CytoSorb™ beads. 
 
 The final set of modified beads contained no pores at all within the polymer structure. 
These beads were characterized in order to determine their usefulness as a negative control for 
the porous CytoSorb™ beads.  Of the poreless beads, we tested two kinds: untreated poreless 
beads and lysozyme-coated poreless beads.  The results of individual capture experiments with 
0
0.2
0.4
0.6
0.8
1
0 60 120 180 240
C
(t
)/
C
(0
) 
t (min) 
Unmodified
CytoSorb
Large pore
CytoSorb
A) IL-6 
0
0.2
0.4
0.6
0.8
1
0 60 120 180 240
C
(t
)/
C
(0
) 
t (min) 
Unmodified
CytoSorb
Large pore
CytoSorb
B) TNF 
 130 
each of the three representative cytokines IL-6, IL-10, and TNF can be seen in Figure 64.  As 
expected, the unmodified CytoSorb™ beads had a significantly higher capture rate than both 
types of nonporous beads for each cytokine. 
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  Figure 64. Removal of A) IL-6, B) IL-10, and C) TNF using unmodified, poreless, and lysozyme-coated poreless 
CytoSorb™ beads. 
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 None of the modified beads tested in this section showed any improvement over the 
unmodified CytoSorb™ beads.  The lysozyme coating appears to slow down cytokine capture 
the most out of all of the possible bead coatings.  This phenomenon is most likely due to the 
relatively large size of the protein compared to all of the other coatings.  The beads are very 
hydrophobic which appears to be the reason that the Evans blue coating had no effect although it 
has been shown to be very effective at binding plasma proteins.  
 Additionally, the coated bead cytokine capture data were much noisier than the 
unmodified bead data.  The same effect was seen in the plain and lysozyme-coated nonporous 
beads.  We hypothesize that this phenomenon is caused by weakened interactions between the 
cytokines and the bead surface to which they are adsorbing, causing higher rates of desorption 
over time.  The cytokine capture results combined with the increased variability in cytokine 
concentration over time makes these modified beads unlikely candidates for inclusion in an 
effective hemoadsorption system for treating sepsis.  The uncoated poreless beads, however, 
provide useful information as a negative control for cytokine capture experiments in the 
following section. 
5.2 TNF-SPECIFIC APTAMER IMMOBILIZATION 
5.2.1 Introduction 
Our device removes a variety of middle-molecular weight proteins in the 10-30 kDa range 
including cytokines generally considered of clinical relevance to sepsis such as IL-6, IL-10, and 
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TNF.  While our device has been effective at removing both IL-6 and IL-10 in both in vitro and 
ex vivo animal studies, the removal rate of TNF has been considerably slower than that of IL-6 
and IL-10 [88].  To address this issue, we have begun studying specific capture of TNF by 
immobilized ligands on the outer surface of the polymer beads currently used in the CAD as a 
means to increase the removal rate of TNF.  An ongoing focus in our group has been 
immobilizing antibodies as specific capture ligands for TNF.  Antibodies have several 
drawbacks, including the substantial cost associated with coating several grams of polymer beads 
with TNF antibodies, in addition to their limited shelf life.  Another concern is the potentially 
harmful immune response that may occur if antibodies leach off of the beads.    
A novel alternative to antibodies is aptamer technology, which uses short strands of 
oligonucleotides as affinity ligands.  Aptamers fold into a unique three dimensional structure 
(similar to antibodies) which allows them to specifically bind to a variety of biomolecules with 
affinity constants comparable to that of antibodies (~10
-9
 M).  These nucleic acid oligomers are 
synthesized via an iterative in vitro selection process called SELEX (systematic evolution of 
ligands by exponential enrichment) [127-128].  Aptamers possess several advantages over their 
antibody counterparts as they are less expensive, synthesized in vitro, have longer shelf lives, 
and are less likely to elicit immunogenicity than antibodies [129-130].  Moreover, various 
chemical functionalities can be added to the 5’ and 3’ ends of the aptamer to allow for easier 
conjugation to a surface.   
In this section, we investigate the TNF specific aptamer sequence, 5’-GCGGCCGATA 
AGGTCTTTCC AAGCGAACGA ATTGAACCGC-3’, reported in the patent submitted by 
Zhang et al [131].  We immobilized this aptamer on the surface of the poreless CytoSorb™ 
beads described in the previous section and tested its ability to bind TNF in the CAD and 
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subsequently deplete it from the circulating serum solution.  We chose to use nonporous 
beads because the aptamers, unlike antibodies, are small enough to diffuse into the porous 
network of our standard CytoSorb™ beads.  In addition, the specificity of this aptamer 
sequence to human TNF alpha was evaluated using the enzyme-linked oligonucleotide assay 
(ELONA) methodologies of Yan et al [132]. 
5.2.2 Methods 
Carboxyl groups were incorporated using the modified polystyrene oxidation protocol previously 
described (Figure 13) onto the surface of the poreless CytoSorb™ beads to provide a 
functionalized surface for aptamer coupling [75].  Batches of 2 grams of poreless beads were 
incubated in manganese (VII) oxide in H2SO4 at 65 °C for 1 hour.  The surface concentration of 
carboxyl groups was measured to be 24 nmol/g polymer using the para-nitrophenol colorimetric 
assay [76] that has already been described in Section 3.2.1 for use with the porous beads.  Beads 
were washed with 6 N hydrochloric acid and DI water.  Functional groups were activated by 
incubating the beads with a 1 mg/ml solution of 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 4.5) for 1 hour.  
The beads were washed with MES buffer followed by DI water.  Aptamers were coupled to the 
beads by adding 11 μg/ml aptamer solution in sodium phosphate buffer (pH 7.0) and incubating 
at room temperature for 2 hours.  Aptamers used in this step were functionalized with an amine 
group at the 5’ end for coupling.  Beads were washed with a .05% Tween solution followed by 
DI water.   
For TNF capture experiments, 1.5 grams of aptamer-immobilized beads or unmodified 
beads were packed in an unused CAD and connected in series with a peristaltic pump.  Inlet and 
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outlet tubes were connected to an 8 ml reservoir of horse serum spiked with TNF at a 
concentration of ~ 1200 pg/ml.  The reservoir was perfused through the CAD at a flow rate of 
0.8 ml/min and samples were taken at t = 0, 15, 30, 60, 90, 120, 180, 240 min.  TNF 
concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) 
(Invitrogen) according to the instructions of the manufacturer.   
The ELONA technique was performed as follows.  Recombinant human TNF 
(ThermoFisher) was diluted to 5 μg/ml using coating buffer (0.05 M sodium carbonate pH 9.76), 
and 100 μl of this solution was incubated overnight at 4°C in a polystyrene microplate.  As a 
negative control, recombinant human IL-6 (ThermoFisher) at the same concentration was used. 
The plate was washed with a 0.15M NaCl buffer, pH 7.4, containing 0.1% Tween 20, and 
remaining adsorption sites were then blocked with 100 μl of 1% bovine serum albumin (BSA) in 
phosphate-buffered saline (PBS) for 2 h at 37°C.  Wells were once again washed followed by 
addition of 100 μl of TNF-specific DNA aptamers at concentrations of 1.10x107, 1.10x105, 1104, 
552, and 276 pg/ml.  100 μl of the 1104 pg/ml aptamer solution was added to the IL-6 coated 
well as a negative control, and 100 μl of biotinylated TNF antibody (Invitrogen) was used a 
positive control.  The aptamer/antibody solutions were incubated at 37°C for 1 h and then 
washed.  100 μl of streptavidin-conjugated horseradish peroxidase (Invitrogen) was added to 
each well and incubated at 37°C for 1h.  The wells were washed for the final time, after which 
100 μl of tetramethylbenzidine (TMB) substrate solution was added to each well.  After 20 min, 
the optical density was measured at 450 nm on a MultiSkan Plus microplate reader 
(ThermoFisher).  
We also evaluated the affinity of a well-established aptamer for its target ligand using 
ELONA to ensure that the technique was being done correctly.  Green et al. published a DNA 
 136 
aptamer sequence, 5’-CAGGCTACGGCACGTAGAGCATCACCATGATCCTG-3’, which 
exhibited high binding affinity towards platelet-derived growth factor BB (PDGF-BB) [133].  
The methods used in the PDGF-BB ELONA were the same as those used in the TNF ELONA.  
Wells were coated with PDGF-BB and the PDGF-BB aptamer was the target analyte.  IL-6 was 
once again used as the negative control. 
5.2.3 Results and Discussion 
Figure 65 shows the results of TNF capture for horse serum perfused through the CAD packed 
with aptamer-immobilized poreless CytoSorb™ beads and unmodified poreless CytoSorb™ 
beads (control).  Neither the aptamer-immobilized nor the unmodified beads were able to 
significantly decrease the circulating concentration of TNF.   
 
  Figure 65. TNF capture with unmodified poreless CytoSorb™ beads and carboxylated poreless CytoSorb™ beads 
containing immobilized TNF-specific aptamers. 
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The results of the human TNF and PDGF-BB ELONAs are shown in Figures 66 and 67, 
respectively.  The TNF ELONA data indicate that the TNF aptamer exhibited no binding affinity 
toward recombinant TNF.  The positive control, a biotinylated human TNF antibody, showed a 
significant amount of binding affinity toward TNF relative to the negative control and test wells.   
 
  Figure 66. TNF aptamer ELONA results. 
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  Figure 67. Platelet-derived growth factor BB aptamer ELONA results. 
 
The ability of CADs packed with aptamer-immobilized or unmodifed beads to capture 
TNF from horse serum was tested.  The results in Figure 65 show that TNF capture with 
unmodified and aptamer-immobilized beads was negligible.  The aptamer-immobilized on the 
surface of the CytoSorb™ beads was reported to specifically bind TNF; therefore we expected 
that the aptamer-immobilized beads would display a significantly higher ability to capture TNF 
than the control beads.  Based on the surface density of carboxyl groups on the beads, we 
calculated that if successfully coupled there would be at least a 10 molar excess of aptamer to 
TNF.  Therefore, one possible explanation is that the TNF aptamer was not successfully coupled 
to the surface of the CytoSorb™ beads.  This is unlikely however, as we have successfully 
coupled antibodies to the CytoSorb™ beads using the same chemistry.  Another possible 
explanation was that the reported aptamer did not bind to TNF.  To characterize the affinity of 
the published aptamer for TNF, we utilized a previously reported enzyme-linked oligonucleotide 
assay (ELONA) [132].   
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From the ELONA data we are able to conclude that the TNF aptamer sequence does not 
specifically bind TNF.  The discrepancies in these data could be a result of differences in the 
protein at which the aptamer was targeted.  Our group used commercially available recombinant 
human TNF, but the recombinant protein used by Zhang et al. was produced in their laboratory.  
The target proteins were synthesized in different environments, which may suggest that the three 
dimensional structure of the proteins may have differed enough to impact the affinity of the 
aptamer toward TNF.  The TNF used in our work was in its correct three-dimensional shape, as 
evidenced by our positive control, a TNF antibody, being able to bind TNF in the ELONA.  A 
TNF antibody was not used as a positive control in either the patent or published description of 
the RNA aptamer [131-132].   
The aptamer sequence, 5’-GCGGCCGATA AGGTCTTTCC AAGCGAACGA 
ATTGAACCGC-3’, reported by Zhang and coworkers does not appear to bind commercially 
available recombinant TNF.  Although aptamers may still prove beneficial as a high affinity 
ligand for cytokine capture, their usefulness in our particular device cannot be determined using 
this aptamer. 
5.3 HEPARIN COATED BEADS 
5.3.1 Introduction 
One of the primary goals of the previously described work was to increase capture of TNF 
without affecting the removal rate of other cytokines.  One potential affinity ligand for TNF is 
heparin, which has been shown to have some affinity for several cytokines, including TNF, and 
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therefore may hold the potential for selective reduction of cytokine concentration as a therapy for 
septic patients [134-136].  Heparin-coated tubing has been extensively studied as a way of 
reducing systemic inflammation during cardiopulmonary bypass (CPB) [137-138].  CPB patients 
show an increase in TNF and IL-6, among other cytokines, and heparinizing the bypass circuit 
leads to a reduction in cytokine release and improves the overall biocompatibility of the loop as 
well as decreasing morbidity and mortality of CPB patients [139]. 
Axelsson et al. [140] have incorporated heparin onto 0.3 mm polyethylene (PE) beads by 
covalently attaching heparin using sodium cyanoborohydride as a reducing agent [141].  
Cytokine concentrations before and after a single pass through a resin-containing column were 
measured using photoluminescence for varying flow rates and masses of beads using both 
control and heparin-bound beads.  Their main conclusion is that “passing blood from septic 
patients through a column packed with surface heparinized beads...significantly reduce[d] 
concentrations of the proinflammatory cytokine tumor necrosis factor (TNF)-α from initially 
very high levels.” [140] 
In this section we explore the usefulness of heparin, a 12-15 kDa glycosaminoglycan, as 
an adsorbed affinity ligand for the selective increase of TNF removal in our CAD system.  Once 
again, IL-6 removal is also characterized to determine the effect of the adsorbed ligand on 
capture of smaller cytokines.  Lastly, we compare our adsorbent material and device to those 
used in Axelsson et al. to determine the relative efficiency of the CAD. 
5.3.2 Methods 
Adsorption was chosen as the immobilization method for heparin based on previously reported 
data for anti-TNF antibodies.  The same adsorption procedure from Section 3.2.4 was used with 
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heparin sodium isolated from porcine intestinal mucosa (Sigma; St. Louis, MO) with an activity 
of approximately 180 USP units/mg.  Both wet and dry beads were used for heparin adsorption.  
CytoSorb™ beads were dried by incubating for 1 h in a 60°C oven on paper towels.  Either 2 or 
20 mg/g of lyophilized heparin was dissolved in 10 ml of sodium phosphate buffer and incubated 
with the wet or dry beads for 3 h at room temperature on a rocker.  Beads were then washed four 
times each with Tween 20 and DI for 5 min.  The dry beads were re-wetted by flushing with ten 
volumes (approximately 10 ml) of 70% v/v isopropyl alcohol followed by four washed for 5 min 
each with DI water.   
 Wet or dry control or heparin-coated beads were then packed into CAD cartridges and 
connected in line with a peristaltic pump, as previously described in Section 2.2.2.2.  Briefly, 
horse serum was spiked with TNF alone or both TNF and IL-6, each at a concentration of 1-2000 
pg/ml.  The cytokine-rich solution was perfused through the column for 4 h and 100 μl samples 
were taken over time and analyzed for TNF or IL-6 concentration using ELISA according to the 
instructions of the manufacturer. 
5.3.3 Results and Discussion 
CytoSorb™ beads were coated with heparin to increase capture of TNF in our hemoadsorption 
device, similarly to Axelsson et al. (2010) [140].  The results of our initial test of these beads, in 
which heparin was physically adsorbed to the beads under the same conditions used previously 
with anti-TNF antibodies, can be seen in Figure 68. 
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  Figure 68. Capture of TNF from horse serum using 20 mg/g heparin coated and unmodified wet beads. 
 
One interpretation from the negative result in the previous experiment is that the heparin 
was adsorbed throughout the bead surface and not isolated to the outer surface of the beads, as 
with the anti-TNF antibodies.  Heparin has a slightly lower molecular weight than IL-6 and IL-
10, which would support this hypothesis.  We suspect that TNF capture was lower in the heparin-
coated beads because so many of the potential adsorption sites were occupied by heparin both on 
the surface and within the pores.  To eliminate this problem, we dried the beads, thereby 
decreasing the likelihood that an aqueous solution would penetrate into the porous network of the 
beads.  We hypothesized that heparin immobilized under these conditions would be confined to 
the outermost surfaces of the beads.  TNF capture was performed upon re-wetting of both the 
baseline and 20 mg/g heparin coated beads.  The results of this experiment show that the 
heparin-coated beads removed 67.8 ± 0.38% of the initial TNF concentration while the 
unmodified beads removed only 36.1 ± 14.2% (see Figure 69).  
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  Figure 69. Capture of TNF from horse serum using 20 mg/g heparin coated and unmodified beads that were dried 
and re-wetted. 
 
We conclude from the TNF capture data with the dried and re-wetted beads that the re-
wetting procedure is insufficient to restore the polymer to its pre-dried state, as demonstrated by 
the decrease in overall capture of TNF with the baseline wet and baseline re-wetted beads 
(Figures 68 and 69).  However, the data can still be useful in concluding that the heparin coating 
significantly increases capture of TNF compared to the unmodified beads.  The beads must still 
be able to remove smaller cytokines at the same level as the unmodified beads for the heparin 
coating to be of use in treating sepsis.  To characterize smaller cytokine removal capabilities of 
the dried and re-wetted heparin coated beads, we measured IL-6 removal simultaneously with 
TNF capture from the previous experiment.  Figure 70 shows that capture of IL-6 with the 
heparin-coated and unmodified beads was not significantly different, at 89.0 ± 3.3% and 82.2 ± 
0.68% overall removal, respectively. 
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  Figure 70. Capture of IL-6 from horse serum using 20 mg/g heparin coated and unmodified beads that were dried 
and re-wetted. 
 
Lastly, we tested the ability of the dried and re-wetted heparin-coated beads to remove 
TNF when heparin was adsorbed at two different concentrations.  We tested both 2 and 20 mg 
heparin/g beads to determine if we were approaching the upper limit of the beads’ capacity for 
heparin at these levels.  The results of TNF capture with these two different concentrations of 
heparin coated beads can be seen in Figure 71; the low and high heparin concentration beads 
removed 53.5 ± 0.68% and 67.8 ± 0.38% of the initial TNF after 4 h, respectively.  From these 
data we can conclude that 20 mg/g has not saturated the beads and TNF capture could be 
increased by increasing the concentration of heparin added during immobilization.  However, at 
higher concentrations, the heparin begins to approach the cost of the anti-TNF antibodies. 
0
0.2
0.4
0.6
0.8
1
0 60 120 180 240
C
(t
)/
C
(t
=
0
) 
t (min) 
20 mg heparin/g
re-wetted beads
Baseline re-
wetted beads
 145 
 
  Figure 71. Capture of TNF from horse serum using 2 and 20 mg/g heparin coated beads that were dried and re-
wetted. 
 
Axelsson et al. (2010) [83] report the initial concentration of TNF to be 50.3 pg/ml as 
measured using the Quantikine enzyme-linked immunosorbent assay (ELISA) (R&D Systems, 
Cat HSTA00D; Minneapolis, MN).  A single pass of 1 ml of blood through a column containing 
1 g and 10 g of the heparin-coated beads reduced the concentration to 21.1 pg/ml (-58%) and 
20.6 pg/ml (-59%), respectively.  In order to maintain this level of removal in a full-scale device, 
the device would have to contain a minimum of 5 kg of material.  A device this size would result 
in a priming volume of at least 1.5 L for a typical void fraction of 30%.  
A more realistic device would be sized at approximately 300-500 g of material per 
patient, similar to the full size CytoSorb™ device [142].  Thus, for their experiments, Axelsson 
et al. should have either used 0.1 g of material and 1 ml of blood or 1 g of material and 10 ml of 
blood.  The authors showed that 1 g of the heparin-coated beads removed a total of 29.2 pg of 
TNF.  In an appropriately scaled experimental setup containing 10 ml of blood instead of 1 ml, 
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the actual amount of removal would have only been 29.2/503 pg TNF, or 5.8%.  Our analyses 
have shown that our device containing unmodified CytoSorb™ removes 20% of TNF in a single 
pass setup mimicking that of Axelsson et al. and that this amount is not significantly increased 
when we incorporate the same amount of heparin on the wet adsorbent material.  
TNF capture with the beads can be increased using heparin only when the beads are first 
dried to ensure that heparin adsorption is relegated to the outermost surface area of the beads.  
Without an adequate re-wetting procedure, however, the increase in TNF capture is still only as 
good as the unmodified wet beads.  Our conclusion from this study is that heparin does not 
demonstrate enough of an effect on TNF capture to justify its use at such high concentrations on 
the beads; a much higher increase in TNF capture can be achieved with the anti-TNF antibodies 
for approximately the same cost.  
5.4 RE-ENGINEERED DEVICE FOR SMALL BEADS 
5.4.1 Introduction 
According to their patent description, CytoSorbents can change the diameter of the beads by 
changing the stir rate of the organic phase droplets in the aqueous phase during polymerization 
[59].  This method has been used to produce beads with an average diameter of both 73 and 117 
μm along with the baseline beads that have an average diameter of 530-580 μm.  Previous 
experiments with the smaller diameter CytoSorb™ beads have shown that cytokine capture rates 
can be significantly improved due to the increase in surface area in the device (Section 2.2.3).  
Another advantage of the small beads is that biocompatibility of the device can be improved by 
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shortening the perfusion time from the typical 4 h treatment time while still achieving the same 
overall removal.  Reducing blood contact time with the perfusion loop and CAD would decrease 
complement and coagulation pathway activation which are of great concern during blood 
purification therapies [143-144].   
Although smaller beads lead to more favorable treatment times, the decreased diameter of 
the beads can have detrimental effects due to the increased shear stress and surface area 
associated with smaller particles.  High shear stress (or lower shear stress sustained over a longer 
time) can cause high levels of hemolysis and platelet activation, the latter of which leads to 
platelet adhesion and thrombus formation [145].  Most devices which use particles in the same 
size range as the small CytoSorb™ beads include a plasmapheresis step to avoid the added 
biocompatibility complications that may arise due to shear stresses within the bead-filled column 
[96].  The CAD is intended to be a single-step hemofiltration unit; therefore, we aimed in this 
section to quantify the shear rates in the device theoretically and experimentally to determine if 
the small beads would be expected to cause hemolysis.  Additionally, we redesigned the device 
itself to accommodate the smaller beads and decrease the effective shear stress on red blood cells 
being perfused through the device.  We present below the design specifications for this re-
engineering cytokine adsorption device (reCAD) and the results of pressure drop testing to 
determine whether the redesigned device would cause hemolysis. 
5.4.2 Methods 
The first step in characterizing the shear stress exerted on blood cells in the original CAD design 
was to experimentally quantify the pressure drop across the column as a function of flow rate.  
Cartridges were connected to a syringe pump (Harvard Apparatus; Holliston, MA) and perfused 
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with DI water at various flow rates ranging from 0-1.0 ml/min.  A pressure transducer was 
connected to the inlet and outlet of the cartridge using three-way stopcocks and voltage outputs 
from the pressure transducer were recorded and manually converted to mmHg.  Readings from 
both ends of the devices tested were taken in duplicate.  The original CAD devices were tested in 
this setup using the small beads, and the beads were contained in the devices with 27, 40, or 75 
μm polypropylene mesh screens (Small Parts; Seattle, WA). 
 We also tested a new configuration of the original CAD to reduce the pressure drop 
across the cartridge with the 40 μm polypropylene mesh filter.  Typically, a porous plastic filter 
is used as the base onto which the mesh filter is glued.  We hypothesized that this plastic piece 
was contributing to the high pressure drop when the cartridge was packed with the small 
CytoSorb™ beads.  The plastic filter was eliminated and the polypropylene mesh was glued 
directly onto the main plastic cartridge body of the CAD using as little silicon glue as possible.  
These altered CADs were packed with the small diameter beads and tested for pressure drop 
using the methods described above. 
We also calculated a theoretical pressure drop for the two different sizes of beads in the 
original CAD using the Ergun equation for fluid flow in a packed bed [146]:  
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where ∆P is the pressure drop, L is the bed length, μ is the viscosity of the solution, VS is the 
superficial velocity, DP is the particle diameter, and ε is the void fraction of the packed bed.  
Using the theoretical pressure drop, we can calculate the shear stress using the following 
equation, obtained from a steady state macroscopic momentum balance: 
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Where τ is the average shear stress on the bead surfaces, Aε is the cross-sectional area of the 
column, and SP is the surface area of the particles in the column [86].  We can also calculate a 
residence time of blood in the device using the size of the cartridge, void fraction, and the 
volumetric flow rate.  A plot of shear stress versus residence time was created and compared to 
the threshold for shear-induced hemolysis taken from Vaslef and Anderson (2002) [147].  By 
varying the aspect ratio of the CAD, we were able to decrease the theoretical shear stress to a 
safe level.  The dimensions of the redesigned column were determined to be 0.5 cm long by 2.2 
cm wide, compared to the original CAD that was 2.5 cm long by 1 cm wide.  The new devices 
were designed to contain approximately 2.5 g of small CytoSorb™ beads while the original CAD 
contained 1.5 g of standard-sized CytoSorb™ beads.  The re-engineered CAD (reCAD) can be 
seen in Figure 72. 
 
  Figure 72. Re-engineered cytokine adsorption device (reCAD). 
 
 The clear end of the reCAD which contains the beads is a 1.13” long section of a 30 ml 
disposable syringe (BD; Franklin Lakes, NJ).  The opaque end of the reCAD is a machined piece 
of Delrin onto which a female luer lock is glued.  The 40 μm polypropylene mesh is punched out 
to fit either end of the reCAD and glued directly onto the plastic ends using silicon glue 
(Permatex; Solon, OH).  Small beads were poured into the clear end and the opaque cap was 
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attached.  The mass of beads in the device was measured in the same way as the original CAD, 
by recording the mass of the entire device before and after filling it with beads.  The reCAD was 
tested for pressure drop versus flow rate in the same way as the original CAD and these data 
were compared to the theoretical shear stress data obtained using the Ergun equation to ensure 
that the devices would be safe for whole blood perfusion. 
5.4.3 Results and Discussion 
In this section we investigated the pressure drop across the cartridge of the original CAD design 
for small CytoSorb™ beads.  High pressure drops lead to high shear stresses in the column 
which can cause detrimental levels of hemolysis during blood perfusion.  Our goal was to 
minimize the pressure drop for the small beads and reduce the associated shear stress to safe 
levels. 
Our initial hypothesis was that the size of the mesh used in containing the beads in the 
original CAD was inversely proportional to the pressure drop, therefore leading to higher shear 
stresses in the column.  To test this theory we measured the pressure drop in the original CADs 
packed with small diameter beads that were contained with one of three sizes of mesh filters.  As 
Figure 73 shows, the hypothesis was partially correct.  The 40 μm mesh demonstrated a lower 
pressure drop compared to the 27 μm mesh as expected.  However, the 75 μm mesh showed the 
highest pressure drop of all three mesh screens.  We concluded that the beads, with an average 
diameter of 73-117 μm, were getting stuck in the holes of the mesh screen and therefore clogging 
the device and leading to higher pressure drops.  A closer inspection of the mesh screen 
following the pressure drop testing confirmed this.  All subsequent CADs and reCADs were 
fabricated with the 40 μm mesh screen. 
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  Figure 73. Flow rate vs. pressure drop data for the small beads in the original CAD contained with 27, 40, and 75 
μm polypropylene mesh screens. 
 
 We attempted to reduce the pressure drop in the original CAD containing small beads by 
changing the configuration of the 40 μm mesh screen.  The hypothesis was that the porous plastic 
filter piece was causing higher pressure drops across the column and that eliminating that piece 
would reduce the pressure drop.  The mesh screen was glued directly into the body of the 
cartridge and pressure drop was tested in the same way. The results of this experiment can be 
seen in Figure 74; the new filter configuration did not decrease pressure drop as we had intended.  
The pressure drop was increased in both trials using the new configuration. 
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  Figure 74. Flow rate vs. pressure drop data for the small beads in the original CAD contained with 40 μm 
polypropylene mesh screens with or without the additional plastic filter. 
 
 Our final attempt to decrease the pressure drop involved a complete redesign of the CAD.  
We changed the aspect ratio of the device to be wider and shorter than the original device.  A 
theoretical calculation of the pressure drops in the CAD and reCAD suggested that the newly 
redesigned device would sufficiently decrease the shear stress in the device to make it safe for 
whole blood perfusion.  Experimental pressure drop data comparing the two devices can be seen 
in Figure 75; the reCAD showed a significantly lower pressure drop than the original device. 
y = 34.475x + 2.3951 
R² = 0.9983 
y = 49.371x - 1.0371 
R² = 0.9979 
0
10
20
30
40
50
60
0 0.2 0.4 0.6 0.8 1 1.2
P
re
ss
u
re
 d
ro
p
 (
m
m
H
g
) 
Flow rate (ml/min) 
original CAD, standard
mesh configuration
original CAD, new filter
configuration
 153 
 
  Figure 75. Flow rate vs. pressure drop data for the small beads in the original CAD contained with 40 μm 
polypropylene mesh screens with or without the additional plastic filter. 
 
 Figure 76 shows the shear stress results for both the CAD and reCAD, which were 
determined from either theoretical or experimental pressure drop data at 1.0 ml/min.  The solid 
black line on the graph represents the threshold for unsafe levels of hemolysis, as described in 
Vaslef and Anderson (2002) [147].  These results confirm that the original CAD packed with 
small beads would not be able to be perfused with whole blood directly without causing 
hemolysis.  Additionally, the shear stress of the small beads in the reCAD would not be expected 
to lead to high levels of hemolysis and could be used for direct hemoperfusion. 
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  Figure 76. Theoretical and experimental results for shear stress versus exposure time for the original CAD and 
reCAD at a flow rate of 1.0 ml/min. 
 
 This new version of the CAD can effectively be used in cytokine capture experiments as 
a way of significantly increasing the removal of all middle molecular weight cytokines.  This 
redesign holds the most potential of all of the improvements we have tested in the CAD because 
we have demonstrated that it would be safe for direct hemoperfusion and the small beads have 
shown very fast removal rates of the cytokines IL-6, IL-10, and TNF. 
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6.0  DEVELOPMENT OF CELL PROGRAMMING DEVICE 
As mentioned in Chapter 1, one of the potential negative effects of systemic inflammation is 
immune paralysis.  Patients in a prolonged septic state often suffer from immune dysfunction and 
death may result due to an inability to clear the original infection or new superinfections [22].  In 
this chapter, we focus on an alternative method of treating diseases like sepsis where white blood 
cells are not responding appropriately to an insult.  Neutrophils and other leukocytes respond to 
stimuli through the binding of their surface receptors to ligands in circulation or along the 
endothelium [83].  Our goal is to use the microcirculation of an extracorporeal device as a 
priming area for neutrophils that will modulate their subsequent cell-cell interactions once they 
leave the device.   
Chemokines are a type of cytokine which are named for their ability to not only perform 
the immunoregulatory functions characteristic of many cytokines but also for their ability to 
induce chemotaxis of leukocytes by binding to specific receptors on their surface [37].  
Chemokines bind to G-protein-coupled receptors (GPCRs) on the leukocyte surface, causing 
internalization and consequently degradation or recycling of the receptor to occur [148].  The 
activation of leukocytes via chemokine binding leads to cellular migration during times of both 
routine immunomodulation and inflammation.  Often, surface GPCRs bind several different 
chemokines, such as interleukin-8 (IL-8) binding to the chemokine receptors CXCR1 and 
CXCR2.  Using chemokine naming conventions, IL-8 is also known as CXCL8, representing the 
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ligand of a CXC chemokine which by definition has two amine-terminated cysteine residues 
separated by a single amino acid residue [37].  Of all 15 identified CXC chemokines, IL-8 
displays the greatest ability to induce migration of neutrophils to sites of inflammation [149].  
Although small amounts have been identified on other cell types, both CXCR1 and 
CXCR2 are expressed almost exclusively on monocytes and neutrophils [37].  Samanta et al. 
(1990) showed that IL-8 downregulated over 90% of its neutrophil surface receptor within 10 
min at 37˚C [150].  These data suggest that IL-8 is a good candidate for neutrophil 
reprogramming in our proposed device.  Downregulation of receptors after binding with 
chemokines is achieved through internalization, which occurs by a number of different 
mechanisms.  For the specific case of IL-8 binding to CXCR1 and CXCR2, the receptors 
undergo phosphorylation in their carboxyl-terminus and intracellular loops by G protein-coupled 
receptor kinases (GRKs).  The G protein subunits then uncouple from the subunits and the 
phosphorlyated areas become associated with adaptor molecules β-arrestin and adaptin 2 (AP-2).  
Clathrin is then recruited by the adapter molecules and clathrin-coated pits are formed.  These 
pits become clathrin-coated vesicles through the localization of dynamin and its ability to cause 
the pits to encapsulate themselves and pinch off from the membrane.  Internalization occurs 
when the vesicle becomes uncoated and is taken up into the early endosomal compartment.  
From here, the chemokine receptor can take one of two actions: it can enter the perinuclear 
compartment and be recycled to the plasma membrane where it will be reexposed to ligand, or it 
can move on to the late endosomal compartment where it will eventually be sorted and degraded 
[148].  Figure 77 shows a diagram of the steps associated with GPCR internalization after 
chemokine binding.  
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  Figure 77. Steps of GPCR internalization: 1. chemokine binding to receptor, 2. formation of clathrin-coated pit and 
association with various cofactors, 3. formation of clathrin-coated vesicle, 4. recycling (a) or degradation (b). 
 
IL-8 receptor downregulation has been well-characterized but very little is known about 
the requirements for binding.   Although both free and bound IL-8 are found in vivo, one study 
suggests that tethering to glycoasaminoglycans (GAGs) on the extracellular matrix and 
endothelial cell wall are necessary to maintain the in vivo activity of chemokines [151]. Little is 
known about whether or not ex vivo binding of IL-8 to its receptors can be accomplished when 
IL-8 is not either anchored to a GAG or present in free solution.  Additionally, the question 
remains as to whether or not IL-8 is internalized with its cell-surface receptors after binding.  
Several groups have investigated the effect of physically adsorbed IL-8 on neutrophil rolling and 
adhesion dynamics, but have never conclusively showed that the IL-8 did not leach off of the 
surface and into free solution [152-153].  
Currently, the only data which exist to show that covalently immobilized IL-8 can initiate 
a downstream response in neutrophils the same way that free IL-8 can is based on micropipette 
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studies with single neutrophils.  Lomakina et al. showed that neutrophil adhesion to intracellular 
adhesion molecule-1 (ICAM-1) was significantly increased in the presence of immobilized IL-8.  
IL-8 was immobilized on a small bead that was brought into contact with a single cell and the 
bead containing IL-8 was almost always engulfed by the neutrophil.  However, in 20% of the 
experiments at the lowest site density of IL-8, the beads were not phagocytosed but adhesion to 
ICAM-1 was still significantly increased [153]. 
The migratory action of polymorphonuclear neutrophils (PMNs) is mediated by CXCR1 
and CXCR2, both of which bind to IL-8.  Low concentrations of IL-8 (10-50 ng/ml) trigger 
activation and migration of white blood cells, while high concentrations (~1000 ng/ml) cause 
migratory activity to shut off [149].  Activation of PMNs in response to inflammation causes the 
release of cytokines such as TNF and interleukin-12, and of chemokines such as macrophage 
inflammatory protein (MIP)-1, MIP-3, and MIP-1 [154].  The increased expression of these 
inflammatory mediators contributes to the worsening immune response seen in septic patients 
[37].  
Experiments in which the gene encoding for CXCR2 (the only murine IL-8 receptor) in 
mice was deleted showed that the mutant mice did not develop sepsis in a peritonitis model, 
whereas control animals did [155].  Rose et al. (2004) also showed that the receptors to IL-8 are 
globally inactivated by agonist concentrations above a certain threshold, which they hypothesize 
corresponds to neutrophils reaching the site of inflammation in vivo [156].  Kaneider et al. 
(2005) proposed to treat systemic inflammatory response syndrome by using chemokine receptor 
pepducins, lipid-conjugated peptides that selectively inhibit GPCR signaling.  Their work 
showed that the CXCR1 and CXCR2-targeted pepducins prevent IL-8 from binding and 
significantly reduce mortality in mice undergoing cecal ligation and puncture (CLP) as a model 
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for sepsis.  They also showed that a pepducin for CXCR4, a neutrophil surface receptor which 
has an effect on migration but does not bind IL-8, had no effect on survival up to 9 days after 
CLP despite showing a similar decrease in migratory activity [157].   
The migratory activity of neutrophils mediated by IL-8 receptors CXCR1 and CXCR2 is 
shut off when the receptors come into contact with high concentrations of IL-8.  CXCR1 and 
CXCR2 undergo phosphorylization, desensitization, and internalization after binding of CXCL8.  
Cells become unavailable for subsequent ligand-induced activation and demonstrate attenuated 
or even abolished responses.  More than 95% of CXCR2 internalizes within 2–5 minutes of 
activation as compared to only 10% of CXCR1.   After removal of CXCL8, CXCR1 recovers 
faster to the cell surface (100% after 90 min) than CXCR2 (35% after 90 min) [158].  
Downregulation of chemotaxis and consequent expression of more inflammatory mediators may 
be a potential new treatment for sepsis.  Similarly, priming of neutrophils with lower 
concentrations of IL-8 may in fact activate them and work against immune paralysis in patients 
in a hypoinflammatory state. 
6.1 IL-8 IMMOBILIZATION ON CELLULOSE TRIACETATE FIBERS 
6.1.1 Introduction 
The first matrix we used for IL-8 immobilization was a cellulose triacetate fiber taken from a 
Baxter CT-110G dialyzer (Baxter; Deerfield, IL).  The chemical structure of cellulose triacetate 
and scanning electron microscope (SEM) images of the inner, outer, and cross-sectional view of 
the fibers can be seen in Figure 78.  Note that in this diagram, all three functional groups on the 
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cellulose monomer contain acetate molecules.  In actuality, the polymer used in the fibers 
contains a mixture of cellulose acetate monomers in which any combination of 0-3 functional 
groups can contain hydroxyl or acetate groups.  These particular fibers have an inner diameter of 
200 μm and a wall thickness of 15 μm.  
 
  Figure 78. Characteristics of Baxter CT fibers: A) cellulose triacetate monomeric unit and SEM images of B) the 
inner lumen, C) the outer lumen, and D) the cross-sectional view of a single fiber. 
 
The exposed hydroxyl groups on the cellulose triacetate fibers allow for simple activation 
and covalent linkage using the well-characterized cyanogen bromide (CNBr) chemistry [71].  
The chemical structure of the fibers is homogeneous and therefore activation is possible on both 
the inner and outer fiber surfaces.  Figure 15 shows a detailed schematic of the CNBr activation 
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reaction for hydroxyl groups on a bead, which can also be applied to the hydroxyl groups of the 
fibers.  Once again, the hydroxyl groups are activated and covalently bound to exposed amine 
groups on the protein. 
Both cyanate esters and cyclic imidocarbonates groups are created when the fibers are 
activated.  The cyanate esters groups form a much stronger covalent bonding with the protein to 
be immobilized but are less prevalent when cellulosic matrices are activated by CNBr.  
Additionally, this type of activation is characterized by a slow, sustained leakage of ligand 
because of the transient nature of the isourea bond formed between the cellulose and the protein.  
Still, the expected efficiency of CNBr activation is about 85% [71]. 
We used two methods to measure the efficiency of our coupling reaction.  In the first, we 
quantified the amount of IL-8 lost during the immobilization and rinsing steps and compared it to 
the approximate amount of IL-8 originally added.  The second method indirectly quantified IL-8 
concentration on the fibers by measuring their ability to bind and retain anti-IL-8, an 
immunoglobulin G type antibody specific to IL-8. 
 
6.1.2 Methods 
The protocol for cellulose fiber activation was adapted from Hermanson et al (1992) [71].  
Briefly, 50 fibers were cut to 4 cm each and placed in a test tube.  The fibers were rinsed with DI 
water for 30 min and then swollen on ice in a solution of 0.2N NaOH.  Fibers were rinsed one 
more time with a 1:1 solution of sodium bicarbonate buffer and 0.5M NaCl.  The fibers were 
then transferred to a beaker containing a stir bar using 10 ml of 0.2N NaOH.  2 g of CNBr were 
dissolved in 3 ml of acetonitrile immediately prior to beginning the activation.  The 
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CNBr/acetonitrile solution was added to the beaker containing the fiber pieces and the mixture 
was continuously stirred throughout the reaction.  To test for nonspecific binding of IL-8 to the 
fibers, one control module was prepared with no CNBr added in this step.  Both pH and 
temperature were monitored in the beaker; pH was maintained above 11.0 by adding single drops 
of 10N NaOH as needed and temperature was kept below 25C by adding ice.  Once the pH 
settled above 11.0 (after approximately 10 min) the reaction was considered complete and the 
fibers were transferred back to the test tube.  Fibers were then washed for one minute each with 
DI water and sodium bicarbonate buffer.  Finally, the test tube was filled with 10ml of sodium 
carbonate buffer before adding 25 μg of recombinant monocyte-derived human IL-8 (Invitrogen; 
Carlsbad, CA).  The test tube was incubated overnight on a rocker at 4C. 
For the first method of IL-8 quantification, 100 μl samples were taken from all wash 
eluents during the immobilization process and the total volumes of each eluent were recorded.  
The concentration of IL-8 in each sample was determined using an IL-8 enzyme-linked 
immunoassay (ELISA) kit (Invitrogen) according to the instructions of the manufacturer.  These 
concentrations were then multiplied by the corresponding wash eluent volume to calculate the 
total amount of IL-8 lost in each step, the sum of which was compared to the original amount of 
IL-8 added (25 μg).  
The second method for characterizing IL-8 immobilization on the fibers was done using 
biotinylated anti-IL-8 (Invitrogen).  The cellulose fiber pieces containing IL-8 were incubated 
with a 5 μg/ml antibody solution in 0.05% Tween 20 and PBS for 4 hours while being gently 
rocked.  100 μl samples were taken before adding the antibody solution to the fibers as well as 
after 15, 30, 60, 90, 120, 180, and 240 min and frozen at -70°C until they could be assayed for 
anti-IL-8 concentration.  These samples were also tested for concentration of IL-8 using ELISA. 
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We used a direct ELISA method to quantify anti-IL-8 concentration.  To do so, we first 
coated the wells of a 96-well microplate with 100 μl of a 5 μg/ml solution of IL-8 in sodium 
carbonate buffer overnight at 4°C.  The plate was then washed using an automated microplate 
washer using a standard wash/diluent buffer for ELISA.  The recipe for the standard diluent 
buffer (SDB) used in this and all other ELISAs can be found in Table 6.  
 
Table 6. Standard wash buffer for ELISA 
Ingredient name, chemical formula Amount to be added 
Sodium chloride, NaCl 8.0 g 
Sodium phosphate (dibasic), Na2HPO4∙2H2O 1.42 g 
Potassium phosphate (monobasic), KH2PO4 0.2 g 
Potassium chloride, KCl 0.2 g 
Bovine serum albumin (BSA) 5.0 g 
Tween (polysorbate) 20, C58H114O26 1.0 ml 
Deionized water, H2O 1.0 L 
 
The wells were blocked by incubating them each with 100 μl of 1% BSA in PBS for 2 
hours at 37°C before being washed again with the SDB.  Next, 100 ul of all standards or samples 
were added in duplicate to the wells and allowed to incubate at room temperature.  The eight 
biotinylated anti-IL-8 standards ranged in concentration from 500 pg/ml to 0 pg/ml and samples 
were prepared 10,000 times diluted in SDB.   After one hour, the wells were washed once again 
and then incubated 30 min with 100 μl per well of a 1 μg/ml solution of streptavidin-horseradish 
peroxidase (HRP) in SDB.  To finish the ELISA procedure, 100 μl of tetramethyl benzidine 
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(TMB) solution was added and wells were incubated in the dark for up to 30 min before adding 
sulfuric acid to stop the color-changing reaction.  Absorbances in the wells were then read at 450 
nm in the microplate reader. 
 
6.1.3 Results and Discussion  
These preliminary results demonstrate the efficiency of using cellulose triacetate fibers as a 
matrix for the immobilization of IL-8.  Cut fiber pieces were used in these experiments that 
characterized the ability of the fibers to bind IL-8 and the immobilized IL-8 to bind its antibody.  
We also quantified the leaching of IL-8 over time from the fiber pieces while they were 
incubating with the anti-IL-8 solution.   
Figure 79 shows the IL-8 mass found in the initial post-immobilization elution and those 
of all other wash steps; 1.35 ± 0.24 μg in total were lost resulting in a 95% efficiency. These 
results assume that all 25 μg of IL-8 that were originally spiked into the coupling buffer 
participated in the binding reaction; in reality, some amount of IL-8 was most likely lost due to 
adsorption onto the test tube during the reaction.  Thus, 95% is in all likelihood an overestimate 
of the binding efficiency.  Additionally, this test does not account for nonspecific binding of the 
IL-8 onto the cellulose fibers that may have occurred. 
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  Figure 79. Total mass of IL-8 eluted during wash steps of cellulose fiber pieces. 
 
As previously stated, CNBr activation can lead to a steady leakage due to instability in 
the covalent bond.  To characterize the amount of leakage from the fiber pieces, we took samples 
of the solution in which the fiber pieces were incubated over a 90 min time period and assayed 
them for IL-8 concentration.  These results can be seen in Figure 80; a total of approximately 
8100 pg of IL-8 were leached during the experiment, corresponding to less than 0.05% of the 
amount of IL-8 previously determined to be immobilized on the fiber pieces.  In 10 ml of blood 
(the amount used in a typical blood experiment, Section 6.5), 8100 pg of IL-8 would correspond 
to 0.81 ng/ml.  This concentration of IL-8 in blood during testing would not be expected to have 
any significant effect on neutrophil activation, as 10-50 ng/ml in free solution are required [149]. 
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  Figure 80. IL-8 leaching over time from cellulose fibers. 
 
 The final characterization test of the cellulose fiber pieces measured anti-IL-8 
concentration as a function of time during incubation with the fibers.  These results, seen in 
Figure 81, show that 64% of the initial 50 μg anti-IL-8 was removed which corresponds to 2-3 
μg IL-8 immobilized on the fibers.  These data do not agree with the IL-8 ELISA data, which 
suggest that nearly 75% of circulating anti-IL-8 would have been removed based on the amount 
of IL-8 present.  As previously described, 95% is most likely an overestimate of the efficiency 
due to adsorption of ligand onto non-fiber surfaces.  This issue is further compounded by the fact 
that CNBr binding does not result in a specific orientation of ligand, meaning that the antigenic 
site on IL-8 for its antibody may or may not have been exposed after binding.  Even if these anti-
IL-8 data are accurate and only 2 μg of IL-8 have been immobilized, however, that amount is 
still within the correct order of magnitude (~1000 ng/ml) to achieve receptor downregulation and 
shut off migratory activity of white blood cells in 10 ml of blood, the amount used in the blood 
experiments described in Section 6.5.  We assume here that the bound IL-8 on the fiber surface 
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behaves the same as free IL-8 did in the experiments performed in Feniger-Barish, et al., the 
study from which the 1000 ng/ml cutoff was obtained [149]. 
 
  Figure 81. Anti-IL-8 removal upon incubation with unmodified cellulose fiber pieces and cellulose fiber pieces 
containing IL-8 (CNBr activated). 
 
 We can conclude from the experiments where concentration of IL-8 on the fibers and 
leaching into solution over time that the amount of IL-8 lost is insignificant compared to the 
amount immobilized and would not have any effect on circulating neutrophils.  These data do 
not, however, give a clear indication of the amount of IL-8 bound on the fibers.  Attempts to 
further characterize IL-8 bound on the fibers using anti-IL-8 capture techniques gave inconsistent 
results with IL-8 ELISA data.  We predict that the amount bound is enough to be expected to 
have an effect on the receptors CXCR1 and CXCR2 during a sufficient incubation time and over 
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a sufficient contact area with neutrophils.  These conclusions are based on studies done on 
neutrophil activation after contacting IL-8 in free solution [149].  
6.2 FIBER MODULE FABRICATION AND CHARACTERIZATION 
6.2.1 Introduction 
Experiments testing blood flow in tubes with diameters under 300 μm show that the hematocrit 
is lower in the tube than at the exit point because hematocrit at the exit is weighted by the local 
velocity.  This phenomenon is known as the Fahraeus effect and it arises due to the two-phase 
nature of blood flow [159].  As a result of red cell aggregation in the center of blood vessels due 
to the Fahraeus effect, white blood cells are marginated to the vessel walls, where they are better 
able to roll along the endothelium and come into contact with various ligands [160].  We aimed 
to take advantage of this behavior by immobilizing IL-8 on the inner lumen of fibers that would 
act as the artificial microcirculation in our cell programming device. 
To facilitate immobilization on and testing of the inner fiber lumens, we potted the fibers 
in modules resembling scaled down dialyzers, approximately 1/400th of a standard dialyzer 
containing 10,000 fibers.  The completed fiber module can be seen in Figure 82.  The same 
process of immobilization and IL-8 quantification was carried out with these modules.  The 
protocols were modified to accommodate the different fiber configuration and chemistry, as 
described in Section 6.3.  
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  Figure 82. 16 cm long fiber module containing 25 aminated polysulfone fibers. 
 
The modules were tested for leaks and fiber blockage prior to using them for any 
experiments.  To do this, we used the Hagen-Poiseuille equation for laminar flow in a cylindrical 
tube [86]: 
4
128
d
LQ
P


  (9) 
Where ∆P is the theoretical pressure drop, μ is the dynamic viscosity, L is the length of the tube, 
Q is the volumetric flow rate, and d is the diameter of the tube.  Once the modules were 
confirmed to be free of any blockages or leaks, they were used for IL-8 immobilization (see 
Section 6.3).    
6.2.2 Methods 
The fibers modules were fabricated in the lab from various polycarbonate components.  The 
body of the device was a clear polycarbonate tube, either 7/5 or 15 cm long with a 0.5 cm inner 
diameter.  Two holes were drilled in the body of the tube into which two female luer lock 
polycarbonate fittings were glued to serve as the shell side ports.  For each module, either 25 
fibers (15 cm long modules) or 50 fibers (7.5 cm long modules) were bound together and fed 
through the module.  UV-curing glue (Permatex; Solon, OH) was used to pot the fibers in the 
device before being trimmed to prevent glue from entering the tube side of the fibers.  Once the 
 170 
glue had cured, the potted ends were trimmed and capped with polycarbonate female luer lock 
fittings. 
Pressure drop measurements across the device were taken to ensure the consistency of the 
fiber modules.  The tube side inlet of one module was first connected to a syringe pump (Harvard 
Apparatus; Holliston, MA) filled with DI water.  The tube side outlet was connected to tubing 
draining into a beaker.  The shell side was filled with DI water and both the inlet and outlet ends 
of the module were connected with a three-way stopcock and water-filled tubing to a pressure 
transducer.  The setup for the pressure versus flow rate experiment can be seen in Figure 83.  
 
  Figure 83. Pressure versus flow rate test setup. 
 
The pressure transducer reported voltages which were recorded and then converted to a 
pressure using the following relationship which was specific to the pressure transducer used: 
Pressure (mmHg)= 20.119 * Voltage (V) (10) 
Inlet and outlet pressures were measured in duplicate for the following flow rates: 1.0, 0.8, 0.6, 
0.4, 0.2, and 0.0 ml/min. The slope of the pressure drop versus flow rate line was compared to 
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the value of R obtained from the following equation, obtained from the Hagen-Poiseuille 
equation (Eq. 9):  

R 
128L
d4N
 (11) 
Where R is pressure drop over flow rate and N is the total number of fibers.  Modules for which 
the slope of the pressure drop versus flow rate data was not within 15% of the theoretical R value 
were not used.   
6.2.3 Results and Discussion 
Scaled-down fiber modules based on full-size clinical dialyzers were fabricated to allow 
for immobilization of IL-8 on the inner lumen of fibers.  Figure 84 shows a representative data 
set for the pressure drop versus flow rate characterization test.  These modules were fabricated 
using a 15 cm polycarbonate body containing 25 aminated polysulfone fibers (described in 
Section 6.3), giving a theoretical R value of 15.52 mmHg∙ml/min for each module.   
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  Figure 84. 15 cm long fiber module containing 25 aminated polysulfone fibers. 
 
 In the data shown in Figure 84, two of the modules failed because their R values were too 
far outside the acceptable range of ±15%, corresponding to 13.19-17.85 mmHg∙ml/min.  Failures 
due to blocked fibers are characterized by a slope that is too high, as the blocked fibers 
effectively decrease the numbers of fibers through which flow occurs.  Conversely, leaking 
within the module due to broken fibers causes a decrease in pressure drop and modules fail the 
pressure drop versus flow rate test because of an unacceptably low slope.  Data for the 7.5 cm, 
50-fiber modules are not shown because the value of N∙L for the two types of devices remains 
the same and therefore their theoretical R value does not change.  
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6.3 IL-8 IMMOBILIZATION ON AMINATED POLYSULFONE FIBERS 
6.3.1 Introduction 
The second fiber type was custom made for our lab out of an aminated version of polysulfone by 
Fresenius (Ogden, UT).  These fibers are easier to work with and more durable than the cellulose 
fibers and thus more ideal for use in the potted fiber modules.  The amine groups add 
functionality to the fibers and provide for easier cross-linking of proteins on the fibers; however, 
polysulfone fibers have been shown to induce platelet aggregation and may not be as 
biocompatible as cellulose [161].  While the exact makeup of this fiber is not available, the 
structure of non-aminated polysulfone, which has a nominal pore size cutoff of 40 kDa, can be 
seen in Figure 85.  Also shown in Figure 85 is the structure of chitosan, the amine-containing 
polymer that was entrapped within the fiber to incorporate the amine functionality.  The inner 
and outer diameters of the fibers are 187 and 278 μm, respectively.  
 
  Figure 85. Chemical structures of A) polysulfone and B) chitosan. 
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 Unlike the cellulose fibers described in Section 6.1, the aminated polysulfone (PS-NH2) 
fibers do not have a homogeneous pore structure.  Figure 86 shows scanning electron microscope 
(SEM) images of the polysulfone-amine fibers.  Like standard dialyzer fibers, the inner lumen of 
the fibers contains smaller pores at a much higher density than the larger pores of the outer 
lumen.   
 
  Figure 86. SEM images of A) cross-section, B) inner lumen, and C) outer lumen of PS-NH2 fibers. 
 
Because they were potted into devices before being activated, only the inner lumens of 
the fibers were used as the support matrix for the immobilized ligand.  Glutaraldehyde was used 
to cross-link the amine groups of the fibers with the exposed amine groups of the protein, similar 
to the reaction presented in Section 3.2.3.  For one experiment, polyethylene glycol (PEG) was 
used as a spacer molecule between the fiber and the protein.  As with the cut cellulose fiber 
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pieces, the modified fibers containing IL-8 were tested for their interaction with neutrophils in 
blood experiments that will be described below in Section 6.5. 
6.3.2 Methods 
The devices used for these experiments were the same ones tested in Section 6.2 for pressure 
drop versus flow rate.  Only modules which were proven to be free of leaking or blocked fibers 
were used.  Modules that passed the pressure test were flushed with DI water to prepare them for 
protein immobilization.  The shell side was filled with water and capped off.  The modules were 
connected to a Masterflex peristaltic pump (Cole-Parmer; Vernon Hills, IL) calibrated to 1.0 
ml/min.  The modules were flushed for 15 min with DI water followed by a 15 min flush with a 
pH 7.0 solution of 0.1M sodium phosphate buffer with 0.15M NaCl (“coupling buffer”).  For 
modules that were to be used for blood experiments, another tubing loop was prepared and 
flushed continuously with a 1.0% BSA in PBS solution for the duration of the fiber activation.  
This tubing was then used for the overnight IL-8 immobilization step. 
Next, 100 ml of a 12.5% w/v solution of glutaraldehyde in coupling buffer with an added 
0.06 g of sodium cyanoborohydride was circulated through the module at room temperature for 4 
hours.  One control module was prepared in the same manner but with no glutaraldehyde added 
in this step to test nonspecific binding of IL-8 to the fibers.  The devices were then rinsed for 15 
min with coupling buffer before a 100 ml solution of coupling buffer spiked with 25 μg of IL-8 
and 0.06 g of sodium cyanoborohydride was circulated through the module overnight at room 
temperature.  The protein solution was kept well mixed throughout the immobilization 
procedure.  The following morning, the protein solution was drained from the module and it was 
rinsed for 15 min each with DI water, 1.0M NaCl, and DI water again. 
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To test whether the IL-8 was being immobilized throughout the fiber or only on the inner 
lumen, either fluorophore-conjugated IL-8 or fluorophore-conjugated goat immunoglobulin G 
(IgG) were immobilized on two different modules.  Approximately 3 nmol of reconstituted IL-8 
or goat IgG (Invitrogen) was diluted to 100 μl with PBS and spiked with 8 μl of 0.67M borate 
buffer.  The protein solution was then added to one vial of DyLight 488 reagent (Pierce 
Biotechnology; Rockford, IL) and briefly centrifuged.  The reaction mixture was protected from 
light and allowed to react for 60 min.  Excess dye was then removed using a protein purification 
column provided with the labeling kit.  The entire labeled protein solution was added to a spin 
column containing purification resin and centrifuged for 45 seconds at 1000 x g.  This process 
was repeated until no more excess protein appeared to be retained in the resin.  The labeled IL-8 
or IgG was stored at -20°C until being immobilized on fibers using the glutaraldehyde protocol 
previously described for unlabeled IL-8.  Following immobilization, the modules were cut apart 
in two sections using a razor blade and the fibers were removed and suspended in PBS.  
Individual fibers were then cut into short segments and stood straight up on a polystyrene petri 
dish.  The modified fibers along with a sample of unmodified fibers were all imaged using an 
Olympus Fluoview 1000 confocal microscope.  Fluorescence intensity as a function of distance 
from the edge of the fiber was quantified using the National Institute of Health’s ImageJ 
software, v1.43 (http://www.rsb.info.nih.gov/ij/). 
Only one module used a modified immobilization procedure that incorporated PEG on 
the fibers as a spacer molecule before adding the IL-8.  For this module, the fibers were activated 
by perfusing the module with 2.0 g of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) dissolved in 100 ml of 0.1M 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer, pH 4.5.  100 mg of carboxy-amine PEG, a 24-unit PEG molecule containing both 
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terminal and carboxyl and amine groups, was also spiked into the activation solution.  The 
reaction was allowed to take place for 3 h at room temperature with the PEG solution being 
continuously mixed.  The module was then flushed thoroughly with MES buffer, DI water, 1.0M 
NaCl, and DI water for 15 min each.  Glutaraldehyde crosslinking was carried out as before, with 
the mass of sodium cyanoborohydride adjusted to 0.24 g dissolved in 40 ml of coupling buffer 
containing 50 μl IL-8.  
As with the cellulose fiber pieces, samples were taken of all wash and immobilization 
eluents and their volumes were recorded to determine the amount of IL-8 bound on the fibers. 
Several modules which were not to be used for blood recirculation experiments were also flushed 
for 90 min with 50 mg/ml BSA in PBS following the completion of the immobilization and 
samples were taken after 5, 15, 30, 60, and 90 min to quantify the amount of IL-8 that would be 
expected to leach during a whole blood experiment (see Section 6.1). These samples were once 
again assayed using an IL-8 ELISA kit (Invitrogen). 
All modules containing immobilized IL-8 intended for use in whole blood experiments 
were used within 24 hours of the start of the immobilization procedure.   
6.3.3 Results and Discussion 
As with the cellulose fibers, we present here data that characterize the efficiency of IL-8 
immobilization on PS-NH2 fibers.  We also quantified the amount of IL-8 expected to leach off 
of the fibers during a 90 minute blood perfusion and imaged the fibers to determine how much, if 
any, of the IL-8 was being immobilized on the inner lumen of the fibers.  These fibers were 
prepared in mini-dialyzer modules for use as part of a cell programming device which modulates 
the activity of neutrophils by bringing them into contact with a powerful chemoattractant. 
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The amount of IL-8 lost in each of the wash eluents following immobilization was 
quantified using an IL-8 ELISA.  The results of this experiment can be seen in Figure 87.  The 
nonspecific binding (NSB) module was incubated with IL-8 but was never activated with 
glutaraldehyde.  The nonspecific binding module lost 2.5 ± 0.15 μg while the glutaraldehyde 
cross-linked module lost 0.21 ± 0.02 μg.  These results suggest high levels of nonspecific 
binding because 25 μg of IL-8 were added initially.  However, we suspected that much of the IL-
8 loss seen in this experiment was the result of nonspecific adsorption of protein onto the tubing 
during the overnight immobilization because there was no carrier protein added into the reaction 
solution. 
 
  Figure 87. IL-8 eluted from nonspecific binding (NSB) and glutaraldehyde (GA) cross-linked fiber modules during 
various washing steps. 
 
 As a control to test the theory that IL-8 was being adsorbed onto the loop during 
immobilization, IL-8 concentration was measured before and after an overnight recirculation 
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experiment, 11 ± 0.73 μg was added initially and only 2.0 ± 0.13 μg remained after the overnight 
recirculation.  Thus, much less IL-8 than originally expected is being spiked into the 
immobilization solution and immobilized on the fibers.  These results also disprove the previous 
conclusion that nonspecific binding is significant.  In fact, only about 0.5 μg was eluted from the 
nonspecific binding module in addition to what was left in the tubing during the wash steps.  The 
immobilization efficiency is between 87-98% depending on the actual amount bound versus 
what is adsorbed on the tubing.  To avoid the issue of nonspecific adsorption onto the tubing 
loop, tubing for all subsequent immobilizations was pre-coated with BSA for up to 4 hours.   
 The whole blood experiments which will be described in Section 6.5 require a 90 minute 
perfusion through the fiber modules containing IL-8.  The goal of our device is to use 
immobilized IL-8 to affect the activity of circulating neutrophils and therefore high levels of 
soluble IL-8 leaching off of the fibers could potentially skew the results.  We measured the total 
concentration of IL-8 leached over time for both the nonspecific binding and glutaraldehyde 
modules.  The results can be seen in Figure 88; a total of 246 ± 4.9 ng leached off of the NSB 
device while only 7.0 ± 0.78 ng leached off of the test device.  While concentrations above 1000 
ng/ml are required to disable the migratory activity of neutrophils, lower concentrations can 
activate them and trigger cellular migration [149].  However, at least 10-50 ng/ml of IL-8 is 
required to initiate the downstream signaling.  Thus, the 7 ng leached during a 90 minute blood 
experiment which uses 40 ml of blood would only expose neutrophils to a concentration of IL-8 
of approximately 0.2 ng/ml, well below the threshold for activation. 
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  Figure 88. IL-8 leached from nonspecific binding (NSB) and glutaraldehyde (GA) cross-linked fiber modules 
during buffer recirculation. 
 
 The PS-NH2 fibers are based on a polysulfone standard dialyzer fiber which has a 
nominal pore size cutoff of 40 kDa.  Assuming the aminated version of the fibers has the same 
pore size, we hypothesized that some or all of the IL-8 being immobilized on the fibers was 
being immobilized beyond the inner lumen, within the porous network of the polymer fibers.  
This type of configuration would not be ideal for the cellular programming device we are 
designing because to be successful, the IL-8 must come into direct contact with its receptors on 
the surface of the neutrophils.  We immobilized fluorophore-labeled IL-8 and IgG on fibers 
within the scaled-down device and imaged them to determine the relative distance of each 
immobilized protein from the inner lumen surface.   
Unmodified fibers were imaged as a negative control.  Figure 89 shows the bright field 
and confocal laser images of one of the unmodified PS-NH2 fibers along with the fluorescence 
0
50000
100000
150000
200000
250000
300000
350000
0 15 30 45 60 75 90
to
ta
l 
IL
-8
 l
e
a
ch
e
d
 (
p
g
) 
time (min) 
NSB
GA x-link
 181 
intensity as a function of distance from the outer edge of the fiber for a total of three fibers.  Note 
that the fibers have a wall thickness of 30 μm, meaning that some of the signal shown in the 
graph in Figure 89 was recorded from beyond the fiber wall.  Each image was analyzed 
separately so the individual edges of each fiber cannot be delineated on this graph.  These 
images, when compared to those of the test fibers in Figure 91, demonstrate that some 
autofluorescence does arise from the unmodified fibers, but the amount of autofluorescence is 
insignificant and does not vary across the fiber wall. 
 
 
  Figure 89. A) Bright field and B) confocal laser images of unmodified fibers and C) fluorescence intensity across 
the fiber walls. 
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Goat anti-human IgG, a 150 kDa antibody, is too large to enter into the pores of the fiber 
and therefore served as the positive control.  By using the point of the highest fluorescence 
intensity as the starting point for the inner lumen, the penetration depth of the immobilized 
antibody can be quantified and averaged for each fiber analyzed.  The data for four fibers 
containing immobilized IgG antibodies along with the bright field and confocal images for 
several fibers can be seen in Figure 90.  The bright spots on the confocal image are anomalies of 
the surface on which the fibers were being imaged, and not of the fibers themselves.  These spots 
were avoided in the fluorescence intensity quantification.  The average penetration depth of the 
IgG for four different fiber pieces was 9.9 ± 1.1 μm. 
 
 
  Figure 90. A) Bright field and B) confocal laser images of fibers containing immobilized IgG and C) fluorescence 
intensity across the fiber walls. 
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 The test fiber samples containing labeled IL-8 were analyzed in the same way as the IgG 
fibers.  The results, seen in Figure 91, show that the intensity profiles were similar to IgG.  The 
average penetration depth for the labeled IL-8 was 9.2 ± 2.6 μm.  The large variation in intensity 
is most likely due to surface imperfections of the fiber where it was cut.  When the results of the 
IgG and IL-8 fibers are compared using a two-sample student’s t-test, the p value is determined 
to be >0.5, which means that the samples do not significantly differ in the penetration depth of 
IL-8 and IgG. 
 
 
  Figure 91. A) Bright field and B) confocal laser images of fibers containing immobilized IL-8 and C) fluorescence 
intensity across the fiber walls. 
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Although the intensity data report that both the IgG and IL-8 are penetrating over 30% of 
the total thickness of the fiber wall, this result is unlikely.  Rather, the uncertainty in measuring 
the starting point of the intensity peak is most likely resulting in seemingly higher penetration 
depths.  In actuality, the IgG cannot diffuse into the pores of the fiber; therefore, we conclude 
that some signal from the immobilized IgG was reflected in the empty space just outside the 
inner lumen of the fiber, which influenced the data analysis.  As the statistical analysis shows, 
the IL-8 and IgG both penetrated the same distance into the fibers.  Our conclusion from these 
experiments is that the IL-8 does not migrate into the pores of the fiber and is primarily 
immobilized on the inner lumen surface.  Although the molecular weight cut off was assumed to 
be 40 kDa and IL-8 has a molecular weight of 8-11 kDa, the protein most likely does not 
penetrate into the porous network because the chitosan groups on the polysulfone make the fibers 
more hydrophilic.   
 These fibers will be tested for their ability to affect the activity of neutrophils in whole 
blood as they are circulated through the device.  PEG was included as a spacer arm in one set of 
fibers to increase the range of motion of the IL-8, not because IL-8 was not immobilized on the 
innermost surface of the fibers.  In the next section we present the results of the final testing of 
these fibers in several different types of blood experiments. 
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6.4 NEUTROPHIL ISOLATION AND CELL COUNTS 
6.4.1 Introduction 
The fiber incubation experiments that will be described in Section 6.5 were originally intended to 
be performed with both whole human blood and isolated human neutrophils.  The neutrophil 
isolation procedure was adapted from the protocol developed by Ferrante and Thong (1980) 
[162].  The purification method begins with dextran sedimentation, which eliminates most 
erythrocytes from the remaining cellular components.  The cells are then washed and any 
remaining red blood cells are lysed before a density gradient is applied which results in the 
granulocytes settling to the bottom of the suspension.  
The cells must also be counted and tested for viability and contaminating cell populations 
before being used in any type of experiment.  Viability is determined by the Trypan blue dye 
exclusion test, in which living cell membranes do not allow the dye into the cytoplasm and dead 
cells do [163].  Once characterized and resuspended, the purified neutrophil solution can be used 
in experiments similar to whole blood. 
6.4.2 Methods 
Blood was collected from healthy human volunteers into glass vacutainers containing acid citrate 
dextrose (ACD) as the anticoagulant (BD; Franklin Lakes, NJ).  The anticoagulated blood was 
pooled together and combined with 50% of the blood volume of a 6% Dextran/0.9% NaCl 
solution.  The blood solution was gently mixed and split into 10 ml aliquots.  The tubes of blood 
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were allowed to stand at room temperature for 1 hour, at which time red blood cell separation 
was complete. 
Plasma was removed from the separated blood and combined before being spun down at 
1150 rpm for 12 min at 4°C.  The supernatant was discarded and the remaining cells were 
resuspended in 12 ml of ice cold DI water.  The pellet was manually broken up and gently mixed 
for 20 sec before adding 4 ml of 0.6M KCl.  The solution was mixed once more and diluted to 50 
ml with phosphate buffered saline (PBS).  Cells were spun down at 1300 rpm for 6 min at 4°C.  
The DI water/KCl wash and subsequent dilution with PBS were repeated two more times to 
ensure adequate red cell lysis and removal.  The remaining cell pellet was resuspended in 2.5 ml 
PBS and then layered over 3 ml of Ficoll-Hypaque with a density of 1.077 g/ml (Histopaque® 
1077, Sigma Aldrich, St. Louis, MO).  This suspension was spun down at 1500 rpm for 30 min 
at 4°C.  The supernatant was removed and discarded and the cells were resuspended in 2 ml of 
Hanks’ balanced salt solution (HBSS, Sigma).  
Cell counts were done manually on disposable Incyto C-chip hemocytometers (Incyto; 
Dusseldorf, Germany), each of which contained two improved Neubauer grids and a sample 
reservoir, as seen in Figure 92.   
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  Figure 92. Incyto C-Chip hemacytometer (A) and improved Neubauer grid system (B). 
 
A single drop of the purified neutrophil solution at a 10 and 100x dilution in HBSS is added to 
the sample injection area on both sides of the chip.  The cell suspension is taken up into the 
counting grid by capillary action and cells are counted using a differential interference contrast 
(DIC) microscope at 100x magnification.  The number of cells in the 16 large squares in the four 
corners of the grid seen in Figure 92 are summed and divided by 4 then multiplied by the dilution 
factor and 10
4
, the volume factor for the chip.  The cell suspension was then diluted 
appropriately to make a final concentration of 10
6
 cells/ml. 
Viability staining was done by preparing a 1:1 dilution of the purified neutrophil solution 
and 0.4% Trypan blue stain.  Once again, dilutions of 1:10 and 1:100 were immediately loaded 
into the hemocytometers and cells in the outer four corners of each grid were counted under a 
light microscope at 100x magnification.  Cells stained dark blue were counted as dead and the 
B) 
A) 
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percentage of viable cells was determined by dividing the number of unstained cells by the total 
number of cells.  
6.4.3 Results and Discussion 
Although no experiments were done with purified neutrophils, a protocol was prepared for the 
complete isolation and characterization of neutrophil populations from whole blood.  Cell counts 
on samples from three human volunteers yielded the following concentrations of neutrophils as 
determined using an improved Neubauer grid system: 5.0E5, 4.0E6, and 9.5E5 cells/ml for an 
average concentration of 1.8E6 cells/ml.  Typical values for such measurements lie between 1.0-
5.0E6 cells/ml.  An example of one square of the 16-square grid used for counting cell 
populations can be seen in Figure 93. 
 
  Figure 93. One square of the improved Neubauer grid used for counting neutrophils. 
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 Cell viability was also quantified as the percentage of living cells in the total amount of 
cells counted.  Trypan blue dye was used to stain non-viable cells and the cells were once again 
counted using the Neubauer grid.  Figure 94 shows an example of the dyed cells, with this 
particular image containing three living cells and one dead cell.  Once again this test was 
performed on blood samples from three human volunteers.  The three samples yielded viability 
results of 86, 90, and 95% for an average viability of 90.3%.  Viability above 90% is considered 
acceptable for such measurements.  
 
  Figure 94. Viability staining of purified neutrophils using Trypan blue; three living cells and one dead cell are 
shown. 
 
 These results confirm that the isolation and testing of neutrophils from human whole 
blood was successful.  However, the experiments described in Section 6.5 that were intended to 
be performed with whole blood and purified neutrophils were never done with purified 
neutrophils because of the large sample size that would have been required to obtain sufficient 
numbers of cells for flow cytometry analysis.  The reservoir for the isolated neutrophil 
experiments would have been nearly depleted by the end of the experiment because of the high 
sample volume required (approximately 1 ml per sample, with two samples required for each 
time point).  Additionally, decreasing volumes would have skewed the data because the 
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neutrophils remaining at the later time points would have significantly longer exposure times to 
the fibers. 
6.5 CELL-FIBER INCUBATION AND FLOW CYTOMETRY ANALYSIS 
6.5.1 Introduction 
The membrane-bound IL-8-specific receptors CXCR1 and CXCR2 are G-protein coupled 
receptors (GPCRs) which recognize both free and endothelial-bound IL-8.  Binding to IL-8 
causes internalization of CXCR1 and CXCR2 and various physical and chemical changes in the 
neutrophil including migration, intracellular calcium flux, and superoxide anion production.  All 
of these outputs are the result of the downstream signaling initiated by the receptor-ligand 
binding [156].  While varying degrees of neutrophil activation can be measured by any of these 
effects, we chose the first sign of IL-8 mediated activation or de-activation, internalization of 
CXCR1 and CXCR2, as the metric by which we determine the effectiveness of our immobilized 
IL-8 cellular programming device. 
Adsorbed and even covalently immobilized IL-8 has been shown to activate neutrophils, 
although in the case of immobilized IL-8, receptor internalization was not measured [152-153].  
The possibility exists for downstream signaling to occur without internalization of receptors.  
Here we test the hypothesis that IL-8 immobilized on fibers has the ability to differentially 
activate or deactivate neutrophils in whole blood by causing internalization of the receptors 
CXCR1 and CXCR2. 
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Receptor internalization is measured using flow cytometry, a technique used for sorting, 
counting, and characterizing small particles such as cells.  For our purposes, whole blood 
samples are stained with fluorophore-tagged antibodies specific to CD15, CXCR1, and CXCR2.  
CD15 is a carbohydrate antigen expressed on glycoproteins, proteoglycans, and glycolipids and 
found on the surface of 95% of human granulocytes, primarily neutrophils and eosinophils [164].  
The stained cells are suspended in fluid which is passed through a laser that detects labeled 
antigens.  Cells are initially sorted based on their size and light scattering properties, which 
represents the presence or lack of granules in the cells.  Populations expressing CD15 can be 
further isolated and from there, the cells on which CXCR1 and CXCR2 are detected can be 
counted.  
6.5.2 Methods 
All blood experiments were performed with either cut cellulose fiber pieces or mini-dialyzer 
modules containing PS-NH2 fibers.  In most experiments, soluble IL-8 in whole blood was used 
as a positive control and unmodified fibers corresponding to the type used in each particular 
experiment were used as the negative control.  The test fibers were covalently bound to IL-8 
using the protocols found in Section 6.1 (cellulose) or 6.3 (PS-NH2) and were used in the blood 
experiment within 24 hours of initiating the immobilization procedure, i.e. when the IL-8 first 
came into contact with the activated fibers.  Four trials with cut cellulose fibers were performed, 
and one trial each with the PS-NH2 modules containing IL-8 alone or PEG and IL-8 were 
performed.  The flow cytometry analysis was the same for all blood samples regardless of the 
type of experiment. 
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Depending on the experiment that was to be done, either the cellulose fiber pieces or PS-
NH2 fiber modules were submerged in or filled with PBS following the completion of the 
immobilization procedure. Blood from healthy human donors was collected into 
ethylenediaminetetraacetic acid (EDTA) vacutainers (BD) and pooled together. All PBS was 
drained from the test tube containing the cellulose fibers or the PS-NH2 module just before 
starting the experiment.  
For the cellulose fiber piece experiments, four test tubes were prepared: 10 ml of whole 
blood, 10 ml of whole blood spiked with 15 μg of IL-8, unmodified cellulose fibers submerged 
in 10 ml of whole blood, and IL-8-immobilized cellulose fibers submerged in 10 ml of whole 
blood.  The same four categories were used in the PS-NH2 fiber module recirculation 
experiment, except that the test or unmodified fibers were potted in devices and 40 ml of whole 
blood was continuously circulated through the devices at 1.3 ml/min once the experiment had 
begun.  Test tubes were incubated at 37°C and gently rocked throughout the experiment while 
the blood reservoirs for the fiber modules were kept covered and stirred the entire time.  A 
picture of the recirculation setup for the PS-NH2 module can be seen in Figure 95. 
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  Figure 95. Whole blood recirculation through unmodified and IL-8-immobilized PS-NH2 fiber modules. 
 
One module was prepared using PEG as a spacer arm for the indirect immobilization of 
IL-8 on the PS-NH2 fibers.  This device and its unmodified counterpart were tested in a static 
incubation with whole blood as opposed to a continuous flow setup.  Blood collected in EDTA-
coated vacutainers was once again pooled and collected in two sterile 30-ml syringes (BD).  The 
syringes were placed in a syringe pump and connected to the test and negative control modules, 
whose other end was connected to tubing that emptied into a beaker.  Three-way stopcocks on 
either end of the fiber module were connected to syringes filled with PBS.  Blood was slowly 
perfused into the devices until reaching the outlet, at which point the stopcocks were closed off 
to the device and the inlet and outlet lines were flushed with PBS.  The blood was allowed to 
incubate in the fiber modules for 1, 5, or 10 min before being perfused through the module into a 
sample collection tube.  Two trials of the 1 and 5 minute incubations and three trials of the 10 
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minute incubation were performed.  Samples were then allowed to settle for approximately 10 
min before excess PBS was pipetted off of the top of the sample.  A picture of the static 
incubation experimental setup can be seen in Figure 96. 
 
  Figure 96. Static incubation experiment with PEG/IL-8 and unmodified PS-NH2 fiber modules. 
 
Two 100 μl samples were taken from each test tube or reservoir at 0, 5, 15, 30, 60, and 90 
min, with the 0 min sample coming from the pooled whole blood prior to splitting it up into the 
various test tubes.  In the PS-NH2 recirculation experiment, two samples were also taken at 120 
min.  As previously described for the static incubation experiment with the PEG/IL-8 PS-NH2 
module, one sample from each module was collected after a 1, 5, or 10 min incubation.  The total 
volume of blood able to fit in each module was only sufficient for one sample and therefore the 
incubation at each time point was immediately repeated to obtain the isotype control sample.  As 
soon as each sample was taken, the staining procedure was started.   All antibodies and flow 
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cytometry reagents were obtained from BD unless otherwise noted.  First the nonspecific Fc 
receptors on the cells (particularly the monocytes) were blocked by incubating samples with 5 μl 
of mouse IgG antibody (ThermoFisher) for 15 min.  Next the staining antibodies were added to 
the samples and incubated in the dark for 30 min at room temperature.  The antibody-fluorophore 
conjugates added to the test samples were as follows: FITC anti-CD15, PE-Cy5 anti-CD181 
(CXCR1), and PE anti-CD182 (CXCR2).  Those added to the isotype control samples for each 
time point were as follows: FITC anti-CD15; PE-Cy5 IgG1, κ isotype control; and PE IgG2b, κ 
isotype control.  20 μl of each staining antibody were added to each sample except for the PE 
anti-CD182, of which only 5 μl was added.  
When the antigen staining was complete, 2 ml of a 1x lysing solution (BD FACSlyse) 
was added to each sample and incubated on a hematology mixer for 10 min.  Samples were spun 
down at 500g for 5 min at 4°C.  The supernatant was discarded and samples were then washed 
twice with 1% BSA in PBS by adding 2 ml of washing solution and centrifuging at 500g for 5 
min at 4°C.  Lastly, cells were fixed in 500 μl 1% paraformaldehyde (PFA) and stored in the 
dark for up to one week before flow cytometry analysis. 
Compensation controls were prepared at least once a month on the day of the flow 
cytometry analysis according to the instructions of the manufacturer on the CompBeads kit (BD).  
Briefly, the CompBeads and negative control beads were vortexed thoroughly and one whole 
drop of each was added to test tubes containing 100 μl fetal bovine serum (FBS) staining buffer.  
Next, each tube received only one type of staining antibody in the following amounts: 20 μl of 
the FITC anti-CD15 and PE-Cy5 anti-CD181 antibodies and 5 μl of the PE anti-CD182 
antibody.  Beads and antibodies were incubated 30 min in the dark before adding 2 ml of FBS to 
each tube and spinning down at 200g for 10 min.  The supernatant was discarded and the bead 
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pellet was resuspended with 0.5ml of FBS.  Compensation controls were run immediately after 
completing the staining procedure. 
Flow cytometry data analysis was done using WinList (Verity House; Topsham, ME).  
First, compensation for all three fluorophores was set using the control data obtained with the 
compensation beads and applied to each subsequent data set that was analyzed.  For each time 
point, the test and isotype control data sets were opened in WinList.  The granulocyte population 
as determined from the forward scatter versus side scatter plot was isolated and used as the gate 
for CD15 versus PE or PE-Cy5 plots.  These subpopulations were then organized into single-
parameter histograms and the isotype control data were subtracted from the appropriate 
histogram in the test data set, leaving only the data for stained CXCR1 and CXCR2 on 
neutrophils.  The mean fluorescence intensity of cells expressing each receptor was then plotted 
as a function of time.  Figure 97 shows an example of the data analysis for both test and isotype 
control samples where the isotype control data have already been subtracted. 
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  Figure 97. WinList analysis of test and isotype control flow cytometry data from a single time point. 
 
 In Figure 97, R1 and R4 represent the forward scatter versus side scatter plots which 
isolates the subpopulation of granulocytes based on size and granulocity.  The regions R2 and R5 
show CD15 and CD181 (CXCR1) expression in cells gated from the granulocyte population 
while R3 and R6 show expression of CD182 (CXCR2).  R2 and R5 are used to gate for the one-
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parameter histograms H1 and H3, respectively, and similarly for R3/H2 and R6/H4.  Lastly, 
WinList automatically subtracts H3 from H1 and H4 from H2 to obtain the final results.  The 
geometric mean in the x-direction in both H1 and H2 is recorded for each time point to plot 
receptor expression over time. 
6.5.3 Results and Discussion 
In this section, the cellulose and PS-NH2 fibers prepared and tested in previous sections were 
incubated or perfused with whole blood to determine the effect that immobilized IL-8 had on 
neutrophil surface receptors CXCR1 and CXCR2.  We began by incubating whole blood with 
cellulose fiber pieces that contained immobilized IL-8 on the outer surface of the fibers.  Figure 
98 shows the result of four trials of this experiment, in which “baseline” represents the whole 
blood over time with no fibers or chemokine added, “test” represents blood incubated with the 
fibers containing IL-8, “control” represents blood incubated with unmodified fibers, and “free” 
represents whole blood spiked with free IL-8.  Although the variability between experiments was 
high, especially for CXCR2 measurements, neither the averaged data nor any of the individual 
results of the four trials show a significant difference between the control and test fibers.  
Additionally, CXCR1 and CXCR2 measurements for the free IL-8 samples in each trial were 
markedly lower than samples from the baseline, control, and test samples at every time point.  A 
student’s t-test confirms that, for both CXCR1 and CXCR2, no significant difference in receptor 
expression was found between the test, control, and baseline samples.  The test samples showed 
significantly higher expression of both receptors compared to the free IL-8 samples, with 
p<0.001 in both cases. 
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  Figure 98. A) CXCR1 and B) CXCR2 expression over time using cellulose triacetate fiber pieces. 
 
 We hypothesized that the reason that the immobilized IL-8 cellulose fiber pieces did not 
have any effect on receptor expression was because the cells came into contact with the fibers 
only transiently if at all.  To overcome this issue, we attempted to exploit the Fahreus effect in 
which neutrophils and other white blood cells marginate toward the outer wall of a small vessel 
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through which they are flowing as the red blood cells aggregate in the center of the vessel.  PS-
NH2 fibers were potted into scaled-down dialyzer devices and IL-8 was immobilized on the inner 
lumen of the fibers.  The IL-8 was confirmed to be present on the innermost surface of the fibers 
by confocal microscopy.  Blood was continuously perfused through the modules during the 
experiment.  The results of one trial with an unmodified PS-NH2 module, an IL-8 immobilized 
PS-NH2 module, and the baseline and free IL-8 samples can be seen in Figure 99.  No statistical 
analysis was performed because only one trial of whole blood recirculation with the PS-NH2 
modules was done. 
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  Figure 99. A) CXCR1 and B) CXCR2 expression over time during recirculation through PS-NH2 modules. 
 
The free IL-8 samples showed a significantly lower expression of CXCR1 and CXCR2 
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in the free IL-8 sample is most likely due to the effect of receptor recycling which occurs 30-60 
min after signaling has been initiated [150].  As with the cellulose fiber pieces, the test fibers did 
not show a significant difference in receptor expression compared to either the control or 
baseline blood samples. 
Although perfusing blood through the fiber modules better ensured that the neutrophil 
surface receptors would come into contact with the IL-8, the underlying hypothesis was still not 
proven to be correct.  As Lomakina and Waugh demonstrated in their 2006 paper, low 
concentrations of immobilized IL-8 resulted in an increased adhesion of single neutrophils to 
immobilized ICAM-1 as a result of IL-8-mediated signaling.  The downstream signaling of IL-8 
was achieved without phagocytosis of the immobilized chemokine.  These experiments used 500 
sites of IL-8/μm2 on a 2.8 μm diameter bead per neutrophil [153], which would scale up to 
approximately 12 ng IL-8 immobilized on the entire module for the PS-NH2 fiber experiment.  
The PS-NH2 modules contain a minimum of 2-3 μg, as determined by IL-8 ELISA on the wash 
eluents following IL-8 immobilization.  Therefore, the concentration of IL-8 should be sufficient 
to achieve receptor internalization, assuming the receptors internalize upon binding to 
immobilized IL-8.  We hypothesize that the time of interaction between the immobilized IL-8 
and the neutrophil surface was not sufficient to achieve downstream signaling.  Lomakina and 
Waugh exposed the neutrophils to immobilized IL-8 for 15-500 seconds under static conditions 
[153]. 
We prepared a PS-NH2 dialyzer module using PEG as a spacer arm, which we 
hypothesized would give the IL-8 a better chance of coming into direct contact with its receptors.  
Additionally, during the testing of this module, it was filled with blood and allowed to incubate 
for up to 10 minutes with no flow.  The goal of this experiment was to eliminate the question of 
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whether or not the interaction between the neutrophils and IL-8 was sustained.  The results of 
this experiment can be seen in Figure 100, where the “control” module contained no PEG or IL-
8. 
 
 
  Figure 100. A) CXCR1 and B) CXCR2 expression over time during static incubation in PS-NH2 modules 
(*p<0.05, **p<0.10, †statistical analysis not possible). 
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 Expression of CXCR1 was significantly decreased in the test module after both 5 and 10 
minute incubations compared to the baseline level.  Expression of CXCR2 was significantly 
lower after a 10 minute incubation in the test module as well as decreased to a lesser extent after 
a five minute incubation.  Statistical analysis was not possible for the one minute incubation for 
either receptor because only one sample from each could be analyzed due to incomplete staining.  
Our conclusion from this experiment is that the hypothesis was correct and that, with an adequate 
contact time and close enough proximity between the IL-8 and its receptor, receptor 
internalization can be achieved by immobilized IL-8. 
Although the static blood experiment was the only one which proved our initial 
hypothesis correct, the other configurations may still have succeeded in altering the activity of 
the neutrophils.  No definitive evidence exists to suggest that receptor internalization is necessary 
for downstream signaling of immobilized IL-8 upon binding its receptors.  Alternative metrics 
for activation, such as respiratory burst or cellular migration, should be used to determine if 
transient interactions between CXCR1 and CXCR2 could initiate the signaling required for 
increased or decreased activation, regardless of receptor expression levels. 
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7.0  SUMMARY AND CONCLUSIONS 
The goal of this work was to develop extracorporeal devices which could treat sepsis using a 
variety of different approaches.  The first approach used blood purification techniques to 
nonspecifically remove cytokines via adsorption onto polymer beads.  Many variations on the 
base polymer were tested to accomplish this goal.  In a separate iteration of the cytokine removal 
approach, we used affinity-based cytokine capture to selectively increase clearance of specific 
cytokines.  The final approach, which could potentially apply to various other autoinflammatory 
disease states, used immobilized chemokines to modulate the activity of white blood cells.  For 
each individual approach, many specialized and unique testing and analysis methods were 
developed. 
 The device we developed for cytokine removal was a scaled down hemoadsorption 
column packed with polymer beads.  All polymer bead types underwent testing in a standardized 
loop in which serum was perfused through the device and cytokine concentration over time was 
measured.  The three representative cytokines we chose to measure were interleukin-6 (IL-6), 
interleukin-10 (IL-10), and tumor necrosis factor (TNF), as all three of these have been shown to 
play an important role in the pathogenesis of sepsis [9, 14-17].  For some experiments, 
conditions such as flow rate or reservoir volume were changed slightly to test certain theories, 
which could make cytokine removal data appear to be much better or worse even though 
clearance was not actually more or less efficient.  We developed a theoretical model of cytokine 
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removal in the cytokine adsorption device (CAD) to avoid such confusion and facilitate the rapid 
characterization of many types of beads. 
 The mathematical model we developed for this study was the first example that we have 
seen of a simple, analytical model describing the simultaneous convection, diffusion, and 
adsorption of a targeted molecule from a relatively large reservoir (or patient).  The model was 
validated by varying the experimental parameters and verifying that Γ, the parameter describing 
the interaction between a given cytokine and polymer combination, did not significantly change 
for each experiment.  Once the model was validated we were able to use Γ for each cytokine that 
we had analyzed to perform theoretical cytokine capture experiments and obtain information 
about device scale-up and comparison to other commercially available polymers. 
 Both experimental and theoretical data confirmed that removal of TNF in the CAD was 
significantly slower than removal of IL-6 and IL-10.  We hypothesized this was due to the 
increased size of TNF, which exists primarily as a trimer in solution [165].  We therefore aimed 
to increase removal of TNF by incorporating anti-TNF antibodies onto the outermost surface of 
the beads.  We characterized antibody coverage on the beads directly with a novel enzyme-based 
assay and indirectly by measuring TNF removal with the beads.  The antibodies were covalently 
immobilized using several different methods, none of which resulted in as significant an increase 
in TNF removal as passively adsorbed antibodies.  Passive adsorption of affinity ligands is less 
ideal because weakly bound ligand may leach off into the bloodstream of the patient.  However, 
we used the horseradish peroxidase (HRP) assay to demonstrate that the amount of antibody that 
leached off of the beads in a full-scale device during the course of a typical hemoadsorption 
treatment would be within a safe range.  These affinity ligand techniques could be easily adapted 
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to any other antibodies or large ligands that show an affinity for a molecule of interest in sepsis 
or other diseases. 
 Other attempts to improve cytokine capture with the CAD were less successful.  Various 
bead coatings such as phenylalanine dimer and vitamin E were tested and showed no 
improvement to cytokine capture.  Beads coated with lysozyme performed significantly worse 
than the baseline polymer.  Two molecules that showed high affinity for TNF, heparin and a 
TNF-specific aptamer, were also covalently bound or adsorbed to the baseline polymer and 
tested.  The TNF-specific aptamer did not show any affinity for TNF in our system.  Heparin did 
show some promise as an affinity ligand but its small molecular weight makes it unsuitable for 
use with the CytoSorb™ beads.  The processing methods required to immobilize heparin 
significantly affect their performance, making the improvement due to heparin irrelevant.  These 
alternative affinity ligands were tested because they are inexpensive and can be immobilized in 
higher concentrations compared to anti-TNF antibodies.  However, we were not able to find a 
coating that could significantly improve TNF capture over the baseline polymer.  The adsorbed 
antibody beads remain the best option for affinity-based cytokine removal. 
 Unlike the bead coatings, decreasing the particle size resulted in significantly increased 
removal rates of all cytokines in the CAD.  This particular modification demonstrated the most 
effective cytokine clearance of all methods tested.  The smaller particles have a dramatically 
increased outer surface area per bead mass which leads to initial cytokine capture rates that are 
significantly higher than the baseline polymer.  Theoretical and experimental pressure drop 
measurements suggested that the pressure drop across the CAD when packed with the small 
beads would lead to unsafe shear stresses on red blood cells, causing high levels of hemolysis.  
We redesigned the device to decrease the pressure drop and shear stress across the device packed 
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with the small beads.  Pressure drop testing of the re-engineered CADs (reCADs) confirmed that 
the shear stress was below the threshold for hemolysis, making the devices safer for whole blood 
perfusion. 
 The last and most unique approach to treating sepsis and related diseases is the 
development of an extracorporeal cellular programming device.  Our hypothesis was that 
chemokines or similar molecules that affect the activity of leukocytes can be immobilized within 
a fiber or bead based device and used to modulate the activation state of circulating white blood 
cells.  We immobilized IL-8, a strong chemoattractant molecule, on cellulose and polysulfone 
fibers to test this theory.  Our initial attempts to detect receptor-ligand binding were 
unsuccessful, which we conclude was due to insufficient reaction time between the IL-8 and its 
neutrophil surface receptors.  We conducted a static incubation of whole blood with a fiber 
module containing immobilized IL-8 that we hypothesized would address the issue of 
insufficient incubation time.  Flow cytometry analysis indicated that receptor internalization had 
occurred in the device containing IL-8 and not in the control device.  While the effect was not as 
pronounced as we had hoped it would be, the possibility exists that neutrophils were activated 
independent of the level of receptor internalization. 
 We believe that the work we have done on the cellular programming device provides 
sufficient evidence that such a device would be effective when the circulation system provides 
for a sustained interaction between the neutrophils and IL-8.  Our recommendation is that 
adhesion molecules such as P-selectin and intracellular adhesion molecule-1 (ICAM-1) be 
immobilized along with IL-8 to induce rolling and adhesion of neutrophils.  In this way, a 
sustained interaction could still be possible as whole blood was perfused through the fiber 
modules.  Additionally, we feel that additional measures of neutrophil activation could be used to 
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determine the specific functional outputs of the cells affected by our device.  With some 
additional research, this device could potentially be modified to either amplify or attenuate an 
immune response for a variety of disease states. 
 The work described in this thesis presents two types of devices which may be useful in 
the treatment of severe sepsis.  The CAD and reCAD will continue to be used in small animal 
experiments, with a possibility of using affinity ligands as needed for molecules identified to be 
important mediators in sepsis.  The cellular programming device, while still in its infancy, uses 
much of the information we have learned about the immune response in sepsis as a result of 
testing the CAD both in vitro and ex vivo.  Our hope is that this device will introduce a new 
paradigm of treatment for autoinflammatory diseases in which an artificial microcirculation 
provides a priming area for an altered leukocyte response in the presence of immune 
dysfunction. 
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APPENDIX A 
EXPANDED DERIVATION OF MATHEMATICAL MODEL 
We describe the cytokine capture process using a multiscale transport approach. The macroscale 
follows the concentration of various cytokines, ),( tZCi , as a function of time and axial position 
(Z) within the CAD. The microscale follows the concentration of the cytokines, ),,( tZrci as a 
function of radial position (r) within the spherical adsorption beads at macroscale axial position 
Z. 
A.1 MULTISCALE TRANSPORT FORMULATION 
A cytokine mass balance on a differential macroscale element ( Z ) yields the governing 
macrotransport equation:  
t
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where A is the cross-sectional area of the device,  εc, is the device porosity (i.e. non-bead liquid 
volume), Q is the axial flowrate,  ρ is the bead density, and ),( tZqi  is the average mass 
concentration of adsorbed cytokines on the beads at axial location Z.  Note that we have not 
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included effects associated with the axial dispersion of cytokines in the CAD as the length of the 
CAD is assumed to be sufficient to render dispersion effects negligible [166]. A cytokine mass 
balance on a differential microscale element (Δr) yields the governing microtransport equation: 
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where ),( trqi  is the mass of cytokine i adsorbed on the bead internal surfaces at radial position r 
on a per unit bead mass basis, Di  is the effective diffusion coefficient of the cytokine within the 
bead accounting for tortuosity of pores and bead porosity, and ),,( tZrci  is the mass 
concentration of cytokine in the liquid phase of the bead pores at location r. 
Adsorption at the microscale is coupled to macrotransport through the boundary 
condition ),(),,( tZCtZRrc ii   based on the assumption that mass transfer is dictated by 
diffusion within the bead rather than film diffusion to the bead surface. Once the microscale 
transport solution is determined, adsorption at the macroscale is driven by temporal changes in 
the average adsorbed concentration: 
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A.2 MICROSCALE TRANSPORT ANALYSIS 
We assume that the rate of local adsorption within the bead is fast compared to diffusion so that 
local adsorption equilibrium applies [86, 167]. Accordingly, adsorption onto the bead surface is 
described using the multicomponent Langmuir isotherm:  
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where qi is the adsorbed mass of the cytokine of interest and qi
max
 is the maximum adsorption of 
that cytokine on the bead surface in the absence of other adsorbing species. The parameters Ki  
and Kj correspond to the adsorption affinity constants of cytokine i and all other solutes, j, 
respectively. Cytokine concentration can be normalized using i n
iii Ccc
* where Ci
in
 is the 
concentration of cytokine in the solution flowing into the device.  The dimensionless form of the 
Langmuir isotherm is given by 
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where i n
iii CKK
*  represents a dimensionless or relative affinity, which can also be expressed 
as 
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in which 
iC50  is the concentration of cytokine that would saturate half the polymer surface with 
that cytokine at equilibrium.  
The iniC  for cytokines in blood is approximately 10
-6
-10
-4
 mg/ml [60].  The value of iC50  
cannot be determined easily for cytokines of interest to us on the beads used in the current CAD 
because the material quantity required for measuring the Langmuir adsorption isotherm would be 
prohibitive.  Generally, for proteins adsorbing on polymer surfaces iC50  is typically on the order 
of 10
-2
-10
-1 
mg/ml [60].  For example, cytochrome C (12 kDa) adsorbing on the PSDVB beads 
used in our current CAD has a iC50  of 0.48 mg/ml.  Thus, 1
* iK  and the microtransport of 
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cytokine corresponds to a low relative affinity regime. In this regime the properly scaled value 
for the dimensionless adsorbed cytokine concentration is )( max* iniiiii CKqqq   and the 
dimensionless Langmuir adsorption isotherm becomes: 
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The cytokine microtransport equation can be put into a dimensionless form by also 
normalizing the independent variables: 
Rrr *  ; sttt 
*
 (19) 
where R is the radius of the bead, , and ts is the time scale over which cytokine levels are being 
depleted from circulation in application of the therapy. The dimensionless microtransport 
equation is 
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where the parameter i  is given by: 
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and represents a characteristic time required to load a bead with a given cytokine i. An estimate 
of i  relative to the time scale ts for removing a given cytokine from circulation can be used to 
simplify the microtransport equation and analysis. The time scale ts can be estimated using: 
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where bA  is the surface area of one bead, 
circ
im  is the mass of circulating cytokine, and mb is the 
mass of adsorbing beads in the device. This time scale relative to the loading time is given by:  
m a x*
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The dimensionless parameter i represents the amount of circulating cytokine relative to 
the cytokine capture capacity of the device and is also a small parameter.  For typical conditions 
of application: 

 i 
2.4 104 mg cytokine
10g beads 103  370 mg cytokine/g bead 
6.5 105   (24) 
A.3 ASYMPTOTIC ANALYSIS OF MICROTRANSPORT EQUATION 
Our microtransport analysis exploits that there are two small parameters, i  and 
*
iK , dictating 
cytokine diffusion and adsorption into the beads of the CAD. An asymptotic analysis of the 
microtransport equation requires that we properly scale the two dimensionless parameters 
relative to one another. The guiding principle of least degeneracy [168] used in asymptotic 
analyses requires that we select  . Accordingly, we define another dimensionless 
parameter  and recast the dimensionless microtransport equation as 
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In the asymptotic limit of 1
* iK , Eq. 28 indicates that the diffusion-adsorption process 
is confined to a boundary layer of dimensionless size )(
*
iKO  at the surface of each bead. 
Introducing a boundary layer coordinate given by )1(
*1* rK i 

 the microtransport equation, 
simplified in the limit as 0* iK , is: 
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The temporal derivative term can be simplified using the dimensionless multicomponent 
adsorption isotherm (Eq. 18): 
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Eq. 13 indicates that in the low relative affinity regime effects related to multicomponent 
adsorption (e.g. affinity-based displacement) will appear, but only in the higher order correction 
terms for the *ic .  The boundary layer microtransport equation becomes: 
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which has the following solution for 1)0(
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In dimensional form, the concentration profile predicted by the asymptotic analysis of the 
microtransport equation is: 
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(Note: In the following section we justify that the macrotransport equation is quasi-steady and as 
such the only relevant effects of time come in from the microtransport analysis. This justifies 
dropping the explicit time dependence from the macroscale concentration in the boundary 
condition for the microtransport equation.) 
A.4 MACROSCALE ANALYSIS AND THE CYTOKINE REMOVAL RATE 
The macroscale average adsorption term (Eq. 14) can be determined from the microscale 
concentration profile using 
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By combining with Eq. 30, the macrotransport equation becomes: 
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An analysis of the first two terms in Eq. 32 provides the following relationship: 
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Since 10  c  and 
QVt cs   , the first term in Eq. 32 can be neglected and the 
macroscale transport is quasi-steady. Integrating Eq. 32 with respect to the macroscale 
coordinate Z, and evaluating at LZ   gives 
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which can be further simplified since    bc mAL 1 . The overall mass removal rate, using 
Eq. 21 for αi, is: 
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The rate of removal depends on one unknown parameter, i , specific to cytokine i and its 
interaction with the bead micropores and polymer surface:  
 iiii KqD
max   (36) 
All the other parameters of the device and its operation are known or are easily determined. 
Using Eq. 35, a mass balance on a cytokine volume of distribution 
rV  within a reservoir (or 
patient in application) yields: 
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APPENDIX B 
MATLAB® CODE FOR MATHEMATICAL MODEL 
B.1 CADS_MODEL_FITTING.M 
% script file to perform nonlinear regression and analysis for the cytokine 
% adsorbing device (CADS) model 
 
% cartridge and bead parameters 
global mb rho R Q Vr deltaV t_exp N 
mb=2.146; % mass of adsorbing beads in the CADS (g) 
rho=1.02; % density of adsorbing beads (g/ml) 
R=50; % radius of adsorbing beads (microns) 
R=R*10^-4; % work in cgs units 
% device operating parameters 
Q=0.8; % flow rate through device (ml/min) 
Vr=8; % initial reservoir volume (ml) 
deltaV=0.2; % sampling size that reduces the reservoir size at each time point 
warning off all 
 
% the experimental data below could also be inputted from a file 
t_exp=[10^-4, 5, 15, 30, 60, 90, 120, 240]; % input time of sampling 
N=length(t_exp); 
tmax=t_exp(N)+t_exp(2); 
tspan=[t_exp(1) tmax]; 
C_exp=[1, 0.591880149, 0.352865983, 0.202661749, 0.145618279, 0.12414411, 0.109351264, 
0.09299095]; % input experimentally measured cytokine values 
 
% determine and evaluate initial guesses for best gamma and Ci 
gamma=1.e-5; % initial guess for the gamma value describing data set 
Ci=C_exp(1); % initial guess for the initial concentration value 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
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figure 
plot(t_exp,C_exp,'o',t_out,C_out) 
axis([0 tmax 0 C_exp(1)]) 
xlabel('Circulation Time (mins)') 
ylabel('Cytokine Concentration') 
legend('Experimental', 'Model Prediction') 
title('Predictions based on initial parameters versus experiment') 
 
% perform nonlinear regressions to estimate best gamma and Ci 
beta=[gamma Ci]; 
[betafit,resids,J]=nlinfit(t_exp,C_exp,@removal_predict,beta); 
confident = nlparci(betafit,resids,J); % 95% confidence intervals for each parameter 
gamma=betafit(1); 
Ci=betafit(2); 
 
 
% graphically evaluate best fit 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
figure 
plot(t_exp,C_exp,'o',t_out,C_out) 
axis([0 tmax 0 C_exp(1)]) 
xlabel('Circulation Time (mins)') 
ylabel('Cytokine Concentration') 
legend('Experimental', 'Model Prediction') 
%titletxt=sprintf(: Gamma_i = %.3e and C_i = %.2f',gamma,Ci); 
title('Best-fit predictions versus experimental data') 
labeltxt=sprintf('Gamma_i = %.3e \n C_i = %.2f',gamma,Ci); 
gtext(labeltxt); 
 
% output the final parameter values and confidence intervals 
fprintf('Gamma_i = %.3e (w/ 95 percent CI from %.3e to 
%.3e)',gamma,confident(1,1),confident(1,2)) 
fprintf('\n\n C_i = %.2f (w/ 95 percent CI from %.2f to 
%.2f)',Ci,confident(2,1),confident(2,2)) 
fprintf('\n') 
B.2 REMOVAL_PREDICT.M 
function C_pred = removal_predict(beta,t); 
N=length(t); 
gamma=beta(1); 
Ci=beta(2); 
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tspan=[0 t(N)]; 
[t_out,C_out]=ode45((@(t,C) C_dot(t,C,gamma)),tspan,Ci); 
C_pred=interp1(t_out,C_out,t,'spline'); 
B.3 C_DOT.M 
function y = C_dot(t,C,gamma); 
% function file for computing the time-derivative of cytokine concentartion 
% predicted by the model 
global mb rho R Q Vr deltaV t_exp N 
% adjust reservoir size for finite sampling size 
Vact=Vr; 
for n=1:N-2 
    if t>t_exp(n+1) Vact=Vact-deltaV; 
    end 
end 
y =-Q/Vact*(1-exp(-3/sqrt(pi)*mb/Q/R*sqrt(gamma/rho/t)))*C; 
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